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ABSTRACT
Cis-dichlorodiammineplatinum(II) (cisplatin) is widely used as an 
anti-cancer agent to treat various tumours particularly ovarian, testicular, 
bladder cancers and tumours of the head and neck. Although the precise 
mechanism of cisplatin-mediated cytotoxicity remains elusive, DNA damage 
is thought to be the therapeutically important interaction. Cisplatin resistance 
is an obstacle to effective treatment of cancer patients. Such resistance may 
arise due to a variety of intracellular changes including enhanced repair of 
DNA lesions caused by cisplatin and reduced susceptibility to DNA damage- 
induced apoptosis. The tumour suppressor protein, p53 is required for DNA 
damage-induced apoptosis in certain cell types.
Cellular levels of p53 protein are increased subsequent to DNA 
damage due to post-translational alterations in p53. Induction of p53 protein 
levels by lpM cisplatin or transplatin peaks at 24 hours for the cisplatin 
sensitive human, ovarian adenocarcinoma cell line, A2780. Levels of p53 
protein increase in the cisplatin resistant derivative, A2780cp70 for at least 48 
hours following treatment with transplatin and at least 72 hours following 
treatment with cisplatin. Also, certain cisplatin resistant cell lines contain 
higher basal levels of p53 protein compared to the cisplatin sensitive parental 
cells from which they were derived. Results of Western blotting experiments 
show an 8 fold higher p53 concentration in the A2780cp70 cell line than 
A2780, the cisplatin sensitive parental line. This difference in p53 protein 
levels does not reflect a mutation of the p53 gene, as direct PCR sequencing of 
p53 from A2780 and A2780cp70 showed both lines to have a wild-type p53 
sequence. Furthermore, the p53 from A2780cp70 has less cross-reactivity with 
mutant-specific anti-p53 antibodies in immunoprecipitation experiments than 
cell lines with known mutations of the p53 gene. No evidence for increased 
MDM2 expression is observed in A2780cp70 suggesting that the p53 protein 
is not being stabilised by binding to the MDM2 protein in this cell line. 
Although increased levels of Hsp70 protein are observed in these cells, this 
may simply reflect a lack of transcriptional repression of the Hsp70 promoter 
in these cells due to the p53 being non-functional.
Altered p53-mediated transcriptional /rawsactivation in A2780cp70 
was examined by use of a luciferase reporter construct and by Northern 
blotting of endogenous genes, known to be transcriptionlly activated by p53. 
A2780cp70 cells have 10 fold lower WAF-1 mRNA levels than A2780 cells 
indicating reduced p53 transcriptional activity in the resistant cell line. 
Introduction of a mutant p53 gene into A2780 cells also provokes a reduction 
in basal p53 levels with a 3 fold decrease detected. Reduced function of p53 in 
the A2780cp70 cell line would be consistent with reduced entry to the 
apoptotic pathway in these cells. This may be one reason why A2780cp70 
cells are more cisplatin resistant than A2780 cells. The DNA damaging 
agents, cisplatin and transplatin, induced WAF-1 mRNA levels 4 fold by 24 
hours after drug removal in A2780 cells. Ionising radiation provoked a more 
rapid induction of 4.5 fold by 4 hours after drug removal in A2780 cells. This 
is consistent with induced p53 protein levels detected in A2780 after similar 
treatments. A2780cp70 cells, by comparison, showed only slight induction of 
WAF-1 following treatment with these agents. Clonogenic assay data shows 
that a pretreatment with cisplatin does not alter sensitivity to a second cisplatin 
dose. Thus intracellular alterations evoked by cisplatin treatment are not 
involved in a protective response.
DNA damage recognition proteins (DRPs) have been proposed to have 
a role in drug resistance, possibly by an involvement in DNA repair although 
other functions are possible. Partial purification of a DRP which binds to 
cisplatin-damaged DNA was carried out. Using nuclear proteins, soluble in 
2% tri-carboxylic acid for anion exchange chromatography and heparin 
column chromatography, this DRP was purified 183 fold. Using recombinant
xv
HMG proteins and using anti-HMG protein antibodies to retard protein-DNA 
complexes in the gel mobility shift assay, the DRP activity was shown to be 
identical to HMGI. Evidence is also presented showing that p53 does not 
directly bind to regions of cisplatin-induced DNA damage. However this does 
not eliminate a possible link between DRP-mediated DNA damage 
recognition and the p53 response to DNA damage.
x v i
Chapter 1
CHAPTER 1; INTRODUCTION
1.1 C/S-DIAMMINEDICHLOROPLATINUM II (CISPLATIN)
1.1.1 THE DISCOVERY OF CISPLATIN
Cisplatin was first synthesized in 1845 when it was known as 
"Peyrone's chloride" and its structure was elucidated in 1893 (Eastman, 1990). 
The toxic effects of cisplatin were first appreciated when an AC current was 
delivered through platinum electrodes to a culture of Escherichia coli bacterial 
cells. The cells stopped dividing and proceeded to form long filaments. At the 
electrodes, the responsible compound was found to be the planar cisplatin 
molecule (Rosenberg et al., 1965). Stereochemistry has important implications 
for these effects as the trans isomer does not inhibit division and merely 
functions as a bacteriocide. The structure of cisplatin, showing the reactive 
chloride groups is depicted below in figure 1.1.1. These chloride ions are 
stable in the extracellular environment but, on uptake to cells, the low 
intracellular chloride concentration causes them to be replaced by hydroxyl 
ions. This gives rise to a bifunctional, charged electrophile which is reactive 
with nucleophilic sites within the cell such as DNA, RNA and proteins. 
FIGURE 1.1.1
The Chemical Structure of Cisplatin
HsN
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1.1.2 CISPLATIN AS A CHEMOTHERAPEUTIC AGENT
Cisplatin was shown to have powerful anti-tumour activity when 
injected into mice with tumour implants. Platinum compounds were able to 
decrease the mass of Sarcoma 180 solid tumours and to increase the mean 
survival time of mice with leukemia L1210 compared to control mice 
(Rosenberg & VanCamp, 1969; Rosenberg & VanCamp, 1970). Cisplatin is 
now used in drug combination strategies to treat testicular, bladder, ovarian 
cancer and tumours of the head and neck (Loehrer & Einhom, 1984).
1.2 POSSIBLE MECHANISMS OF CISPLATIN MEDIATED CELL 
DEATH
1.2.1 CISPLATIN INDUCED DNA DAMAGE
Approximately 1% of the total cellular platinum binds to the DNA, 
forming a range of adducts which have been detected in vitro and in vivo. 
These lesions, which are represented pictorially in figure 1.2.1 include 
monofunctional, intrastrand, interstrand and intermolecular adducts involving 
a second molecule such as glutathione (GSH) or protein. The majority of 
cisplatin interactions with DNA take the form of intrastrand cross-links with 
65% between neighbouring guanines at the N7 position, i.e 1,2 d(GpG), 25% 
are between adjacent adenine and guanine residues, i.e 1,2 d(ApG), and the 
remainder are between guanines separated by another nucleotide i.e 1,3 
d(GpNpG) (Fichtinger-Schepman et al., 1984; Pinto & Lippard, 1985a; Eastman, 
1986).
Such DNA damage could result in reduced viability of cells which are 
unable to repair lesions before the genome is replicated at S phase of the cell 
cycle. Thus rapidly dividing cells, such as one often observes in tumours, 
would be targeted more efficiently. Indeed there is evidence that cisplatin 
preferentially kills proliferating rather than quiescent rat thymocytes (Evans et 
al., 1994). Damaged DNA might result in aberrant separation of the
3
chromatids at M phase of the cell cycle, giving rise to daughter cells with an 
abnormal complement of chromosomes. It could also interfere with the 
progress of replicative enzymes along the DNA strand or with transcription of 
genes essential for cellular survival.
FIGURE 1.2.1
The Main Types of Cisplatin-DNA Adducts
monofunctional interstrand intrastrand intermolecular
r-L J-, I— 1— I rrJ— I
\  protein
glutathione
Transplatin is stereochemically incapable of forming the main 
cisplatin DNA adduct, the 1,2 d(GpG) intrastrand crosslink. This may account 
for the differential toxicities and anti-tumour capacities of these two isomers 
(Pinto & Lippard, 1985a). Within CV-1 cells given a continuous lOpM dose, 
of cisplatin or transplatin, transplatin lesions increased rapidly for 6 hours, as 
measured by atomic absorption spectroscopy (AAS), then declined suddenly. 
On the other hand cisplatin adducts rose steadily throughout the course of the 
48 hour experiment, indicating that cells are less proficient at repairing 
cisplatin-mediated damage (Ciccarelli et al., 1985). DNA damage is the most 
likely explanation for the cytotoxicity and anti-tumour activity of cisplatin and 
interactions with DNA would certainly have more drastic effects than
4
interactions of cisplatin with more transient intracellular molecules such as 
proteins and mRNA.
1.2.2 MUTAGENESIS
In certain instances, cisplatin mediated DNA damage may be incurred 
in essential, "housekeeping" genes. Such mutations might cause the gene 
product to be inactive or to be abnormally expressed. This would result in 
reduced viability of affected cells and so represents a further mechanism by 
which cisplatin could kill cells. One would expect the majority of such 
mutations to occur at nucleotide sequences rich in guanines adjacent to either 
other guanines or adenines. Studies using the Chinese hamster ovary (CHO) 
aprt gene have shown 5AGG and 5'GAG sequences to be hotspots for 
cisplatin induced mutations and there is no apparent overlap with UV induced 
mutations (deBoer & Glickman, 1989).
1.2.3 INHIBITION OF DNA SYNTHESIS
Cisplatin may exert its effects by prevention of normal cellular 
functions such as DNA synthesis. DNA synthesis is impaired by cisplatin 
(Harder & Rosenberg, 1970) and this may be due to direct inhibition of 
polymerases. Progress of DNA polymerases has been shown to be halted in 
vitro by DNA intrastrand crosslinks (Pinto & Lippard, 1985b). An alternative 
means of DNA synthesis inhibition would be to block the cells in a cell cycle 
phase where DNA replication does not occur for example in G1 or G2 phases. 
Cisplatin has been shown to cause cell cycle blocks in both G2 (Sorenson & 
Eastman, 1988; Ormerod et al., 1994) and G1 phases (Brown et al., 1993).
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1.2.4 APOPTOSIS
Apoptosis is a form of programmed cell death which exhibits certain 
distinct morphological features (Kerr et al., 1972). Cells become rounded, 
membrane blebbing can be detected, and in some cases, non-random DNA 
fragmentation to multiples of 180-200bp occurs and, probably as a result of 
this, the chromatin becomes condensed. This is rapidly followed by separation 
of the nucleus into discrete masses of condensed chromatin and, finally, 
fragmentation of the cell into several membrane bound vesicles known as 
apoptotic bodies which are then phagocytosed by other cells such as 
macrophages. The process of apoptosis is involved in cell turnover within 
tissues, tumour regression, focal elimination during embryonic development 
and it also seems to occur in response to toxic substances.
Apoptosis is a thermodynamically uphill process and requires the 
expression of certain gene products. The c-myc protein is required for 
activation-induced apoptosis of T-cell hybridomas (Shi et al., 1992). 
Deregulation of the c-myc gene causes apoptosis of rodent fibroblasts 
following serum withdrawal (Evan et al., 1992). Apoptotic induction by c-myc 
occurs via its interaction with the splice variant products of the max gene 
(Amati et al., 1993). Apoptosis in response to DNA damage seems to require 
p53 protein (Lowe et al., 1993a) although p53 independent apoptotic pathways 
have been reported (see section 1.4.7 for further details). Another important 
protein is bcl-2, a 25KDa integral, inner mitochondrial membrane protein, 
which antagonises apoptotic death (Hockenberry et al., 1990). It forms 
heterodimers in vivo with bax, a protein which promotes apoptosis (Oltvai et 
al., 1993). The bcl-2 protein has 23% amino acid homology with the product 
of the ced9 gene from Caenorrhabditus elegans which suppresses the ced3 
and ce*/4-mediated programmed cell death in this worm species (Hengartner et 
al., 1994). The C.elegans cell death programme requires the ced3 and ced4 
genes to effect the regulated demise of 131 of the 1090 cells present in the
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developing worm. A mammalian homologue of the ced3 gene has been found 
(Yuan et al., 1993) which encodes a 45KDa protein, the interleukin B 
converting enzyme (ICE). Other genes implicated in the apoptotic pathway 
include TRPM-2/SGP and Fas/APO-1 (for a review see Martin et al., 1994).
Apoptosis can be induced by anticancer drugs including cisplatin (for a 
review see Dive & Hickman, 1991). This has been demonstrated in CHO cell 
lines which were proficient (AA8) or deficient (UV41) in DNA excision repair 
(Barry et al., 1990). The UV41 cell line was 100 fold more sensitive to a 2 
hour cisplatin dose. Treatment of either of these cell lines with a 90% lethal 
dose of cisplatin caused the DNA fragmentation, symptomatic of apoptosis, 
which was detected 48 hours after drug treatment and earlier for higher doses. 
The DNA fragmentation was followed by cell shrinkage and by loss of 
membrane integrity as measured by trypan blue exclusion. There appears to be 
a fairly linear relationship between drug dose and apoptosis for each of several 
cytotoxic drugs including cisplatin (Frankfurt et al., 1994).
Rat thymocytes, unlike hepatoma cells, did not seem to show 
sensitivity to cisplatin-induced apoptosis despite their extreme sensitivity to 
apoptosis induced by other conditions (Evans & Dive, 1993). However, this 
was probably due to 95% of the thymocyte population being quiescent. The 
minority sub-population of larger, proliferating thymocytes exhibited 
increased levels of apoptosis as detected by acridine orange staining of nuclei 
and agarose gel electrophoresis of fragmented DNA, upon treatment with a 2 
hour, 50pM cisplatin dose when compared to both untreated controls and 
quiescent thymocytes (Evans et al., 1994). As no differences in either cisplatin 
intracellular levels (AAS) or cisplatin-DNA adducts were detected (ELISA), it 
may be that cells must be in a certain cell cycle phase in order to succumb to 
cisplatin-induced apoptosis or that DNA replication is necessary to couple the 
induced DNA damage to the apoptotic response.
7
1.3 MECHANISMS OF RESISTANCE TO CISPLATIN TREATMENT
1.3.1 THE ACQUISITION OF DRUG RESISTANCE
The development of drug resistance is a problem which has marred the 
progress of chemotherapy for many cancer sufferers. The ability to understand 
and hence modulate such resistance is one of the major goals of oncology 
today. In some large tumours drugs are not efficiently delivered to the 
cancerous cells. This is due to the extensive, collagen-enriched interstitium 
and the higher pressure and greater viscosity of the blood supply, which 
reduces blood flow and so, convection. Thus larger molecules which require 
the blood to "carry" them cannot reach cancerous cells as readily as small 
molecules which travel principally by diffusion (Jain, 1994). Therefore such 
tumours do not respond well to chemotherapy and so could be termed 
"resistant".
Certain cell types display increased tolerance of drugs than others and 
this is termed "innate" or "inherent" resistance. For example, bladder cells 
have a greater tolerance of cisplatin than testicular cells and this difference is 
maintained in cell lines derived from them (Walker et al., 1987). For instance 
testicular cell lines are generally 3- 5 fold more sensitive to cisplatin than 
bladder cell lines (Bedford et al., 1988 and many others). "Acquired" 
resistance on the other hand, is resistance which develops due to a phenotypic 
change in the affected cells. This can be mimicked in vitro by selection of 
spontaneous mutants by exposure of cell lines to high doses of the drug 
(Behrens et al., 1987; McLaughlin et al., 1991).
1.3.2 DRUG RESISTANCE DUE TO REDUCED INTRACELLULAR 
ACCUMULATION
One mechanism by which cells could become resistant to 
chemotherapeutic drugs is by decreasing the concentration of the drug in the 
cell either by lowering the uptake or by increasing efflux of the substance. A
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classic example of such a mechanism is the MDR phenotype where resistance 
to a multitude of hydrophobic, natural product, cytotoxic drugs develops due 
to overexpression of the MDR1 gene which encodes p-glycoprotein, a 170KDa 
membrane protein (Juliano & Ling, 1976). High levels of p-gly coprotein
I
expression lare sometimes detected in cancers derived from certain tissues. 
Increased p-glycoprotein expression has also been detected in acute 
leukemias, neuroblastomas ovarian and breast cancers which have relapsed 
after chemotherapy and in acute non-lymphocytic leukemia and chronic 
myelogenous leukemia. However the MDR1 gene does not confer resistance to 
cisplatin (Bradley et al., 1988; Deuchars and Ling, 1988). A gene has been 
identified which expresses its product, the ATP binding MRP , at relatively 
high levels in non-p-glycoprotein mediated MDR cells (Cole et al., 1992; 
Slovak et al., 1993). MRP is a 190KDa membrane protein which is located 
principally at the endoplasmic reticulum (Krishnamacery & Center, 1993).
i
I Another protein has been described which, like MRP, is associated with| MDR 
but not cisplatin resistance. This | llOKDa protein is overexpressed [in cells which 
have an ATP dependent | defect in drug accumulation! (Scheper et al., 1993).
Reduced accumulation of cisplatin has been reported for some 
cisplatin tolerant, human ovarian carcinoma cell lines although it does not 
appear to be a universal mechanism (Andrews et al., 1989; Schmidt and 
Chaney, 1993). A 200KDa protein, which displays increased expression in 
cisplatin resistant cell lines, has been detected by raising antibodies to the 
plasma membrane of murine thymic lymphoma cells (Kawai et al., 1990). The 
level of cisplatin resistance correlated with a decrease in intracellular 
concentration of the drug. Another manner by which cisplatin accumulation 
might be reduced, is by increased binding to extracellular proteins which 
would make cisplatin effectively impermeable to cells. Using a human cell 
line, NHIK3025, it has been demonstrated that the cytotoxicity of cisplatin can 
be decreased by binding to serum proteins (Melvik et al., 1992).
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1.3.3 INACTIVATION OF CISPLATIN BY CELLULAR COMPONENTS
If the reactivity of cisplatin were obliterated by increased interaction 
with nucleophilic molecules such as glutathione (GSH) or metallothioneins 
before it was able to carry out its destructive effects within the cell, resistance 
might arise. GSH, with a concentration within cells of 0.5-1 OmM, is the main 
intracellular thiol and is reactive with cisplatin. An association between 
increased GSH levels and cisplatin resistant cell lines have been detected in 
certain cases (Andrews et al., 1989). Incubation of cisplatin with GSH reduced 
its toxicity. Exposure of CHO fibroblast cell lines to 5mM buthionine 
sulphoximine caused a 90% reduction in cellular GSH levels resulting in the 
cells becoming sensitized to cisplatin treatment (Spitz et al., 1993). However 
there is scant evidence for GSH levels being a causative factor in modulation 
of cisplatin toxicity in vivo.
Metallothioneins are proteins of 6-7KDa in size, which are thought to 
be involved in zinc homeostasis and the detoxification of heavy metals in 
cells. In primates there are at least five MT-1, one MT-2 and one brain specific 
MT-3 genes which encode such proteins. A correlation between elevation of 
the cellular metallothionein content and transient cisplatin resistance in a 
murine fibrosarcoma cell line has been observed (Eichholtz-Wirth et al., 
1993). However this was not shown to be a cause-effect phenomenon and the 
transient nature of the resistance suggested that it was not due to a mutation or 
gene amplification event. Curiously, the cells used for these experiments 
became cisplatin resistant following irradiation yet exhibited no resistance to 
y-radiation. Overexpression of metallothioneins in cisplatin resistant, human, 
carcinoma cell lines following exposure to heavy metals was associated with 
resistance to cisplatin, chlorambucil and melphalan and transfection of cells 
with the human metallothionein-IIA gene conferred resistance to these drugs 
(Kelley et al., 1988). However transfection with a mouse metallothionein gene
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(MT-1) seemed to enhance cisplatin sensitivity, rather than resistance, of a 
CHO cell line (Koropatnick and Pearson, 1993).
An extensive study using three untreated ovarian, carcinoma cell lines 
including A2780 (a cell line which will be referred to in several subsequent 
sections), five A2780 derivatives selected for cisplatin resistance in vitro and 
five ovarian, carcinoma cell lines from patients who had been treated with, 
and acquired tolerance of cisplatin, has been performed (Schilder et al., 1990). 
There was no overall correlation between basal levels or inducibility of 
metallothionein II gene expression and cisplatin resistance.
1.3.4 INCREASED REPAIR OR TOLERANCE OF CISPLATIN- 
MEDIATED DNA DAMAGE
As DNA damage seems to be an important cytotoxic event following 
cisplatin treatment, enhanced repair of such lesions may represent the primary 
cause of cisplatin tolerance. In addition, increased tolerance of DNA adducts 
may occur for example, if DNA distortions are minimised due to binding of a 
protein which corrects the resultant kink in the DNA structure.
There are three classes of DNA repair and these are direct repair, 
recombinational repair and excision repair (Lindahl et al., 1982). Direct repair 
involves reversal of covalent modifications as occurs in the photoreactivation 
reaction of yeast where photolyase breaks the cyclobutane ring of pyrimidine 
dimers, caused by UV radiation, and restores the DNA to its native state. 
Recombinational repair happens when polymerases encounter DNA adducts. 
They cease replicating and initiate lOOObp beyond the adduct, where they 
continue, leaving a region of single stranded DNA which, in Escherichia colit 
is filled using the RecA protein. Excision repair consists of several stages 
which are, in chronological order, damage recognition, formation of the 
preincision complex, incision of the phosphate backbone at both sides of the
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adduct, excision of the abnormal nucleotide, repair synthesis, release of the 
post-incision complex and DNA ligation.
Cisplatin resistant cells show elevated DNA repair compared to 
sensitive cells as detected by loss of [3H]-cis-DEP adducts (Eastman & 
Schulte., 1988) or by elevated [3H] thymidine incorporation indicating 
increased repair synthesis (Lai et al., 1988). Cells which are sensitive to 
cisplatin are less able than resistant derivatives to repair a damaged 
chloramphenicol acetyl transferase (CAT) gene as measured by CAT activity 
in murine LI210 cells (Sheibani et al., 1989), human fibrosarcoma lines (Chu 
& Chang, 1990) and HeLa cells (Chao et al., 1991d). Gene specific, as 
opposed to total genome, repair of DNA interstrand crosslinks formed by 
cisplatin have been found to be increased in two cisplatin resistant cell lines 
when compared to their sensitive parentals (Zhen et al., 1992). This was 
demonstrated for the dihydrofolate reductase, y-globin and MDR1 genes using 
a denaturation-reannealing protocol then neutral gel electrophoresis, to 
separate crosslinked DNA from single stranded DNA, and subsequent 
Southern blotting. A comparison of sensitive SUSA bladder cells with the 
more resistant RT112 bladder cell line, using alkaline elution and ELISA, 
incorporating antibodies against cisplatin damaged DNA, revealed that 
although there was no overall difference in platinum adduct removal between 
these cell lines, SUSA cells had a defect in removal of intrastrand crosslinks 
involving two adjacent nucleotides (Bedford et al., 1988). This provides 
evidence that this is the main cytotoxic lesion formed by cisplatin and that 
repair of intrastrand crosslinks may be important in the development of 
cisplatin resistance.
1.3.5 OTHER FACTORS WHICH INFLUENCE CISPLATIN RESISTANCE 
Altered expression of the ras, fos and myc oncogenes have been 
implicated in cisplatin resistance, as have alterations in activity of protein
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kinase A, a cyclic AMP dependent enzyme which has a possible role in gene 
transcription, and protein kinase C inhibition or down regulation (for reviews 
see Andrews & Howell, 1990; Keith & Brown, 1991). Elevation of cyclic 
AMP has been shown to accentuate both cisplatin accumulation and 
sensitivity in 2008 cells probably by phosphorylation of a protein which 
modulates cisplatin influx or efflux. Also an increase in phosphorylation of 
32KDa and 20KDa proteins in cisplatin resistant PC-9/CDDP cells compared 
to sensitive PC-9 human, lung, adenocarcinoma cells has been detected by 
SDS/PAGE after 32P labelling, with no concurrent increase in protein levels 
(Nishio et al., 1992). The observation that tamoxifen increased the efficacy of 
a cisplatin combination therapy used against malignant melanoma cells, 
provoked a study demonstrating synergy between these two compounds in the 
T-289 melanoma cell line (McClay et al., 1992). No increase in uptake of a 
tritiated cisplatin analogue, dichloro(ethylenediammine)platinum II(DEP) 
could be determined by scintillation counting. ELISA showed no difference in 
metallothionein levels and, GSH levels, determined by a HPLC method, 
remained unaltered by tamoxifen presence. Also, tamoxifen had no affect on 
the repair of DEP-DNA adducts determined by the quantity of tritium in DNA 
samples prepared at various times after exposure of the cells to tritiated DEP. 
This suggests some novel form of cisplatin resistance is counteracted by 
tamoxifen. Thus the development of drug resistance is a complex process 
which cannot be accounted for by one, sole mechanism.
1.4 A ROLE FOR p53 PROTEIN IN CISPLATIN RESISTANCE ?
1.4.1 p53, THE TUMOUR SUPPRESSOR
The nuclear phosphoprotein, p53 was discovered by 
coimmunoprecipitation from SV40 transformed mouse cells, due to an 
association with SV40 large T antigen (Lane & Crawford, 1979). Association 
of p53 protein with viral proteins, such as SV40 large T antigen, adenovirus
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E1B and the E6 proteins of HPVI6 and 18 human papillomaviruses, indicates 
that it is an important regulatory protein whose function must be overcome in 
order to permit viral replication. Indeed, SV40 replication has been shown to 
be inhibited by wild type but not mutant p53 protein in vitro (Friedman et al., 
1990). Several nuclear localisation sequences are located in the C terminal 
region of p53 protein (Shaulsky et al., 1990). Expression of p53 can be 
discerned in many multicellular eukaryotic species and the gene is located on 
the short arm of chromosome 17 at 17pl3.1 in humans, a region which is often 
deleted in cancers. The sequence of the p53 protein has remained highly 
conserved throughout evolution indicating a critical function.
The wild type form is a tumour suppressor and mutations or deletions 
of the p53 gene are one of the most frequent genetic alterations observed in 
human cancer as determined by immunohistochemistry,^Western blotting and 
ELISA (Malkin et al., 1990; Srivastava et al., 1990; Brash et al., 1991; Hsu et 
al., 1991; Moll et al., 1992; Cunningham et al., 1992; Allred et al., 1993; 
Bums et al., 1993). Mutantp53 can cooperate with ras to transform primary 
embryonic rat fibroblasts and there was some initial confusion as to which 
form of p53 protein represented the native, wild type (Finlay et al., 1988).
There does appear to be a common conformational change of p53 
protein which occurs on mutation of the gene. This was suggested, as certain 
antibodies can bind a range of different mutant p53 proteins but not to the wild 
type protein (Gannon et al., 1990). Changes in p53 conformation have also 
been detected under different growth conditions (Milner and Watson., 1990). 
This protein has fundamental importance in the development of cancerous 
conditions and may, as will be discussed in subsequent sections, also have an 
effect on how well such diseases respond to chemotherapy and radiotherapy.
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1.4.2 EVIDENCE FOR AN INVOLVEMENT OF p53 IN CISPLATIN 
RESISTANCE
DNA damaging agents such as cisplatin, mitomycin C, etoposide and 
UV radiation have been shown to induce levels of intracellular, particularly 
nuclear, p53 protein in cells of both human and murine descent (Maltzman & 
Czyzyk, 1984; Kastan et al., 1991; Brown et al., 1993; Fritsche et al., 1993). 
Such an increase has also been detected in vivo in response to UV by 
immunohistochemistry of paraffin wax-embedded human, forearm biopsies 
(Hall et al., 1993). This implicates p53 protein in the response of cells to DNA 
damage, possibly as a mediator of signal transduction to downstream events 
such as altered gene transcription, cell cycle arrest or the decision to enter the 
apoptotic pathway. Bone marrow or spleen cells from transgenic mice with 
p53 mutations show an increased tolerance of ionizing radiation induced DNA 
damage compared to cells from wild type littermates (Lee and Bernstein., 
1993). Mutant p53 protein enhances, and wild type p53 represses, 
transcription of the MDR1 gene promoter placed upstream of a CAT reporter 
construct in SW13, human adrenocortical, carcinoma cells and NIH3T3 cells
resistance genes involved in cisplatin tolerance in a similar manner. Also 
cisplatin resistant cell lines selected using multiple exposures to cisplatin or 
one, single, chronic 15pM dose have an increased incidence of constitutive 
p53 protein elevation which cannot be accounted for by mutation of the p53 
gene (Brown et al., 1993).
1.4.3. STABILIZATION OF p53 PROTEIN
The enhanced levels of p53 protein detected in cisplatin resistant cells, 
and following exposure of cells to DNA damaging agents, could arise by 
elevation of p53 gene transcription. This is unlikely as drug induced p53 
protein stabilization has been shown to occur in the absence of any increase in
(Chin et al., 1992) and could theoretically alter transcription of!/ drug
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p53 mRNA levels (Kastan et al., 1991; Fritsche et al., 1993). It is also 
independent of the cell cycle phase which cells are in when exposed to DNA 
damaging agents.
Certain types of p53 gene mutations cause the p53 protein half life to 
increase from 15-45 minutes to 120-360 minutes, as determined by pulse 
chase experiments after transfection of cells with plasmids expressing p53 
(Finlay et al., 1988). It also shows increased binding to the heatshock protein 
Hsp70 from coimmunoprecipitation data and the region of p53 involved in this 
association has been elucidated (Hainaut & Milner, 1992; Lam & Calderwood, 
1992). SV40 large T antigen is also able to prolong p53 longevity without 
increasing p53 mRNA levels as can be seen by comparing pulse chase 
experiments in 3T3 cells and in the SV40 transformed cell line, SV3T3 (Oren 
et al., 1981) Binding to proteins such as Hsp70 and SV40 large T antigen may 
protect p53 from degradation by masking a protease recognition site on the 
p53 molecule. E6 viral proteins which complex with p53, on the other hand, 
destabilize p53 protein (Scheffner et al., 1990).
Other p53 interactive proteins include the phosphoprotein, MDM2 
which inhibits p53 mediated transcriptional /ra/isactivation (Momand et al.,
1992). It binds to a region from amino acids 18-23 of mouse and human p53 
proteins, which differ in one residue within this peptide sequence (Picksley et 
al., 1994). There appear to be several forms of this protein derived by 
alternative mRNA splicing. Four naturally occurring forms have been found in 
mice, of which one was unable to bind p53 protein possibly due to its lacking 
an N-terminal region (Haines et al., 1994). These variant forms may react with 
p53 protein in different circumstances and thereby provide fine tuning of p53 
function. Amplification of the MDM2 gene, found at the chromosomal region 
12ql3-14, is another frequent genetic alteration associated with cancerous 
disease (Oliner et al., 1992; Leach et al., 1993). Major 45KDa, 56KDa and
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70KDa proteins, as well as many minor proteins from non-small cell lung 
carcinoma lysates have been found to interact with the conserved p53 
conformational domain encompassing amino acids 115-295 and these 
associations were reduced by 40-80% after point mutations at codon 273 or 
175 of the p53 sequence (Maxwell & Roth., 1993). Quantitative differences in 
various p53 binding proteins were detected between cell lysates of different 
origins.
There may be several pathways by which p53 protein levels can be 
induced. Although a reduced or delayed ionising radiation p53 induction is 
apparent for cells from at least four complementation groups of ataxia 
telangiectasia (AT), induction of p53 protein following treatment with UV-B 
light is normal (Khanna & Lavin, 1993). Patients who suffer from AT are 
highly cancer prone and hypersensitive to ionising radiation but not UV-B 
light. Induction of p53 protein levels in response to both agents was inhibited 
by calphostin A, a protein kinase C inhibitor and by the serine/threonine 
phosphatase inhibitors, okadaic acid and calyculin A, indicating a role of 
protein kinase C and serine/threonine phosphatases in the stabilization of p53 
protein. Inhibitors of protein kinase A, tyrosine kinases or tyrosine 
phosphatases did not inhibit p53 induction.
Nuclear accumulation of p53 may arise due to excessive, unrepaired 
DNA damage in actively transcribed genes rather than due to damage which 
occurs randomly throughout the genome. Cells from patients with a defect in 
repair of transcribed genes for example, Cockayne's syndrome or xeroderma 
pigmentosum group A, showed induction of p53 protein at much lower doses 
of UV radiation than normal cells or cells with a defect in overall genome 
repair, such as those from xeroderma pigmentosum group C patients 
(Yamaizumi & Sugano, 1994).
1.4.4 INTRACELLULAR DEGRADATION OF p53 PROTEIN
Within cells, breakdown of proteins which have outlived their 
usefulness is carried out by lysosomal autophagy, various ATP dependent 
proteases or by the ubiquitin pathway. In w’/ro-translated p53 protein 
coimmunoprecipitates ubiquitin when ATPyS is used to inhibit HPV E6 
protein-stimulated p53 breakdown, indicating an involvement of ubiquitin in 
p53 degradation (Scheffner et al., 1990). Also, using a cell free degradation 
system followed by SDS/PAGE, the ubiquitin pathway has been shown to be 
involved in degradation of in vftro-synthesized, radiolabelled p53 protein 
(Ciechanover et al., 1991). Degradation of p53 does not occur in the absence 
of ATP, it can be inhibited by depletion of El, the ubiquitin activating protein, 
using immunoprecipitation and subsequently restored by addition of purified 
El.
The degradation of proteins by the ubiquitin pathway involves several 
proteins. After activation of ubiquitin by El, ubiquitin is transferred to a 
carrier protein, E2, El is recycled and then E2 conjugates ubiquitin to the 
protein to be destroyed, which has been recognised by the ubiquitin protein 
ligase, E3, of which there are four types. E2 is recycled at this point, multiple 
moieties of the 76 amino acid, ubiquitin become attached and ATP dependent 
degradation is carried out by the 26S protease complex. A free a  amino group 
is important in the recognition of proteins for rapid turnover by this system, 
also the identity of the N-terminal residue plays a role in its recognition and t- 
RNA seems to be involved in covalently modifying substrates for binding (for 
reviews see Hershko, 1988; Ciechanover, 1989). Modulation of p53 
recognition by the ubiquitin system may have implications for the p53 DNA 
damage response pathway.
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1.4.5 HOW p53 MAY BE INVOLVED IN THE DEVELOPMENT OF 
DRUG RESISTANCE
DNA damage caused by cisplatin and other cytotoxic treatments 
results in increased wild type p53 protein in the nucleus of cells exposed to 
these agents. This may, under normal circumstances, cause cell cycle arrest in 
response to DNA damage which then affects the decision of cells to 
commence apoptosis. Alternatively, p53 may influence the entry of cells to the 
apoptotic pathway, independently of any cell cycle affects. P53 probably 
mediates its effects by altering transcription of relevant genes. An aberration 
in a component of the p53 DNA damage response pathway could thus result in 
drug resistance due to inappropriate survival of cells following drug exposure.
1.4.6 THE INDUCTION OF CELL CYCLE ARRESTS BY p53 PROTEIN
Overexpression of wild type p53 protein in osteosarcoma cell lines 
blocks growth of osteosarcoma (Diller et al., 1990) and colorectal carcinoma 
cell lines (Baker et al., 1990) as determined by differences in the colony 
forming ability of these cells. The transfection of wild type p53 protein into 
Li-Fraumeni syndrome cells with mutant p53 alleles restored normal cell cycle 
control (Yin et al., 1992). Wild type, but not mutant p53 protein blocks growth 
of both S.pombe, when overexpressed from a thiamine inducible promoter 
(Bischoff et al., 1992), and S.cerevisiae, when expressed from a galactose 
inducible promoter (Nigro et al., 1992). In the latter case this was shown to 
involve a G1 phase block.
A glioblastoma cell line, T98G, when transfected with a 
dexamethasone inducible p53 gene, exhibits a dexamethasome inducible G1 
block and prevents entry to S phase following release from stationary growth 
by 86% (Mercer et al., 1990). Cycloheximide has been employed to 
demonstrate that protein synthesis is required in order to enter S phase of the 
cell cycle after release from a G1 phase cell cycle block resulting from
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overexpression of wild type p53 from a dexamethasone inducible promoter 
(Lin et al., 1992). It was also shown that the p53 induced block corresponded 
with the mammalian restriction point as determined by expression of genes 
known to be transcribed just before and after this cell cycle event. Using 
Northern blotting, B-MYB and DNA polymerase a  were found to be repressed 
but c-FOS, c-JUN, JUN-B and c-MYC, which are expressed earlier in the cell 
cycle, were not.
DNA damage induction of p53 protein levels by ionising radiation has 
been shown to correlate with acquisition of a G1 block in ML-1 and 
proliferating, normal bone marrow progenitor cells (Kastan et al., 1991). Also 
cycloheximide, a protein synthesis inhibitor, or caffeine, an inhibitor of 
phosphodiesterase which breaks down cAMP, were both shown to prevent the 
induction of p53 protein levels and G1 arrest. Cells which lack wild type p53 
protein did not arrest in G1 phase of the cell cycle but did show a G2 arrest. 
Cell lines derived from AT patients, which do not induce p53 protein, after 
ionising radiation exposure had a defect in their ability to arrest in G1 in 
response to ionising radiation suggesting that the AT gene products may be 
upstream of p53 in the p53 mediated response to DNA damage (Kastan et al.,
1992). In several cell lines, a strong correlation between ionising radiation- 
caused p53 inducibility, G1 arrest propensity and radiosensitivity has been 
demonstrated (McIlwrath et al., 1994). A direct relationship of p53 protein in 
causing the G1 arrest was shown because transfection of wild type p53 into 
HL60 cells, which lack p53, resulted in acquisition of a G1 arrest in response 
to ionising radiation (Kuerbitz et al., 1992). Also, loss of G1 arrest in response 
to ionising radiation, occurred when a mutant p53 gene was expressed in RKO 
cells which have endogenous, wild type p53. Similar experiments have been 
performed on A2780 cells (MCI1 wrath et al., 1994). Thus p53 protein is very 
important for normal, regulated cell growth in the cells of multicellular 
eukaryotic organisms.
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1.4.7 p53 AND THE INDUCTION OF APOPTOSIS
Thymocytes from 4.5-7 week old mice whose p53 genotype was either 
wild type, heterozygous or homozygous mutant were used to demonstrate an 
involvement of p53 in apoptosis. A wild type p53 function was necessary for 
radiation induced, but not glucocorticoid induced apoptosis as determined by 
electrophoresis of fragmented DNA (Lowe et al., 1993b). Ionising radiation- 
induced, p53-dependent apoptosis has also been reported for murine, intestinal 
crypt cells in vivo (Clarke et al., 1994). A requirement for p53 protein to carry 
out apoptosis in response to etoposide but not calcium influx, stimulated by 
use of a phorbol ester and a calcium ionophore, was demonstrated in a similar 
system using acridine orange staining of nuclear chromatin to assess the 
induction of apoptotic death (Clarke et al., 1993). Apoptosis in mouse embryo 
fibroblasts, resulting from treatment with anti-cancer agents such as 5- 
fluorouracil, etoposide, adriamycin or ionising radiation has been shown to 
require a functional p53 protein (Lowe et al., 1993a). The percentage of 
apoptotic nuclei in the embryonic mouse lens, resulting from a homozygous 
mutation of the retinoblastoma gene, was reduced by 94% in mice which were 
also homozygous mutants for the p53 gene, indicating that wild type p53 is 
involved in execution of the apoptotic programme in this situation 
(Morgenbesser et al., 1994). Prevention of p53 expression by transfection of 
antisense p53 mRNA into cells obtained from acute myeloblastic leukemia 
patients or a human erythroleukemia cell line, suppressed the growth factor 
deprivation-induced apoptosis which occurred in 21-54% of control cells (Zhu 
et al., 1994). It is apparent therefore, that p53 is involved in promoting 
apoptosis in certain situations, particularly in response to DNA damage and so 
it is likely to be influential in the response of cells to DNA damaging drugs 
such as cisplatin.
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Neither cycloheximide or actinomycin D prevented ionising radiation 
induced, p53 dependent apoptosis in GHFT1 cells (Caelles et al., 1994). Thus, 
it has been proposed that rather than activating genes involved in the 
promotion of apoptosis, p53 protein acts by repression of those necessary for 
survival. This is supported by the finding that wild type p53 represses 
expression of the bcl-2 gene (Myashita et al., 1994a & b), whose product is 
known to protect cells from apoptosis.
1.5 REGULATION OF TRANSCRIPTION BY p53 PROTEIN
1.5.1 THE CAPACITY OF p53 PROTEIN TO BIND DNA
An ability to regulate transcription of specific genes is one way by 
which p53 protein may mediate its affects and the first indication that this 
could be the case was the demonstration that p53 has affinity for DNA. Using 
DNase I footprinting, it has been shown that wild type human or murine p53 
proteins, but not mutant p53, can bind to SV40 DNA adjacent to the SV40 
origin of replication and this can be inhibited by SV40 large T antigen 
(Bargonetti et al., 1991). In vitro translated, wild type p53 proteins of mouse 
or human origin were shown to bind to calf thymus DNA, using 
electrophoresis of [35S]-methionine labelled proteins eluted from a DNA- 
cellulose column (Kern et al., 1991a). Several mutant p53 proteins had 
reduced binding affinity and enhanced binding of both mutant or wild type 
varieties occurred when p53 protein molecules were treated with potato acid 
phosphatase to remove phosphate molecules which indicates that 
phosphorylation may restrict DNA binding by p53. A DNA sequence, 
5'ACGTTTGCCTTGCCTGGACTTGCCTGGCCTTGCCTT3', which binds 
p53 specifically was isolated by incubation of 32P end-labelled DNA 
fragments with lysates of cells overexpressing p53 from a viral promoter 
(Kern et al., 1991b). Also a consensus sequence of nucleotides for p53 binding 
has been defined as 5'GGACATGCCCGGGCATGTC3' and this sequence is
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capable of binding to p53 protein specifically, as determined by gel mobility 
shift analysis in the presence of competitor DNA (Funk et al., 1992). Thus 
there is much evidence for an intrinsic DNA binding capability of p53 protein 
and this is probably relevant to the function of this protein in vivo.
Deletion of the 47 C-terminal amino acids, but not the 70 N-terminal 
amino acids, obliterated the ability of murine p53 protein to bind to calf 
thymus DNA in the South-western binding assay, although in both cases the 
protein conformation was defined as "wild-type" due to affinity for the 
antibody PAb 246 (Foord et al., 1991). Recombinant, human p53 protein was 
shown to require a domain within the 90 carboxy-terminal amino acids in 
order to bind specifically to the p53 consensus sequence in the gel mobility 
shift assay, as deletion of this region abolished binding (Hupp et al., 1992). 
Thus a DNA binding domain of the p53 protein seems to reside at the C- 
terminal end of the protein, which is highly basic although it has since been 
suggested that there are several regions of p53 protein which may mediate 
DNA binding. A peptide encompassing amino acids 80-320 of p53 protein is 
able to bind DNA specifically, in the gel mobility shift assay, and forms only 
monomers as determined by gluteraldehyde crosslinking then SDS/PAGE, 
whereas a peptide representing amino acids 280-390 binds DNA non 
specifically and can form tetramers (Wang et al., 1993). This data, if relevant 
to p53 protein conformation in vivo, may have implications for whether p53 
oligomerization is necessary for DNA binding to take place.
The ability of p53 protein to bind a consensus DNA sequence, in the 
gel mobility shift assay, has been shown to increase in response to several 
drugs such as hydrogen peroxide, actinomycin D, adriamycin, etoposide, 
camptothecin, 5-fluorouracil, mitomycin C, cisplatin and ionising radiation 
(Tischler et al., 1993). This lends further support to the theory that p53 has a 
role to play in mediating the effects of chemotherapy and radiation therapy.
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1.5.2 THE ABILITY OF p53 PROTEIN TO ACTIVATE TRANSCRIPTION
The DNA binding affinity of p53 protein could indicate one of several 
physiological roles. For example it could be taken to suggest that p53 was 
involved in maintaining the structure of the DNA, or it could mean that p53 
was associated with processes such as replication of the genome, repair of 
aberrant nucleotides or transcription of certain specific genes. The 
transcriptional control function of p53 was first examined by use of chimeric 
proteins formed by fusion of p53 segments to regions of DNA binding 
proteins. When placed in a p53 null background, this allowed the 
measurement of transcriptional control separately from DNA binding function 
and overcame the obstacle of having to find genes which respond to 
transcriptional control by p53.
The use of GAL4-p53 fusion proteins, containing the GAL4 DNA 
binding domains which do not activate transcription alone, and varying 
amounts of human p53 protein, showed that the first 73 N-terminal amino 
acids of p53 were sufficient to direct transcription in yeast (Fields and Jang, 
1990). This was assessed by |3-galactosidase activity, produced from the lacZ 
gene, in a yeast strain which lacked GAL4 and had an integrated lacZ gene 
with a GAL4-binding promoter. Transfection of plasmids containing the 
GAL4-p53 sequences into CHO cells along with CAT reporter constructs 
which direct transcription of CAT activity under control of GAL4 binding 
sites confirmed that such activity was also possible in mammalian cells. Also, 
the 73 amino terminal residues of p53 protein were as potent at activating 
transcription as the VP16 protein, a highly active transcriptional regulator, 
from herpes virus. A similar study using CHO cells demonstrated that whilst 
the N-terminal 160 amino acids can activate CAT 17 fold, the entire p53 
protein sequence activates CAT 13 fold and the C-terminal 233 amino acids 
provide negligible activation of transcription (O'Rourke et al., 1990). As the 
N-terminal region shows greater activity than the whole molecule, there may
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be regulatory regions also present in the p53 protein structure. The N terminus 
of p53 is 20% acidic and as such, resembles that of other transcription factors 
for example Fos, GAL4 and the glucocorticoid hormone receptor. This is 
followed by a proline rich stretch which is also characteristic of transcription 
factors, being found in CTF, Fos, Jun, Oct-2 and SRF which are all involved 
in transcriptional control.
Two transforming mutants of p53, when fused to GAL4 DNA binding 
domains and transfected into HeLa cells, were unable to activate transcription 
of a CAT reporter construct (Raycroft et al., 1990). This suggests that 
transcriptional control by p53 protein is required for a normal, untransformed 
phenotype and that the loss of this ability by p53 protein may be the event 
responsible for the unregulated growth of cells lacking wild type p53. Further 
experiments using a range of human and murine p53 fusion proteins to 
activate CAT reporter constructs, in HeLa, CHO and NIH 3T3 cell lines 
demonstrated that many mutant p53 proteins have lost the ability to activate 
transcription (Raycroft et al., 1991). One mutant p53 protein however, which 
is found in Li-Fraumeni syndrome sufferers, contains a substitution at amino 
acid 245 and retains the ability to activate the reporter gene.
After the discovery of a p53 DNA binding consensus sequence, it was 
possible to directly assess p53 transcriptional tfwisactivation by using reporter 
gene constructs inserted downstream of this in a plasmid vector. These studies 
demonstrate that intact p53 protein is able to direct transcription of genes 
alone and the transcriptional activity reported for fusion proteins is not an 
artefactual result of using an artificial system. A 33bp sequence, which had 
been shown to bind p53, was able to direct transcription of p-galactosidase in 
Saccharomyces cerevisiae when wild type human or murine p53 was also 
expressed, from a different plasmid (Scharer & Iggo, 1992). Cotransfection of 
a CAT reporter system with a human p53 expression plasmid, into the human 
colorectal cancer cell line, HCT 116, showed that wild type, but not mutant,
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p53 activates transcription from its binding site and that activity increases with 
increasing numbers of binding sites in the reporter construct (Kem et al.,
1992). A mutated p53 binding site was unable to direct transcription. The 
luciferase gene has also been placed downstream of a p53 DNA binding 
consensus sequence or the "fragment A" p53 binding sequence and luciferase 
activity was observed on transfection of such constructs into a p53 null cell 
line, HI 299. A requirement for the C-terminal DNA binding regions of p53 
protein in order to permit transcriptional /7ms,activation has been examined by 
the use of three human p53 deletion mutants incorporating amino acids 82- 
393,160-393 or 1-326, and found to depend on the binding site used (Zhang et 
al., 1994a).
1.5.3 REGULATION OF p53 MEDIATED TRANSCRIPTIONAL 
77MAtfACTIVATION
Regulation of the DNA binding and transcriptional tamsactivation 
functions of p53 protein may be performed by interaction with proteins or by 
post translational modifications such as phosphorylation. Proteins which 
complex with wild type p53 such as SV40 large T antigen and mutant p53 are 
able to prevent site specific DNA binding by wild type p53 protein as 
measured by gel mobility shift analysis (Bargonetti et al., 1992). A CAT 
reporter construct whose expression was driven by several copies of the p53 
binding motif, 5'TGCCT3', was used to show that wild type SV40 large T 
antigen or HPV-16 E6 oncoprotein were able to prevent p53 mediated 
transcriptional regulation probably by causing its rapid degradation before p53 
was able to carry out transcriptional transactivation (Mietz et al., 1992). 
Native cellular proteins may operate in a similar way to modulate p53 activity. 
It has also been reported that E6 proteins from HPV-6 and HPV-11 are able to 
prevent p53 mediated transactivation of CAT activity and that they may also 
interact with p53 protein, albeit more weakly than the "high risk" HPV viruses
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(Crook et al., 1994). These HPV viruses do not enhance degradation of the 
p53 molecule. MDM2 protein has been shown to inhibit p53 associated 
transcriptional control and, as mentioned in section 1.4.3, the different splice 
variants of this protein may be responsible for controlling p53 activity in a 
sophisticated manner.
It has been suggested that p53 requires activation for DNA binding, 
for example by CKII phosphorylation (Hupp et al., 1992). However mutation 
of the proposed CKII site on the p53 molecule did not alter its DNA binding 
affinity (Rolley and Milner., 1994). Reduced phosphorylation may be 
important as potato acid phosphatase activated DNA binding by p53 protein 
(Kern et al., 1991a). However, okadaic acid, a phosphatase inhibitor, was able 
to reduce p53 mediated transcriptional transactivation and yet increase DNA 
binding (Zhang et al., 1994b). Possibly such experiments are too crude to 
provide insights into the possibly contradictory effects of phosphate groups at 
different sites on the p53 molecule.
1.5.4 GENES WHICH BIND AND/OR BECOME 7KA/V5ACTIVATED BY 
p53 PROTEIN
activation of the transcription of specific genes by p53 probably 
occurs by p53 binding to a DNA site similar to the consensus sequence in 
vivo. This would then assist the binding of further proteins involved in the 
production of mRNA. A region from 3300-2800bp upstream of murine muscle 
creatine kinase (MCK) has been shown to respond to transcriptional 
/ra/zsactivation by wild type murine p53 protein (Weintraub et al., 1991). A 
50bp region within this element was identified as important for human and 
murine p53 binding by DNase I footprinting and, when placed upstream of a 
minimal promoter adjacent to a CAT gene, it conferred p53 responsiveness so 
CAT activity was induced by p53 (Zambetti et al., 1992). Wild type human 
and murine p53 proteins have been shown to activate transcription of a CAT
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construct placed downstream of a human ribosomal gene cluster (RGC) DNA 
sequence in vitro using transcription factors from HeLa nuclear extracts 
(Farmer et al., 1992). The region of this element to which p53 binds has also 
been mapped by DNase I footprinting.
The GADD45 gene, which is also induced by DNA damaging agents 
such as ionising radiation (Papathanasiou et al., 1991), has been shown to 
contain a p53 responsive element (Kastan et al., 1992). Normal lymphoblasts, 
fibroblasts and tumour cells with a wild type p53 gene showed between 2 fold 
and 9.9 fold induction of GADD45 mRNA following a 20Gy ionising 
radiation dose whereas cells lacking a wild type p53 protein due to point 
mutation or deletion do not exhibit greater than 1.4 fold induction. This 
correlated with the ability of these cell lines to arrest in G1 phase of the cell 
cycle following irradiation. A 20bp DNA sequence with identity to the p53 
consensus binding sequence in all but one nucleotide was found in the third 
intron of the GADD45 gene and this fragment was shown to have affinity for 
p53 by gel mobility shift and by coimmunoprecipitation of a radiolabelled 
oligonucleotide containing the putative p53 binding site. MDM2 mRNA is 
induced in fibroblast cells by ionising radiation so long as the endogenous p53 
gene is wild type, not mutated or deleted (Price and Park., 1994). Northern 
blotting shows that MDM2 transcription increases rapidly in cells containing 
a temperature sensitive mutant p53 protein when the temperature drops from 
37.5°C to 32.5°C, where p53 is in its wild type conformation (Barak et al.,
1993). This induction occurs even in the presence of cycloheximide, 
indicating a direct interaction with the p53 protein. A region downstream of 
exon 1 in the MDM2 gene has p53 binding activity as demonstrated by its 
ability to direct p53 dependent transcription of a CAT gene (Juven et al.,
1993). This may affect not only the level, but also the range, of MDM2 
transcripts. P53 protein was able to coimmunoprecipitate an end labelled 
oligonucleotide corresponding to this region.
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The p53 protein is able to bind to a region from +22 to +67 
nucleotides within its own gene in gel mobility shift assays and to direct 
transcription of a CAT reporter gene linked to thep53 promoter (Deffie et al.,
1993). A mutant p53 protein was found to lack this activity. The cyclin G gene 
also seems to respond to p53 protein. Mouse embryonic fibroblasts from a p53 
deficient mouse showed a more than 10 fold reduction in the level of cyclin G 
mRNA when compared to embryonic fibroblasts from a wild type mouse 
(Okamoto and Beach, 1994). A fragment from 1.5kb upstream of the cyclin G 
gene was shown to have affinity for p53 by coimmunoprecipitation of the end 
labelled oligonucleotide and by gel mobility shift analysis. It was also able to 
carry out p53 mediated transcription of a luciferase gene when inserted 
upstream of it in a plasmid construct. This may have implications for the 
effects of p53 protein on cell cycle regulation, although the specific function 
of cyclin G has yet to be elucidated.
Another cell cycle associated gene which p53 regulates is WAF-1 or 
CIP-1 as it is otherwise known. This gene was identified by a subtractive 
hybridisation approach using dexamethasone inducible p53 protein in a colon 
cancer cell line (El-Deiry et al., 1993). It was also simultaneously discovered 
due to the association of the gene product, p21, with cyclin dependent kinase 2 
(cdk2) when cDNA for the gene was expressed in yeast. This was detected 
using a system whereby binding of a protein to cdk2 activates transcription of 
HIS3 and lacZ genes on a reporter plasmid (Harper et al., 1993). WAF-1 
inhibits phosphorylation by cyclin A-cdk2, cyclin E-cdk2 and cyclin Dl-cdk4 
of proteins such as the Rb gene product, which behaves as a negative regulator 
of growth when hypophosphorylated. This may prove to be one manner by 
which p53 exerts its effects on the cell cycle as these cyclins are associated 
with the G1 to S phase transition. Induction of WAF1 seems to occur during 
p53 mediated G1 arrest and apoptosis as demonstrated using a dexamethasone 
inducible p53 gene, but not in cells with a mutant p53 gene or cells which
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undergo apoptosis by a p53 independent pathway (El-Deiry et al., 1994). 
During radiation induced G1 arrest, accumulation of cyclin A was blocked, 
cyclin E accumulated but was inactive as a kinase and the responsible 
molecule was shown to be the WAF-1 gene product (Dulic et al., 1994). 
Removal of p21 from irradiated cell lysates, using a p21 specific antibody 
attached to protein A beads, prevented inhibition of cyclin E activity as 
measured by phosphorylation of histone HI. Cyclin E is normally activated in 
late G1 and is thought to be involved in making the commitment to enter S 
phase. Thus the p21, WAF-1 gene product may be an important mediator of 
p53 function.
1.5.5 GENES WHICH ARE REPRESSED BY p53 PROTEIN
Certain genes respond to p53 transcriptional control by repressing the 
level of mRNA transcripts produced. Serum stimulation of the CAT gene, 
under control of the interleukin 6 (IL-6) promoter, in HeLa cells was repressed 
by transfection with wild type murine or human, but not mutant p53 
(Santhanam et al., 1991). Wild type mouse p53 has been shown to repress 
transcription from the SV40 enhancer promoter as determined by use of a 
CAT reporter gene in HeLa cells (Jackson et al., 1993). A temperature 
sensitive mutant p53 has been used to show that wild type p53 can repress 
transcription from c-fos as determined by Northern blotting and activation of a 
CAT gene downstream of the c-fos promoter (Ginsberg et al., 1991). Also data 
was presented showing that p53 repressed CAT constructs containing 
promoter regions from the p53, c-jun, |3 actin and hsc70 genes but not the 
MHC promoter. This agrees with other data showing p53 mediated repression 
of the gene encoding Hsp70 protein. It does conflict however, with data 
showing an activation of thep53 promoter by p53 protein (Deffie et al., 1993).
P53 protein can repress transcription from a minimal promoter 
probably by interfering with the action of the TATA binding protein (TBP).
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TBP, immobilised on Affi-Gel beads to produce an affinity column, was used 
to show that wild type p53 protein has TBP binding activity (Seto et al., 1992). 
The p53 protein is thereby able to inhibit the transcriptional transactivation 
activity of TBP. This was demonstrated by heat inactivation of the 
transcription factor, TFIID, in HeLa extracts. Human TBP could partially 
rescue the defective transcription which resulted but this rescue capacity was 
negated by incubation of wild type p53 protein with TBP prior to inclusion in 
the transcription reaction. Another transcriptional regulatory protein which 
p53 binds is the CAAT binding factor (CBF) as was shown using an affinity 
column consisting of glutathione S transferase-CBF attached to glutathione 
agarose (Agoff et al., 1993). Coimmunoprecipitation was also used to 
demonstrate this interaction.
The MDR1 gene has been shown, using CAT reporter constructs, to be 
activated 7-180 fold by mutant p53 protein but repressed by wild type p53 
protein (Chin et al., 1992). CAT constructs and a temperature sensitive p53 
mutant were used to demonstrate that p53 can repress transcription from the 
Rb gene (Shiio et al., 1992). Deletion of the Rb gene enabled the responsible 
cis acting element to be defined as the sequence, 5GGAAGTGA3'. Regions 
from both the amino and the carboxyl terminals of p53 were important for this 
transcriptional repression. Northern and Western blotting both demonstrate 
that wild type p53 protein enhances expression of bax and represses 
expression of bcl-2 in a murine leukemia cell line transfected with a 
temperature sensitive mutant p53 protein which is in the mutant conformation 
at 37°C and is functionally wild type at 32.5°C (Miyashita et al., 1994a). 
Immunohistochemistry and Western blotting confirmed that levels of these 
two proteins are altered in a consistent manner in tissues from mice which are 
deficient in wild type p53. Also a 195bp DNA sequence from a region 
comprising -279 to -85bp upstream of the bcl-2 transcriptional start site was
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able to confer p53 dependent repression when inserted adjacent to a CAT 
reporter gene on a plasmid (Myashita et al., 1994b).
1.6 DNA DAMAGE RECOGNITION PROTEINS (DRPs) IN 
CISPLATIN RESISTANCE
1.6.1 THE DNA BINDING SIGNAL
In order for ceils to respond to DNA damage either by repair of the 
damage or by apoptosis, the DNA adducts must be recognised. The p53 
protein might directly bind to the damaged DNA and this might effect some 
alteration in p53 activity. Alternatively another protein may transduce the 
signal from the site of damage to the p53 molecule. For example, p53 protein 
has been shown to be phosphorylated by a DNA dependent protein kinase 
(Lees-Miller et al., 1990) and this modification occurs within a region which 
is thought to be important in /raws-activation of transcription by p53 (Lees- 
Miller et al., 1992). Such a kinase could be the link between DNA damage and 
a p53 DNA damage response pathway. Proteins which recognise DNA 
adducts may be involved in the initial stages of such a pathway or may be part 
of an alternative DNA damage response mechanism.
Obvious roles for DNA damage recognition proteins (DRPs) in drug 
tolerance would be as repair proteins or proteins which can bind to both the 
site of DNA damage and a repair protein at once, thereby recruiting repair 
proteins to the region of damaged DNA. Also, proteins which bind to 
damaged DNA could be irrelevant proteins which serendipitously minimise 
the DNA distortion caused by the adduct thereby allowing the normal 
interaction of proteins involved in DNA replication and transcription. It is 
possible that certain DRPs are replicative or transcriptional proteins which are 
trapped on the DNA by the adduct. In which case they may be irrelevant to 
drug resistance although they may enhance toxicity of the drug by protecting 
the damage site from recognition by repair enzymes or they could be titrated
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away from their own natural site of action and this might affect cisplatin 
toxicity. Such proteins may include the human upstream binding factor 
(hUBF), a 94-97KDa protein involved in transcription of ribosomal RNA 
(Treiber et al., 1994). Proteins which are involved in maintaining the 
chromatin structure such as histones could also become attached to the 
damage site. Although such an interaction may not be significant for drug 
resistance, gross alterations in the levels or activity of such proteins might 
influence the access of drugs to the DNA and so affect the levels of DNA 
damage. However such proteins would be unlikely to show specificity for 
cisplatin-damaged DNA.
1.6.2 THE DETECTION OF DRPs
Proteins which recognise cisplatin-damaged DNA were detected by gel 
mobility shift analysis in the human, ovarian carcinoma cell lines A2780 and 
2008 but there was no increase of binding activity in cisplatin resistant 
derivatives of these cell lines compared to sensitive parentals (Andrews & 
Jones, 1991). Also, no differences in levels of cisplatin DRPs were detected 
between the CHO ceil line AA8 and cisplatin hypersensitive derivatives UV4 
and UV5. However, lower levels of DRP activity were detected in the kidney 
cell lines, MDCK and LLC-PK when compared to 2008 cells which are more 
cisplatin sensitive. DRPs of 26, 28 and 97KDa were detected with the same 
cisplatin-damaged probe on South-western blotting of 2008 cells and 
2008/Cl 3*, the cisplatin resistant derivative.
A cisplatin DRP of approximately lOOKDa was identified in human 
HeLa cell extracts by South-western blotting (Toney et al., 1989). This DRP 
has apparent specificity for the intrastrand d(GpG) and d(ApG) adducts 
(Donahue et al., 1990). In order to isolate the gene encoding this DRP, a 
library of DNA fragments prepared from human B cells was screened by 
expression of these fragments from X phage vector in Escherichia coli
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bacterial cells. Out of three hundred and sixty thousand phage plaques, only 
two showed affinity for a radiolabelled, cisplatin damaged DNA probe. These 
two contained regions of the same gene and this was used as a probe in 
Northern blotting of RNA from HeLa, hamster V79 and murine L1210 cells. 
A mRNA species of 2.8kb was detected in each case. This gene was shown to 
be expressed in brain, heart, ileum, jejenum, kidney, liver, muscle and spleen 
by Northern blotting of tissues derived from baboon but there was no increase 
of mRNA expression on acquisition of cisplatin resistance as determined by 
Northern analysis of HeLa cells selected in vitro for cisplatin resistance 
(Bruhn et al., 1992).
A 125KDa UV-damage specific nuclear protein, UVBP1, has been 
purified from HeLa cells by FPLC and phosphocellulose chromatography (van 
Assendelft et al., 1993). It seems to be specific for the 6-4' (pyrimidine-2'- 
one) type of pyrimidine dimer rather than the cyclobutane form as it binds 
more efficiently to a substrate containing one UV damage site at a TC pair of 
nucleotides rather than at a TT, CT or CC sequence. Also DNA photolyase 
was unable to reduce DNA binding by this factor when incubated with the 
DNA before addition of UVBP1. This protein exhibited no cross reaction with 
cisplatin-damaged DNA.
1.6.3 DRPs WITH ALTERED EXPRESSION IN CELLS RESISTANT TO 
CHEMOTHERAPY AND/OR RADIOTHERAPY
DRPs with altered expression on development of cisplatin resistance 
are of particular interest as this indicates a possible direct involvement in 
cisplatin resistance. DRPs whose expression is altered when they become 
resistant to other DNA damaging agents are also interesting as there may be 
some degree of cross-talk between different DRPs. The DRPs concerned may 
not necessarily be exclusive to one form of DNA lesion. Also effects 
downstream of damage recognition may converge to a similar response 
mechanism. Even if DRP levels are not significantly altered between resistant
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and sensitive cells, this does not mean that a DRP response mechanism is not 
involved in cisplatin resistance. If DRPs do not represent a rate limiting step 
in the damage response mechanism, it may be that factors involved in 
subsequent stages are altered in cisplatin resistant lines instead.
A cisplatin resistant HeLa derivative, selected by stepwise exposure 
to cisplatin doses up to 8pM, showed increased expression of two DRPs when 
compared to sensitive HeLa cells (Chao et al., 1991a). These proteins were 
130KDa and 95KDa in size and were identified by South-western blotting 
with a cisplatin treated DNA probe. These proteins were inducible with a 4 
hour, 3pM cisplatin dose and cross-reacted with UV damaged DNA. Also a 
25KDa protein band was detected with reduced expression in the resistant cell 
line and after cisplatin treatment of the sensitive cell line. Using the gel 
mobility shift assay two bands of retardation activity were seen for cisplatin 
damaged DNA and a further two bands were seen for a UV damaged DNA 
probe. These DRPs have been further characterised and found to be mainly 
nuclear, protease sensitive and independent of RNA (Chao et al., 1992). 
Increased DRP activity has been found by other investigators for cisplatin 
resistant, compared to sensitive, HeLa and HT1080 cell lines (Chu & Chang, 
1990).
A protein whose expression correlates with cisplatin sensitivity has 
been found in Saccharomyces cerevisiae (Brown et al., 1993). This protein is 
encoded by the IXR1 gene and inactivation of the gene conferred increased 
resistance to cisplatin. The mutant strain was twice as resistant to a 2 hour 
cisplatin dose in the concentration range 50-1000pM but no difference in 
transplatin toxicity was detected. This was probably due to reduced 
accumulation of cisplatin induced DNA lesions as these appeared to be 
reduced to a third of the levels seen in cells which contained an active IXR1 
gene. This yeast species appears to have several cisplatin DRPs of 100, 80, 55 
and 20KDa in size as detected by South-western blotting. The 80KDa protein
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is missing from an ixrl strain and thus probably represents the IXR1 gene 
product. The predicted amino acid sequence of this protein contains several 
long stretches of asparagine and glycine residues which is often seen for 
transcription factors and it has 56 identical residues to ABF2, the ARS- 
binding factor, in a 151 amino acid sequence.
A cisplatin resistant cell line contains increased levels of two UV 
specific DNA binding proteins by comparison to a cisplatin sensitive line 
using the gel mobility shift assay (Chao et al., 1991c). These cells also showed 
cross resistance to UV light compared to their parentals. The human ovarian 
carcinoma cell line, OvlP contains four DRPs of 25, 48, 70 and 97KDa from 
Western blotting and the levels of the 97KDa and 48KDa proteins are elevated 
in a cisplatin resistant derivative, OvlPDDP (McLaughlin et al., 1993). 
Several bladder and testicular cell lines were also examined for expression of 
these proteins as bladder cells are known to be more tolerant of cisplatin than 
testicular cells. Bladder cells expresses more 25KDa protein whereas testicular 
lines seem to express more 70KDa protein. Neither of these cell types 
expressed much 97KDa protein and the 25KDa DRP seemed to be present as a 
doublet rather than one discrete band.
South-western blotting of HeLa cells shows repression of a DNA 
binding protein along with induction of several DRPs in cisplatin resistant 
HeLa extracts compared to extracts from sensitive HeLa cells (Chao et al., 
1991b). Also 2 dimensional gel electrophoresis showed reduction of at least 
four nuclear proteins in the resistant and cells levels of these were relatively 
enhanced in cells which had reverted to a cisplatin sensitive phenotype and 
which had reduced repair capacity.
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1.6.4 DRPs ASSOCIATED WITH DNA REPAIR PROCESSES
An obvious reason why DRPs could be involved in cisplatin resistance 
is that they might be repair proteins or proteins which recruit repair proteins to 
sites of DNA damage so DRPs which are linked to repair processes are 
especially interesting. Cisplatin resistant HeLa cells selected by exposure to 
doses of cisplatin up to 8pM exhibit enhanced DNA repair activity as detected 
by their ability to repair a damaged CAT reporter gene and thus give rise to 
measurable CAT activity (Chao et al., 1991d). These cells also contained 
increased UV specific DRP activity as determined by an increase in the 
intensity of the band observed on gel mobility shift analysis. This factor did 
not cross react with cisplatin damaged DNA in competition experiments 
unless competitor was added at excessive levels, although another DRP was 
observed on gel mobility shift analysis using radiolabelled, cisplatin damaged 
DNA as a probe. Likewise this DRP activity could only be competed for by 
adding high levels of UV damaged probe. The increased repair in these cells 
was later shown to correlate with enhanced recognition and incision of DNA 
adducts but not elevated repair synthesis (Chao et al., 1993).
An absence of DRP activity has been found in cells from patients 
suffering from the disease xeroderma pigmentosum group E (Chu & Chang, 
1988). There are seven complementation groups for this DNA repair 
deficiency syndrome, which have been defined by the use of cell fusion 
studies. HeLa cell nuclear, but not cytoplasmic, extracts were shown to give 
rise to two retarded bands when subjected to the gel mobility shift assay using 
UV damaged DNA and they also had affinity for cisplatin damaged DNA 
from competition of DRP activity with unlabelled, cisplatin-damaged DNA. 
The upper band had 10 fold higher affinity for damaged than undamaged 
DNA and the lower band had 100 fold greater affinity for damaged DNA. 
Both of these bands were absent from xeroderma pigmentosum
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complementation group E cells but not from cells from the other 
complementation groups examined and so the binding activity was referred to 
as XPE binding factor.
It was postulated that the DRP activity which was missing in the 
human, xeroderma pigmentosum complementation group E cells might be a 
homologue of Saccharomyces cerevisiae photolyase. This was based on their 
similar affinities for DNA damaged by various agents, intracellular 
localisation, dependence on magnesium ions and their abundance relative to 
genome size (Patterson & Chu, 1989). Yeast nuclear extracts contained DRP 
activity which gave rise to two bands on gel mobility shift analysis, in a 
similar manner to that seen for HeLa nuclear extracts. This activity was not 
found for nuclear extracts from yeast cells mutant for the phrl gene. However 
the two bands differed in mobility between the two species and human DRP 
activity did not respond to light as yeast DRP did. When the yeast gel mobility 
shift assay was incubated in the presence of light, reduced DNA binding 
activity was detected compared to an assay incubated in the dark. This is 
consistent with dissociation of yeast photolyase from the DNA following light 
stimulated repair of DNA damage.
The photolyase enzyme uses visible light, absorbed through associated 
chromophores, as an energy source to repair pyrimidine dimers, a UV specific 
DNA lesion. Expression of this protein is induced by various DNA damaging 
agents as determined by use of a PHRl-lacZ fusion construct transfected into 
yeast cells and by Northern blotting (Sebastian et al., 1990). As yeast cells are 
more amenable to genetic manipulation than those of higher eukaryotes, 
elucidation of DNA damage response mechanisms within such organisms may 
provide information relevant to analogous mammalian pathways. The XPE 
binding factor showed increased expression in HeLa and HT1080 human 
fibrosarcoma cells selected for cisplatin resistance in vitro as compared to the 
original, sensitive cell lines (Chu & Chang, 1990). Resistant HT1080 cells
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were also examined for DNA repair capacity by use of a cisplatin damaged 
CAT reporter construct. They displayed increased CAT activity, indicative of 
increased repair, compared to the parental cell line. A further DRP was also 
identified in HeLa nuclear extracts. This factor, named CCD due to affinity for 
cisplatin crosslinked DNA had specificity for cisplatin damaged DNA and so 
neither UV damaged or single stranded DNA could compete for binding by 
this factor on gel mobility shift analysis. This was unlike the XPE binding 
factor which possessed affinity for all three of these DNA types but not for 
double stranded DNA. A DRP which is inducible by UV, mitomycin C or 
aphidicolin and absent in xeroderma pigmentosum group E extracts, was 
observed using the gel mobility shift assay (Hirschfeld et al., 1990). This 
factor was observed in the monkey kidney cell line, CV-1 and may be 
homologous to the XPE binding factor.
Another DRP associated with xeroderma pigmentosum has been 
identified (Robbins et al., 1991). This 40-42KDa protein has 1000 fold greater 
affinity for UV damaged than undamaged DNA as determined by retention of 
DRP-radiolabelled DNA complexes on nitrocellulose filters. Cell extracts 
were assayed for DNA damage repair ability by incorporation of radiolabelled 
ATP into UV-damaged plasmid DNA followed by electrophoresis of plasmid 
DNA. This was used to demonstrate that deficient repair in xeroderma 
pigmentosum group A extracts could be complemented by addition of the 
purified 40-42KDa protein.
The product of the DNA repair gene, ERCC1 has a helix-tum-helix 
motif indicating DNA binding capacity and this may represent another DRP. 
This gene appears to be expressed at 2.6 fold higher levels in patients with 
cisplatin resistant tumours compared to patients with cisplatin responsive 
tumours (Dabholkar et al., 1992). The ERCC1 gene was identified due to its 
ability to complement repair deficiency in UV sensitive CHO cells. The 
ERCC1 has some degree of homology to the RADIO gene from yeast which is
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involved in DNA repair (van Duin et al., 1986). There is therefore, a possible 
role for DRPs in cisplatin resistance and as such they warrant further 
investigation.
1.7 AIMS OF THIS THESIS
The aims of this thesis are to molecularly define some of the possible events 
leading from cisplatin-induced DNA damage to cell cycle arrest and cell 
death.
1) In this thesis an attempt will be made to examine differences in p53 
protein expression in cisplatin sensitive and resistant cells.
2) Alterations in p53 transcriptional activity in these experimental 
models will also be characterised as this may have relevance to DNA damage 
induced apoptosis and the development of cisplatin resistance.
3) A scheme for purification of a cisplatin DRP, which is active in the gel 
mobility shift assay, will be developed using extracts from human ovarian 
carcinoma cell lines.
4) The cisplatin DRP mentioned in 3) will be characterised in order to 
discover its identity and thus any possible relevance of this protein to cisplatin 
resistance.
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Chapter 2
CHAPTER 2: MATERIALS AND METHODS
2.1 MATERIALS
The following section lists routinely used materials. Less frequently 
used materials are described in the appropriate figure legends.
2.1.1 CHEMICALS
All chemicals were of the highest available quality and were obtained 
from BDH Chemicals Ltd, Gibco BRL, Pharmacia LKB or Sigma Chemicals 
except the following;
Acrylamide Severn Biotech, Kidderminster.
Phenol Rathbum, Walkerbum, UK.
2.1.2 RADIOCHEMICALS
(a32P)dCTP and (y32P)dATP for labelling probes were obtained from 
Amersham International pic.
2.1.3 EQUIPMENT
Routine equipment which would be an integral part of any laboratory is not 
listed.
1. Electroblotting System: Milliblot SDE, Millipore, Watford.
2. Gel Tanks: tanks for agarose & acrylamide gels were from IBI Ltd, 
Cambridge & Biorad Labs Ltd, Watford, Hertfordshire.
3. Hybridisation membranes: Hybond-N, Amersham International. 
Nitrocellulose 0.45um, Schleicher & Schuell via Anderman Lab Supplies, 
Kingston-upon-Thames. Immobilin-P, Millipore, Bedford.
4. Hybridisation Oven & Bottles: Hybaid Ltd, Middlesex.
5. Laser densitometer: autoradiographs were analysed at a SUN workstation 
using a Molecular Dynamic Densitometer and PDI Quantitation 1 software.
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6. Chromatographic protein separations were performed on FPLC equipment 
from Pharmacia Ltd or on a "Waters" HPLC system from Millipore Ltd.
2.1.4 RESTRICTION ENDONUCLEASES & OTHER ENZYMES 
Restriction Enzymes
The majority of restriction endonucleases (RE) were from Pharmacia 
Ltd, Boeringer Mannheim Corporation or Northumbria Biologicals. Bulk 
ordering of RE's by the Department meant that the same "brand" of RE could 
not be used throughout this work.
Other Enzymes
T4 Polynucleotide kinase Northumbria Biologicals
2.1.5 SIZE MARKERS
DNA size markers; Hind III digested phage X,BRL 
RNA size markers; 0.24 - 9.5kb RNA ladder, BRL 
Protein size markers; Prestained standards, 14,300-200,000, BRL.
2.1.6 BUFFERS, SOLUTIONS & MEDIA
Where mentioned, autoclaving was carried out at 121°C for 20 
minutes.
General Buffers & Solutions 
TMS
lOmM Tris (pH 7.5)
5mM MgCl2 
8.6% sucrose
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RNA Lysis Buffer 
0.3M Na acetate 
0.5% SDS
5mM EDTA. Made to pH8 with 10M NaOH then autoclaved.
TAE(lx) pH8 
40mM Tris base 
2mM EDTA 
20mM NaCl 
20mM Na Acetate
TBE(lx) pH8 
89mM Tris borate 
89mM Boric acid 
2.5mM EDTA
BLOTTO (lx)
50mM Tris (pH 7.5)
50mM NaCl 
ImMEDTA
Spacer gel Buffer 
0.5M Tris 
4% SDS
Running Buffer 
1.5M Tris
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4% SDS
Storage Buffer (SB)
50mM NaCl
20mM Hepes
5mM MgCl2
0. ImMEDTA
20% glycerol
ImM DTT (added fresh)
TE
lOmM Tris 
ImM EDTA
High Salt Lysis Buffer 
500mM NaCl 
1% NP-40 
50mM Tris (pH 7.5)
ImM DTT (added fresh) 
protease inhibitors lx (added fresh)
Protease Inhibitors (lOOx)
0.1 mg/ml aprotinin 
0.1 mg/ml pepstatin 
0.1 mg/ml chymostatin 
0.05M benzamidine 
0.05M PMSF 
0.1 mg/ml leupeptin 
These were stored at -70°C
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TNE-50 (lOx) 
lOmM Tris pH 7.5 
50mM NaCl 
ImM EDTA 
ImM DTT (added fresh)
Tank Buffer 
0.26M Tris 
2% glycine 
0.5% SDS
Phosphate Buffered Saline (PBS)
0.8% NaCl 
0.115% Na2H P04 
0.02% KC1 
0.02% KH2 P04
Denaturation Buffer (for Southern blotting) 
0.5M NaOH 
1.5M NaCl
Neutralisation Buffer (for Southern blotting) 
1M Tris 
1.5M NaCl 
pH to 7.4 with HC1
Formaldehyde Gel Running Buffer
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0.1M MOPS (pH 7)
40mM Na acetate 
5mM EDTA
Loading Buffers
Dye Mixture
30% w/v Glycerol
0.25% w/v Bromophenol blue
0.25% w/v Xylene cyanol
Formaldehyde Gel Loading Buffer (for Northern blotting) 
50% glycerol 
ImM EDTA (pH 8)
0.25% bromophenol blue 
0.25% xylene cyanol FF
Acrylamide Gel Loading Buffer
80% Formamide
lxTBE
ImMEDTA
0.1% Xylenecyanol
0.1% Bromophenol blue
Western Loading Buffer(x5)
0.25M Tris (pH 8)
10% SDS
lOmM EDTA
50% glycerol
0.25% bromophenol blue
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0.25% xylene cyanol FF 
Transfer solutions
Phosphate buffer "Genescreen"(20x), used to transfer both RNA & DNA. 
0.5M Na2HP04 
0.5M NaH2P04
Transfer Buffer (for proteins)
48mM Tris base 
39mM Glycine 
0.037% (v/v) SDS 
20% methanol
Hybridisation Solutions
Hybridisation mix (for Southern and Northern blotting)
50mM Pipes 
lOOmM NaCl 
50mM Na2PG4 
50mM NaH2P 0 4 
ImM EDTA 
5% SDS
South-western Binding Buffer 
30mM Hepes 
lOmM MgCl2 
2mM MnCl2 
0.25% marvel
Tissue culture media
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RPMI
88 ml RPMI-1640 (lOx) from Gibco BRL
800ml sterile distilled water
26.6ml 7.5% Na(C03)2
10ml lOOmM Na pyruvate
10ml 200mM L-glutamine
lml 1M NaOH
100ml foetal calf serum
Dulbecco's Modified Eagles media (DMEM)
50ml Dulbecco's MEM (10X) from Gibco BRL
400ml sterile distilled water
5ml lOOmM Na pyruvate
5ml 200mM L-glutamine
25ml 7.5% Na(C03)2
Special Liquid Medium | (Gibco BRL)
500ml Special Liquid Medium 
50ml 200mM L-glutamine 
50ml foetal calf serum
2.1.7 CELL LINES
A2780 A human, ovarian adenocarcinoma cell line obtained
from R.F. Ozols and T.C. Hamilton, Fox Chase Cancer Center, Philadelphia. 
A2780cp70 A cisplatin resistant derivative of A2780.
For a more complete description of A2780 and A2780cp70 see Behrens et al., 
1987.
OvlP A human, ovarian adenocarcinoma cell line obtained
from J. Benard, Institut Gustav Roussy, France.
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OvlPDDP A cisplatin resistant line derived from OvlP.
For further information concerning OvlP and OvlPDDP see Teyssier et al., 
1989.
2.1.8 MONOCLONAL AND POLYCLONAL ANTIBODIES AND 
IMMUNOLOGICAL REAGENTS 
Monoclonal Antibodies
PAb419 A control antibody reactive against SV40 large T antigen
(Harlow et al., 1981).
PAb 240 A p53 mutant-specific antibody.
PAb DO-1 A pantropic anti-p53 antibody.
The three antibodies listed above were used for immunoprecipitation of p53 
protein. For a more detailed explanation of these reagents see Vojtesek et al, 
1992.
AB-2 A pantropic anti-p53 antibody derived from mouse and
purchased from Oncogene Science, Cambridge, used as a primary antibody on 
Western blots at a 1 in 1000 dilution.
Anti-HMGl This was a gift from Dr P. Billings, University of Pennsylvania. 
Anti-HMGI This was donated by Dr R. Reeves, Washington State
University.
IF2 An anti MDM2 antibody from Oncogene Science, Cambridge
which was used at a 1 in 1000 dilution for Western blots.
Anti-PCNA This was obtained from Boeringer-Mannheim, Germany and 
was used at a in 1000 dilution as a control antibody for Western-blotting. 
Anti-Hsp70 This was obtained from Sigma, Dorset and was used at a 1 in 
1000 dilution for Western blots.
Polyclonal Antibodies
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CM1 A polyclonal anti-p53 antibody from rabbit which was used as
a primary antibody for Western blotting at a 1 in 200 dilution. See Midgely et 
al., 1992 for further details.
Immunological Reagents
Anti-mouse Ig Horseradish peroxidase conjugate (from sheep). This was 
obtained from Amersham International and was used at a 1 in 5000 dilution in 
Western immunoblots.
Anti rabbit Ig Horseradish peroxidase conjugate (from mouse). This was 
obtained from Dako Ltd, Aylesbury, and used at a 1 in 150 dilution as a 
secondary antibody for Western blotting.
2.1.9 MOLECULAR PROBES
WAF-1 This 12.4 kb cDNA fragment was used for Northern blotting
and was derived from the plasmid, pCEP-WAF-l-S (El-Deiry et al., 1993).
GAPDH This 7.2 kb cDNA probe was obtained by digestion of the
construct, pCRII GAPDH (a gift from M. Walker, BICR) , and was used to 
normalize for loading on Northern blots. For further information on GAPDH 
seeTso et al., 1985.
Both of these probes were prepared by digestion of the plasmid, using the 
appropriate restriction enzymes. The DNA fragments were separated out by 
electrophoresis through an 0.8% (agarose , lx  TBE gel containing 
0.25pg/ml ethidium bromide at 150v for 2 hours using lx TBE as a buffer. A 
fragment of the expected size was visualised under UV and the appropriate 
agarose slice was cut from the gel. The slice was sealed, along with 400pl lx 
TBE, in a piece of dialysis tubing which had been pre-boiled for 10 minutes 
in autoclaved water. This was then placed in a tank of lx  TBE and subjected 
to electrophoresis at 50V for 75 minutes. The current was reversed for 1 
minute then reversed again for 30 seconds. The lx TBE, containing the DNA,
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was removed from the tubing, the DNA was recovered by ethanol 
precipitation and resuspended in TE.
2aG7 This 54bp DNA probe was used in platinated and non-
platinated forms in the gel mobility shift assay. For a more detailed 
description see K. McLaughlin, PhD thesis, Glasgow University, also 
McLaughlin et al., 1993.
2.2 EXTRACTION OF NUCLEIC ACIDS & PROTEINS
All work with RNA & DNA was carried out using autoclaved 
solutions & where appropriate DEPC treated solutions & equipment. 
Disposable gloves & plasticware were used throughout. DNA & RNA 
quantitation was performed using a combination of visual assessment on a 
0.8% agarose, lx TBE, 0.25mg/ml ethidium bromide gel when run against 
known standards and spectrophotometrically using O.D.260.
2.2.1 RNA EXTRACTION
Monolayer cultures were lysed in the flasks with TRIzol™, BRL. The 
extraction procedure followed the manufacturers instructions.
2.2.2 DNA EXTRACTION
Cell lines were lysed with 0.3M Na Acetate equilibrated phenol pH7.6. 
lOmls of phenol was used per 175cm2. An equal volume of RNA lysis buffer 
and chloroform isoamyl alcohol was added & the samples mixed for 20 
minutes. The samples were then spun at 3000g for 20 minutes at room 
temperature. The upper aqueous phase was collected & precipitated with an 
equal volume of isopropanol at 4°C for at least one hour. The DNA was spun 
down at 3000g for 20 minutes at 4°C, airdried then resuspended in sterile 
water. This procedure simultaneously extracts DNA & RNA.
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2.2.3 EXTRACTION OF NUCLEAR PROTEINS FROM CELL LINES
This protocol was carried out at 4°C and was adapted from Emerson 
and Felsenfeld., 1984. Cells were harvested during exponential growth, 
washed with RPMI, then ice cold PBS, osmotically swollen with a TMS wash 
and lysed with 0.25% TRITON X-100. NaCl was added to 0.3M, followed by 
spinning at 3,500g for 20 minutes. To the supernatant, 1/5 volume Glycerol 
Brj 35 and DTT to 1M was added, it was dialysed against storage buffer 
overnight and pelleted. The supematent was collected and stored at -70°C. 
Protein estimation was carried out using the Biorad kit method.
2.2.4 LYSIS OF MONOLAYER CELLS
Unless otherwise stated, cells were washed with PBS, then lysed at 
4°C for 10 minutes using high salt lysis buffer supplemented with lx protease 
inhibitors (section 2.1.6). The lysate was spun at 12000g for 10 minutes and 
the supernatant stored at -20°C. Protein content was estimated using the 
Biorad kit method and by comparison of gels stained with coomasie stain 
(0.2% coomasie brilliant blue R250 in a 50:50:7 v/v ratio of 
methanol:H20:glacial acetic acid) then de-stained using a 25:68:7 v/v ratio of 
methanol:H20:glacial acetic acid.
2.3 PREPARATION OF 32P RADIOLABELLED PROBES
With the exception of end labelled 2aG7 (see 2.3.1), all other probes 
were separated from unincorporated ^P-labelled nucleotides using disposable 
Sephadex containing "NICK" columns from Pharmacia.
2.3.1 PREPARATION OF PROBES USING AGAROSE GELS
10 picomoles of oligonucleotide were incubated with 12 units of T4 
polynucleotide kinase and 1.85 MBq of 32P y-ATP in One-Phor-All-Buffer- 
Plus at 37°C for 45 minutes. Samples were then electrophoresed on a IX
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TBE,0.8% agarose, non-denaturing gel for 90 minutes at 150V. The gel was 
exposed to Kodak XOMAT-AR film and the developed film was used as a 
template to remove the labelled oligonucleotide. This gel fragment was placed 
in a Spinex tube with 400pl distilled H20  overnight. The contents of the 
Spinex tube were spun down to separate the oligonucleotide and the gel 
fragment.
2.3.2. RANDOM PRIMING OF dsDNA
32P labelled dsDNA probes were produced with the aid of the 
"Prime-it" random primer kit from Stratagene. Between 50ng and lOOng of
I
template DNA was used and random primed usingaStratagene-recommended 
protocol.
2.4 SEPARATION & HYBRIDISATION OF NUCLEIC ACIDS
2.4.1 DIGESTION, SEPARATION & SOUTHERN TRANSFER OF DNA
Separation and transfer of DNA was essentially as described by 
Southern., 1975. 20pg of genomic DNA was digested for at least 16 hours in a 
total volume of 150pl using 150 units of restriction enzyme. The
digested DNA was then ethanol precipitated with 0.1 volume of 3M Na 
Acetate and 1 volume of isopropanol at -20°C for 1 hour. The DNA was 
pelleted by centrifugation at 13,000g for 15 mins followed by air-drying and 
resuspension in 25pl of sterile water. Resuspension continued overnight at 
37°C and then transferred to 4°C until use (usually within one week). 5pi of 
Dye Loading Buffer was added to the DNA and this was run on a 0.8%-1.2% 
TAE gel. Gels were run overnight at 50V using a buffer recirculation system. 
The next morning, gels were stained with ethidium bromide for 20 minutes to 
allow polaroid photography on a UV transilluminator. DNA was denatured for 
20 minutes in 1.5M NaCl/0.5M NaOH followed by neutralization in 3M 
NaCl/0.5M Tris-HCl pH7.0 for 30 minutes. The gel was then rinsed in 
Genescreen buffer (lx) and transferred onto either Genescreen or Hybond N
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membranes overnight using Genescreen buffer. The membranes were exposed 
to UV for 6 seconds to fix the DNA onto the membrane.
2.4.2 SEPARATION & NORTHERN TRANSFER OF RNA
Methodology for separation and transfer of RNA followed instructions 
in Sambrook et al., 1989. 0.8% (w/v) agarose gels were prepared by 
dissolving 2.4g of agarose in 187.5mls of water then cooling to 60°C. 54mls 
of 37% formaldehyde plus 59mls of gel running buffer (5x) were then added, 
mixed and immediately poured.To 20pg of total RNA in 5pl, lOpl formamide, 
7pi formaldehyde and 2pl of RNA gel running buffer were added . The 
samples were heated to 65°C for 10 minutes then chilled on ice before 
addition of 2pi RNA gel loading buffer and subsequent loading onto the gel. 
Gels were electrophoresed for 3 hours at 200V. The gels were photographed 
then soaked in 50mM NaOH for 20 minutes. They were rinsed with RNAse 
free water and soaked in Genescreen (lx) for 45 minutes prior to transfer onto 
Hybond N using Genescreen as the transfer buffer. Membranes were rinsed & 
exposed to UV as previously described for DNA transfer.
2.4.3 HYBRIDISATION OF SOUTHERN AND NORTHERN BLOTS
Hybridisations in hybridisation buffer (recipe in section 2.1.6) were 
carried out at 65°C (for a minimum of 16 hours) using a Hybaid oven and 
Hybaid roller bottle system.
2.4.4 WASHING FILTERS
Following non-formamide hybridisation, membranes were washed at 65°C 
using 1 x SSC plus 5% SDS for at least 90 minutes with a minimum of 3 
changes of wash buffer.
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2.4.5 AUTORADIOGRAPHY
Following washing, filters were blotted dry, wrapped in clingfilm and 
exposed to Kodak AR film in a film cassette with fast tungstate intensifying 
screens. Loaded film cassettes were held at -70°C until developed.
2.5 GEL SEPARATION & IMMUNODETECTION OF PROTEINS
2.5.1 SAMPLE PREPARATION
Protein extracts were prepared & quantified as detailed in section 
2.2.3, 2.2.4 or 2.6.5. 50-200pg of total protein was loaded per lane in western 
loading buffer after boiling for 3 minutes to facilitate denaturation .
2.5.2 GEL & RUNNING CONDITIONS
Denaturing protein gels were cast and run in the Protean gel tank 
system (Biorad).
8% acrylamide gels were prepared as follows;
8.6ml acrylamide (30% acrylamide with 0.8% bis acrylamide)
1.6ml polyacrylamide (1%)
8ml running buffer 
12.2ml H20
90pl ammonium persulphate (10%)
20pl temed (from Biorad)
This mixture was poured leaving a 3-4 cm gap at the top for the stacking gel; 
1.6ml acrylamide (30% acrylamide with 0.8% bis acrylamide)
1.2ml polyacrylamide (1%)
3ml spacer gel buffer 
6.2ml H20
250pl ammonium persulphate (10%)
20pl temed
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The proteins were electrophoresed through the stacking gel at 200v 
then the gel was run overnight at 50v in lx Tank buffer.
2.5.3 WESTERN TRANSFER OF PROTEINS BY ELECTROBLOTTING 
(Kyhse-Andersen et al., 1984)
Electroblotting was performed using a millipore semi-dry 
electroblotter. The Immobilin-P, Millipore membrane was wetted in methanol 
then transfer buffer; 6 sheets of 3M Whatmans filter paper was sandwiched 
next to the anode and cathode with the membrane and gel layered in between. 
Transfer took place over 1 hour at 200mA. The gel was then stained in 
Coomasie stain overnight and destained as described in section 2.2.4 . This 
allowed a visual assessment to be made of the evenness of the transfer and the 
integrity of the proteins.
2.5.4 SILVER STAINING OF PROTEIN GELS
Proteins were separated on a 5-15% acrylamide concentration gradient 
gel, pre-fixed with 50% methanol, 10% acetic acid for 1 hour, fixed for 30 
minutes in 10% gluteraldehyde and then washed in H20  for 2 hours. They 
were sensitized with 1M DTT for 1 hour, stained with silver nitrate for 1 hour, 
rinsed with water and developed using 3% sodium carbonate, 0.05% 
formaldehyde. The reaction was stopped with 5% acetic acid.
2.5.5 IMMUNODETECTION OF PROTEINS ON WESTERN BLOTS 
(adapted from Harlow and Lane.,1988)
Chemiluminescence method
Blocking, and all antibody dilutions, were in IX Blotto, 5% Marvel, 
0.01% Tween-20, ImM DTT. Washes were in PBS,0.01% Tween-20. All 
procedures were carried out at 4°C. Block was applied overnight followed by 
incubation with primary antibody overnight. The first wash in PBS, 0.01%
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Tween-20 was for 25 minutes with 3 changes of buffer. The second antibody, 
was applied for at least 2 hours. The second wash, for 25 minutes, had a 
further 3 buffer changes. The membrane was then incubated with a 
chemiluminescense substrate (ECL kit from Amersham) as per manufacturers 
instructions and exposed to radiographic film.
2.5.6 SOUTH-WESTERN TRANSFER OF PROTEINS (Bowen et al., 1980)
This protocol was essentially the same as for Western blotting 
(sections 2.5.1-4) with the following exceptions: Samples were
electrophoresed through a 5-15% acrylamide concentration gradient gel; 
proteins were transferred onto nitrocellulose membranes (blocking solution did 
not contain tween-20). After blocking, the membrane was washed twice with 
lx TNE-50 then placed in south-western binding buffer with lOpg/ml of poly 
(dI.dC):(dI.dC) and radiolabelled oligonucleotide (2x104 d.p.m./ml) for 90 
minutes; membranes were washed for 9 minutes in 30mM Hepes (pH 7.5), 
0.25% marvel. Then autoradiography was carried out as in section 2.4.5.
2.6 PROTEIN SEPARATION TECHNIQUES
2.6.1 TCA TREATMENT
TCA was added to crude nuclear extracts (see
section 2.2.3) to give a final concentration of 2%. This was incubated on ice 
for 30 minutes then spun in the microfuge at 12000g for 15 minutes. The clear 
supernatant was removed and (3-mercaptoethanol added to lOmM.
2.6.2 ANION EXCHANGE CHROMATOGRAPHY
Samples were de-salted using a sephadex G25 column. Buffer A was 
0.1M NaCl, 0.02M Tris (pH 7.6); buffer B was 2M NaCl, 0.02M Tris (pH7.6). 
The MonoQ™ column (from Pharmacia) was washed with 100% buffer A, 
0% buffer B then 100% buffer B,0% buffer A and finally, 100% buffer A, 0% 
buffer B. A gradient of 0% buffer B to 100% buffer B was set up. Proteins
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were eluted at 25-50% buffer B. Fraction volume was 2ml, collected at a 
speed of 1 ml/minute.
2.6.3 HEPARIN COLUMN CHROMATOGRAPHY
Buffer A was 0.1M NaCl, 0.02M Tris (pH 7.6); buffer B was 2M 
NaCl, 0.02M Tris (pH 7.6). The heparin-sepharose column (Pharmacia) was 
washed with 100% buffer A, 0% buffer B, then 100% buffer B, 0% buffer A 
and finally 100% buffer A, 0% buffer B. Samples were prepared as for 2.6.2. 
A gradient of 0% buffer B to 100% buffer B was set up. Proteins were eluted 
at 25-50% buffer B. Fraction volume was 1ml collected at a speed of 
lml/minute.
2.6.4 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
Buffer A was 0.1% TFA (tri-fluoro acetic acid) in H20  (pH 0.5); 
buffer B was 0.1% TFA in acetonitrile:H20  at a v/v ratio of 95:5 (pH 2.11). 
Buffers were degassed using helium. The Biorad Hipore butyl C4 silica-based 
reverse phase column (30nm pore, 4.6x250mm dimensions was equilibrated 
for 1 hour then purged. A gradient of 15% buffer B to 50% buffer B over 60 
minutes was set up. Buffer B then remained at 50% for 30 minutes. After the 
run was completed, buffer B rose to 100% over 30 minutes. A zinc lamp 
(214nm filter) was used for monitoring. Fraction volume was 1ml collected at 
a speed of lml/minute.
2.6.5 SEPARATION OF SPECIFIC PROTEINS BY 
IMMUNOPRECIPITATION (Harlow and Lane., 1988)
Monolayer cells were washed twice with PBS. 700pl of high salt lysis 
buffer was added per 175cm2 flask, cells were scraped off, mixed, left on ice 
for 30 minutes and mixed every 10 minutes then spun at llOOOg for 30 
minutes at 4°C. 15pl of protein G was added to the supernatant and this was
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rotated at 4°C for at least 40 minutes. After spinning at llOOOg for 5 minutes 
at 4°C, lpg of antibody was added to the supernatant and this was left 
overnight at 4°C. 20pl of protein G was added and after 40 minutes, it was 
spun at llOOOg for 1 minute at 4°C, the pellet washed three times with high 
salt lysis buffer then resuspended in lx western loading buffer. This was 
boiled for 8 minutes at 1 lOOOg and the supernatant stored at -20°C.
2.7 TISSUE CULTURE TECHNIQUES
2.7.1 GENERAL TECHNIQUES
Asceptic manipulations were performed using sterilised glassware in a 
class II microbiological safety cabinet with vertical airflow. Cells were grown 
at 37°C as monolayers in supplemented RPMI (Rosswell Park Memorial 
Institute) medium in the presence of 5% C 02. They were stored by freezing 
lxlO6 cells/ml, along with 10% di-methyl sulphoxide (DMSO), at -70°C then 
they were maintained in liquid nitrogen. For RPMI supplements see page 49.
2.7.2 CLONOGENIC ASSAY
103 cells were used per 75cm2 flask. Following drug treatment 
colonies were grown for 10-14 days then stained with lx Giemsa stain (BDH 
Ltd.) for 10 minutes and rinsed.
2.7.3 TRANSFECTION OF PLASMID DNA INTO CELL LINES
All solutions were filtered before use. 106 cells per 75cm2 flask were 
incubated with appropriately supplemented Special Liquid Medium. 5pg 
plasmid DNA and lpg G418 resistance marker plasmid, pHSG272, per 
sample were used, to which 2.5M CaC12 (Rf 1.401) was added giving a final 
concentration of 0.2M. This was added dropwise to an equal volume of 
280mM NaCl, 50mM Hepes, 0.5mM Na2H P04 (final pH 7.12) whilst air 
was bubbled through. This was incubated at room temperature for 30 minutes,
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mixed, added to cells and incubated at 37°C for 16-20 hours. After 48 hours, 
transfectants were selected with 1 mg/ml G418 and maintained in 400pg/ml 
G418.
2.8 GEL MOBILITY SHIFT ASSAY (Gamer and Revzin., 1981)
2.8.1. REACTION CONDITIONS
2pg of nuclear extract was incubated with 32P end labelled 
oligonucleotide (5x10^ d.p.m.), 2pg poly(dI.dC):(dI.dC) made up to 20 pi 
with storage buffer, for 30 minutes on ice.
2.8.2. GEL RUNNING CONDITIONS
The gel was pre-electrophoresed at 200V for 30 minutes. Reactions were then 
electrophoresed (at 200V for 2-3 hours) through the "retardation gel":
20ml aciylamide (30% acrylamide with 0.8% bis acrylamide)
4ml TBE (lOx)
56ml H2 O 
300pl APS (10%)
30pl temed
The buffer used was 0.5% TBE and dye mixture was placed in the end lane 
only. Once the dye front had reached the bottom of the gel, the gel was 
sandwiched between 3mm Whatman paper and clingfilm and dried under 
vacuum then subjected to autoradiography as detailed in section 2.4.5.
2.9 LUCIFERASE ASSAY
2.9.1 PREPARATION OF CELL LYSATES
All solutions were equilibrated to room temperature. 106 cells were 
lysed with 250pl of 25nM Tris phosphate (pH 7.8), 2mM DTT, 2mM 
diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10% glycerol, 1% TRITON 
X-100. After 15 minutes they were scraped off and the lysate was spun briefly. 
The supernatant was removed to a separate tube.
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2.9.2 ASSAY OF LYSATES FOR LUCIFERASE ACTIVITY
To the cell lysates, 1.5 volumes of 20mM tricine, ImM (MgC0 3 ) 4 
MgC0H2.5H20, 2.7mM MgS04, O.lmM EDTA, 33.3mM DTT, 270pM 
coenzyme A, 470pM luciferin, 530pM ATP (final pH 7.8) was added then 
light production was measured for 1 minute in a luminometer.
2.10 MICROBIOLOGICAL TECHNIQUES
2.10.1 BACTERIAL CULTURE
Bacteria were maintained on Luria agar (1.5% agar in L-broth) plates 
at 4°C and stored for long periods in 50% glycerol in L-broth (1% tryptone, 
0.5% yeast extract, 1% NaCl) at -20°C.
2.10.2 TRANSFORMATION OF BACTERIAL CULTURES 
WITH PLASMID DNA
lOOpl of competent bacteria were added to 10-50ng of transforming 
DNA and left on ice for 30 minutes. 5 minutes after a 37°C heat shock, lml L- 
broth was added and the samples were vortexed before incubation for 1-1.5 
hours at 37°C. Appropriate dilutions were plated on selective medium (L-agar, 
lOOpg/ml) using glass beads to distribute transformed bacteria. Plates were 
incubated at 37°C.
2.10.3 RECOVERY OF PLASMID DNA FROM BACTERIAL CULTURES 
5ml of a 10ml culture was used to innoculate 500ml of L-broth
containing lOOmg/ml ampicillin (for selection) and this culture was grown to 
stationary phase overnight. The Quiagen Maxi Preparation kit, Quiagen Inc. 
was used according to manufacturers recommendations to obtain plasmid 
DNA.
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Chapter 3
CHAPTER 3: THE ROLE OF P53 PROTEIN IN CELLULAR
RESISTANCE TO CISPLATIN 
INTRODUCTION
3.1.1 WHY ONE SHOULD SUSPECT THAT p53 PROTEIN IS 
RESPONSIBLE FOR CISPLATIN RESISTANCE
DNA damaging agents such as cisplatin induce p53 protein levels via 
post translational means (Maltzman & Czyzyk, 1984; Fritsche et al., 1993) 
and this is inhibited by caffeine (Kastan et al., 1991). Also, when normal 
human skin is exposed to sunlight, p53 protein levels rise over a twenty four 
hour period (Hall et al., 1993). This evidence lends support to the theory that 
p53 is a component of a physiological DNA damage response pathway. 
Overexpression of wild type p53 protein in vivo has been reported for the 
normal tissue of an individual with a familial susceptibility to breast cancer 
(Barnes et al., 1992). Another in vivo situation where p53 protein levels are 
temporarily raised without mutation is in the cytoplasm of normal lactating 
breast tissue (Moll et al., 1992). Thus there are circumstances where p53 
protein concentration is enhanced in vivo and application of our in vitro 
knowledge to clinical scenarios would not be totally contrived. There are 
several possible means by which p53 could affect the cellular tolerance of 
cisplatin and these will be discussed in the ensuing sections.
3.1.2 G1 ARREST AS A POSSIBLE MECHANISM BY WHICH p53 
PROTEIN COULD MODULATE SENSITIVITY TO CISPLATIN
One hypothesis proposed was that raised p53 protein might cause cells 
to remain longer in G1 phase of the cell cycle thereby allowing more time for 
repair of DNA damage before DNA replication at S phase. DNA damage- 
induced p53 protein causes G1 arrest of cells (Kastan et al., 1991) and this 
appears to be dependent on expression of a wild-type p53 gene (Kuerbitz et
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al., 1992). Patients with the disease ataxia telangiectasia (A-T), who exhibit 
radiosensitivity and susceptibility to cancer, have altered induction of p53 and 
GADD45 in response to DNA damage (Kastan et al., 1992). Therefore, the A- 
T genes and GADD45 are implicated as elements of this pathway. There is a 
correlation between the ability to arrest in G1 phase of the cycle in a p53 
dependent manner after DNA damage, and the level of radiosensitivity in cell 
lines from a wide variety of tissues (McIlwrath et al., 1994) Suppression of 
growth is observed when a glioblastoma cell line conditionally overexpresses 
wild type p53 (Mercer et al., 1990) and p53 acts as a control protein in 
osteosarcomas (Diller et al., 1990). Even in the yeast, Schizosaccharomyces 
pombe, overexpression of wild type p53 from a plasmid inhibits growth 
(Bischoff et al., 1992). However, the observation that there is a loss of, rather 
than an increase in, the G1 checkpoint when A2780cp70 cells become 
resistant to cisplatin invalidates this as the method by which this cell line 
achieves resistance (Brown et al., 1993). The G1 arrest following DNA 
damage is one p53 mediated property which is amenable to quantitative 
analysis and so it provides us with a measure of p53 function.
3.1.3 GENE AMPLIFICATION AS A POSSIBLE MECHANISM FOR p53 
INDUCED DRUG RESISTANCE
Introduction of wild type p53 to cells with mutant p53 alleles results in 
inhibition of gene amplification (Yin et al., 1992). A defect in such a 
mechanism could give rise to amplification of drug resistance genes, leading 
to increased probability of cells acquiring a drug resistant phenotype.
3.1.4 p53 DEPENDENT APOPTOSIS AND DRUG RESISTANCE
At high concentrations, | chemotherapeutic drugs cause apoptosis
i
(Dive & Hickman, 1991; Eastman, 1990) and this may link p53 to drug 
resistance. Some cells, e.g. Ml clone S6 myeloid leukemic cells, require p53
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for progression to an apoptotic-like cell death (Yonish-Roach et al., 1993). 
There is no p53-inducible growth arrest in these cells but they are particularly 
vulnerable to cell death when in the G1 phase of the cell cycle. A fault in the 
p53 dependent apoptotic pathway would permit the survival of cells which 
would otherwise be eliminated following DNA damage and thereby allow 
resistance to drugs such as cisplatin. As described in section 1.4.7, genetic 
inactivation of p53 in mice causes increased resistance to DNA damaging 
agents such as ionising radiation and topoisomerase inhibitors (Lowe et al., 
1993b; Clarke et al., 1994).
3.1.5 THE IMPLICATIONS FOR DRUG RESISTANCE OF ALTERED 
TRANSCRIPTIONAL CONTROL BY p53
The functions performed by p53 leading to drug resistance could 
involve p53 protein acting directly on other regulatory or structural 
components of the cell. Alternatively p53 could bind to and alter the 
transcription of genes conferring drug resistance. Transcription of m drl, 
encoding a transmembrane pump known as p-glycoprotein, which when 
overexpressed causes MDR, is induced by a mutant jp53 containing an arginine 
to histidine substitution at amino acid 175. (Chin et al., 1992). However there seems to 
be scant evidence for a correlation between p53 mutations and p-glycoprotein 
overexpression in vivo at least in the case of advanced myelodysplastic 
syndromes (MDS), a clinically relevant situation for p-glycoprotein 
abnormalities (Preudhomme et al., 1993). Also p53 can function as a 
transcription factor when expressed in yeast (Scharer & Iggo, 1992). Site 
specific binding of DNA by p53 has been demonstrated (Kern et al., 1991; 
Zambetti et al., 1992) as has its intrinsic transcriptional frwzsactivation activity 
(Raycroft et al., 1990; Raycroft et al., 1991; Kem et al., 1992; Farmer et al.,
1992). Using GAL4-p53 fusion proteins transcriptional toms activation has
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been found to be associated with the N-terminal portion of p53 protein (Hupp 
et al., 1992). This arrangement is fairly common amongst transcription factors.
p53 mediated repression of the human hsp70 promoter (Agoff et al.,
1993) and the SV40 enhancer promoter (Jackson et al., 1993) has been 
reported. This also involves the N-terminus of p53. Proteins which have p53- 
binding affinity, such as SV40 large T antigen, HPV E-6 and mutant p53, can 
inhibit site specific binding to DNA (Bargonetti et al., 1992) and 
transcriptional activation by p53. The protein, p53 has been implicated in 
transcriptional Jra/tsactivation of MDM2 (Barak et al., 1993; Juven et al., 
1993; Price and Park., 1994), a putative transcriptional control protein in its 
own right and WAF-1 (El-Deiry et al., 1993) which may have a role in cell 
cycle control. If the major function of p53 protein were to enhance 
transcription of inherent, cellular "suicide genes", perturbation of the p53 gene 
cascade would result in inappropriate cell survival and drug resistance. Also if 
p53 were conformationally altered it might activate transcription of genes 
which when aberrantly expressed could inactivate cisplatin, pump cisplatin out 
of a cell, prevent entry of cisplatin to the cell or repair DNA damage more 
efficiently. Alteration of p53-mediated transcriptional /nms’activation is 
another means by which p53 functional activity can be assessed and this has 
been made use of in section 3.4 in order to compare p53 activity between cell 
lines.
3.1.6 AIMS OF THE WORK PRESENTED IN THIS CHAPTER
1) To examine the sensitivity of the cells used to cisplatin or transplatin.
2) To examine differences in p53 protein expression between cisplatin 
sensitive and resistant cell lines and to investigate possible mechanisms 
leading to any differences observed.
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3) To examine differences between cisplatin sensitive and resistant cells in 
p53 transcriptional /razzsactivation activity as determined by the level of 
expression of downstream targets such as the WAF-1 gene.
4) To examine whether there is any alteration in cisplatin sensitivity of the 
cells induced by prior cisplatin treatment during the time when one would 
expect p53 protein levels to have risen.
Cellular sensitivity assays performed in this chapter employ the 
clonogenic assay. This assay provides a very direct measure of cell survival. 
Also it has the advantage over other sensitivity assays in that one does not 
confuse growth arrested cells with dead cells.
Much use will be made in this section of a model system comprising a 
highly chemosensitive, human, ovarian, tumour cell line, A2780 and a more 
cisplatin tolerant derivative, A2780cp70. These cell lines are interesting 
because of their origin. Ovarian carcinomas are frequently treated with 
cisplatin regimes and sometimes develop cisplatin resistance. Using resistant 
and sensitive pairs such as A2780cp70 and A2780 is more relevant to 
acquisition of drug tolerance and patient relapse than the study of cells from 
tissues which have innate cisplatin resistance.
The p53 protein could theoretically be involved in cisplatin resistance 
due to one or all of the mechanisms outlined in section 3.1.1. A fuller 
comprehension of how p53 protein becomes stabilised and how its activity is 
altered in cisplatin resistant cells may increase our understanding of drug 
resistance. The knowledge gleaned from this research may ultimately assist in 
modulation of cellular sensitivity or at least help in the diagnosis of which 
tumours will respond to chemotherapy.
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RESULTS
3.2 STABILISATION OF p53 PROTEIN IN CISPLATIN RESISTANT 
CELL LINES
3.2.1 A COMPARISON OF DRUG SENSITIVITIES OF THE A2780 CELL 
LINE AND ITS CISPLATIN RESISTANT DERIVATIVE, A2780cp70
Several experiments, which will be described in subsequent sections, 
involve comparisons of the cisplatin sensitive A2780 cell line and its resistant 
counterpart, A2780cp70 following treatment with lpM cisplatin for 1 hour. It 
was therefore of interest to compare the sensitivities of these two cell lines to a 
1 hour cisplatin exposure. Also their sensitivities to a 1 hour dose of the trans 
isomer (transplatin), which lacks anti-tumour activity, were examined. As the 
ID50 value for A2780 cells treated with cisplatin for 24 hours is 0.6pM 
(McLaughlin et al., 1991), cisplatin doses of this order were chosen. 
Transplatin was anticipated to be less toxic than cisplatin so higher 
concentrations of this were used to treat the cells.
A2780 or A2780cp70 cells were seeded out at 103 per 75cm2 flask, left 
overnight and then given a 1 hour exposure to either cisplatin (0, 0.5, 1, 1.5, 2 
or 5pM) or transplatin (0, 0.5, 1, 1.5, 2, 5, 10, 15 or 20 pM). Three'replicates 
were performed at each dose and the results presented are the average of two 
such experiments. The cells were allowed to grow for 10 days, after which 
time they were stained with Giemsa stain, the colonies were counted and 
surviving fractions at the various doses were determined. The data obtained is 
represented graphically in figure 3.2.1.
As one can see, A2780cp70 is significantly more resistant to both 
cisplatin (fig. 3.2.1a) and transplatin (fig. 3.2.1b). Transplatin however, 
appears to be considerably less toxic to either of the two cell lines than 
cisplatin. The ID50 value determined for A2780 cells treated with cisplatin for 
1 hour is 2pM (table 3.2.1). As one would expect, this value is higher than 
those calculated for a 24 hour drug exposure as cells will have less total
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FIGURE 3.2.1 (legend overleaf)
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FIGURE 3.2.1
A2780cp70 (black circles, solid lines) or A2780 (white squares, dotted lines) cells 
were seeded out at 10^ cells/75cm^ flask in RPMI medium, cultured overnight, then treated 
with either cisplatin (a) or transplatin (b) for 1 hour. Doses were 0, 0.5,1,1.5, 2 or 5 pM for 
cisplatin and 0, 0.5, 1, 1.5, 2, 5, 10, 15, or 20 pM for transplatin. Cells were cultured for a 
further 10 days in drug free RPMI medium then stained with Giemsa stain and the colonies 
were counted. Each point is the average of at least 3 flasks/ experiment from 2 separate 
experiments. Surviving fractions are calculated from the ratio of number of colonies at a given 
dose /number of colonies at OpM of drug. Error bars shown represent standard deviations.
TABLE 3.2.1 Survival Of A2780 and A2780cp70 Cells After A 1 Hour 
Exposure To Cisplatin Or Transplatin
Cell T .ine Drug ID50
(pM)
ID20
(jiM)
Fold
Resistance
Percentage Degree of
Survival at Resistance
(from ID20 iuM to l^iM
values)
A2780 cisplatin 2 0.5 1 73 1
A2780cp70 cisplatin >5 2.7 6 92 1.3
A2780 transplatin 16 1 1 80 1
A2780cp70 transplatin >20 17 17 96 1.2
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accumulated cisplatin and therefore are less likely to be subject to its toxic 
effects.
The concentrations of drugs used were not high enough to determine 
ID50 values for A2780cp70 with any degree of accuracy so fold resistance was 
calculated from the ID2o concentrations. Using these values, A2780cp70 cells 
were found to be approximately 6 fold resistant to cisplatin and 17 fold 
resistant to transplatin as compared to A2780 cells (table 3.2.1). The 
A2780cp70 cell line has previously been calculated to be 4 fold more resistant 
to cisplatin than A2780 cells (Brown et al., 1993) but this figure was estimated 
from ID50 rather than ID2o concentrations and a 24 hour exposure time was 
used.
Certain experiments, which will be described later, involved a lpM, 1 
hour drug dose so it seemed relevant to determine the relative toxicity of drugs 
at this dose. The degree of resistance o f : ; A2780cp70, compared to A2780
cells is 1.3 for cisplatin and 1.2 for transplatin, following a lpM,
lhour drug treatment (table 3.2.1). The percentage survival of cells after such 
drug doses was 73% for A2780 and 92% for A2780cp70 in the case of 
cisplatin and on exposure to transplatin 80% of A2780 cells and 96% of 
A2780cp70 cells survived. It is important to know whether the majority of a 
cell population will survive a particular drug treatment as this affects the yield 
of lysate, protein, DNA or RNA obtained in an experiment. As the majority of 
A2780 and A2780cp70 cells do survive a lpM, 1 hour dose of either cisplatin 
or transplatin, it is feasible to prepare various cellular extracts after such a 
treatment in order to examine responses to these compounds at the 
intracellular level. The data presented in this section confirm that A2780cp70 
cells are more resistant to both cisplatin and transplatin than their parental line 
A2780 and that a lpM dose of either drug can be used without compromising 
experimental viability.
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3.2.2 INDUCTION OF p53 PROTEIN BY CISPLATIN AND 
TRANSPLATIN
It has been reported that p53 protein levels increase in response to a 
variety of DNA damaging agents (Kastan et al., 1991; Fritsche et al., 1993; 
Maltzman & Czyzyk, 1984). Due to its potential role in a DNA-damage 
response pathway, p53 is a likely target for alteration on acquisition of 
cisplatin resistance. Thus it seemed interesting to compare both basal and 
induced levels of p53 protein in cisplatin resistant and sensitive cell lines. This 
was carried out using either cisplatin or transplatin for induction. The effects 
of transplatin were interesting as this substance differs from cisplatin in that it 
is unable to form 1,2 d(GpG) adducts which represent the major cisplatin 
adduct.
A2780 and A2780cp70 cells were seeded out at 106 cells per 75cm2 
flask. The following day they were given a lpM dose of either cisplatin or 
transplatin for a period of 1 hour or a medium change for control cells. After 
this they were rinsed with PBS then incubated in drug-free medium. The cells 
were lysed in their flasks at 2, 4, 24, 48 or 72 hours after removal of the drug. 
The cell lysates were subjected to Western blotting and the blots probed with 
an anti-p53 antibody. Then relative p53 protein levels were quantified by laser 
densitometry after correction for protein loading.
On average, there was 8 fold more p53 protein in non-induced 
A2780cp70 cells than the cisplatin sensitive A2780 parental line (lanes 1 and 
7 of figs 3.2.2 and 3.2.3). Following cisplatin treatment (fig.3.2.2), p53 protein 
in the A2780 cell line increased from control levels (lane 1), to peak with a 9 
fold induction at the 24 hour time point (lane 4). It then decreased again to 
approach basal levels by 72 hours post-treatment, where a 1.6 fold induction 
was observed (lane 6). In the case of A2780cp70, the quantity of p53 protein 
increased steadily from control levels (lane 7) to a 4 fold induction at 24 
hours. It then, unlike for the A2780 line, continued to rise and was still on the
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FIGURE 3.2.2
a) A Western Blot Showing p53 Protein 
Induction bv Cisplatin
1 2 3 4 5 6 7 8 9 10 11 12
•  -  _  -p53
Time After A2780 A2780cp70
Treatment: C 2 4 24 48 72 C 2 4 24 48 72
b) Relative Levels of p53 Protein
Lane: 1 2 3 4 5 6 7 8 9 10 11 12
Relative p53
protein levels: 1 1.4 3 9 7 1.6 8 8 20 31 57 59
A2780 (lanes 1-6) and A2780cp70 (lanes 7-12) cells were seeded out at 10^/75cm^ 
flask and grown in RPMI medium overnight. Cells were then either given a medium change 
(lanes 1 & 7) or treated with 1 pM cisplatin for 1 hour and allowed to recover for 2 (lanes 2 &
8), 4 (lanes 3 & 9), 24 (lanes 4 & 10), 48 (lanes 5 & 11) or 72 (lanes 6 & 12) hours. High salt
lysis buffer was used to lyse the cells and large cell debris was removed by spinning in a 
microfuge. Protein concentration was determined by the Biorad kit assay, 50pg loaded/lane 
and proteins were separated on an 8% polyacrylamide gel. Western blotting (section 2.5) was 
carried out using Ab-2, an anti-p53 antibody, from Oncogene Science as primary antibody at a 
1/1000 dilution. Anti-mouse Ig horseradish peroxidase conjugate from Amersham 
International was used as secondary antibody at a 1/5000 dilution. Protein sizes were 
determined by comparison to prestained size markers from BRL. Relative p53 levels were 
estimated by densitometry.
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increase 72 hours after treatment, when p53 protein level was 7 fold higher 
than control levels (lane 12). Cisplatin can therefore induce p53 protein 
accumulation in A2780 and A2780cp70 cell lines, but although the former 
achieves maximum levels by the 24 hour timepoint, the latter still has 
increasing levels 72 hours after drug withdrawal.
A similar situation was observed on treatment with transplatin (fig. 
3.2.3). In A2780 cells induction occurred to a comparable degree to that seen 
for cisplatin. An exception was that the peak p53 protein level detected 24 
hours after transplatin removal was induced 14 fold (lane 4) which is 
somewhat higher than seen for cisplatin.
In the cisplatin resistant A2780cp70 cell line, induction with 
transplatin did not seem to occur to the same extent as one sees for cisplatin. 
By the 24 hour time point, p53 protein levels had doubled whereas following 
cisplatin induction, they would have quadrupled. A 2 fold peak induction was 
seen at 48 hours after which levels declined to a 1.3 fold induction at 72 hours. 
Levels of p53 protein were still rising at this timepoint following cisplatin 
treatment. This difference may be accounted for by the lower toxicity of 
transplatin resulting in the cells attaining confluency more rapidly and thus 
switching off expression of p53. An alternative explanation is that p53 
production is no longer being induced by transplatin due to repair of the 
transplatin-DNA adducts. Cisplatin-induced DNA damage accumulates for up 
to 48 hours but the number of adducts formed by transplatin only increase for 
6 hours after treatment and then begin to recede (Ciccarelli et al., 1985).
Transplatin is therefore able to induce p53 protein within A2780 and 
A2780cp70 cell lines in a similar manner to cisplatin, but not always to the 
same degree. In both experiments there was approximately 8 fold more 
uninduced p53 protein in the resistant line than in the sensitive cells.
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FIGURE 3.2.3
a) A Western Blot Showing p53 Protein 
Induction bv Transplatin
1 2 3 4 5 6 7 8 9 1011 12
-p53
A2780 A2780cp70
Time After
Treatment: C 2 4 24 48 72 C 2 4 24 48 72
b) Relative Levels of p53 Protein
Lane: 1 2 3 4 5 « 7 8 9 10 11 12
Relative p53
protein levels: 1 1.4 3 14 7 1.2 8 10 16 17 20 10
A2780 (lanes 1-6) and A2780cp70 (lanes 7-12) cells were seeded out at 10^/75cm^ 
flask and grown in RPMI medium overnight Cells were then either given a medium change 
(lanes 1 & 7) or treated with lpM  transplatin for 1 hour and allowed to recover for 2 (lanes 2 
& 8), 4 (lanes 3 & 9), 24 (lanes 4 & 10), 48 (lanes 5 & 11) or 72 (lanes 6 & 12) hours. High
salt lysis buffer was used to lyse the cells and large cell debris was removed by spinning in a
microfuge. Protein concentration was determined by the Biorad kit assay, 50pg loaded/lane 
and proteins were separated on an 8% polyacrylamide gel. Western blotting (section 2.5) was 
carried out using Ab-2, an anti-p53 antibody, from Oncogene Science as primary antibody at a 
1/1000 dilution. Anti-mouse Ig horseradish peroxidase conjugate from Amersham 
International was used as secondary antibody at a 1/5000 dilution. Protein sizes were 
determined by comparison to prestained size markers from BRL. Relative p53 levels were 
estimated by densitometry.
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3.2.3 THE p53 STATUS IN CISPLATIN RESISTANT AND SENSITIVE 
CELL LINES
OvlP is a human, ovarian adenocarcinoma cell line and OvlPDDP is a 
more cisplatin tolerant derivative (Teyssier et al., 1989). As in the case of 
A2780 and A2780cp70, the resistant cell line contains more p53 protein than 
the sensitive parental. Also several cisplatin resistant clones were selected by 
exposure of A2780 cells to 15 pM cisplatin (McLaughlin et al., 1991) and 
many of these exhibit increased p53 protein as compared to randomly selected 
A2780 clones (Brown et al., 1993). Although this does not suggest that 
increased p53 protein is the sole cause for cisplatin resistance, it does identify 
p53 as a potential contributory factor in the acquisition of cellular resistance to 
the drug.
Increased intracellular p53 protein is frequently indicative of a mutant 
p53 gene (Bartek et al., 1990). The p53 status within the cisplatin sensitive 
cell lines A2780 and OvlP was compared to that of their resistant partners, 
A2780cp70 and OvlPDDP respectively, by immunoprecipitation using 
antibodies specific for p53 in the mutant conformation. A semiconfluent 
175cm2 flask (2x107 cells) of each cell line was harvested using high salt lysis 
buffer. The lysate was precleared to reduce background, then divided into 
three aliquots of equal volume which were each subjected to 
immunoprecipitation using one of three antibodies, PAb DO-1 which reacts 
with all forms of p53 protein, PAb 240 which binds to p53 protein in the 
mutant conformation and PAb 419, a control antibody reactive with SV40 
large T antigen (Vojtesek et al., 1992). The immunoprecipitated p53 protein 
was then subjected to Western blot analysis (fig. 3.2.4).
No p53 protein was precipitated by the control antibody (lanes 1, 4, 7 
and 10). An increased amount of p53 protein was immunoprecipitated with 
PAb DO-1 from the resistant lines, A2780cp70 (lane 6) and OvlPDDP (lane 
12) than from the sensitive parental lines, A2780 (lane 3) and OvlP (lane 9)
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FIGURE 3.2.4 Immunoprecipitation Of p53 Protein From Cisplatin Sensitive 
And Resistant Cell Lines
Immunoprecipitation (section 2.6.5) was performed followed by separation of 
proteins on an 8% polyacrylamide gel and Western blotting (section 2.5) of p53 protein from 
A2780 (lanes 1-3), A2780cp70 (lanes 4-6), O vlP  (lanes 7-9) and O vlPDDP (lanes 10-12). 
Extracts were immunoprecipitated with the antibodies PAb DO-1 (lanes 3, 6, 9 & 12), PAb 
240 (lanes 2, 5, 8 & 11) and PAb 419 (lanes 1, 4, 7 & 12). PAb DO-1 is a pantropic anti-p53 
antibody, PAb 240 is specific for mutant p53 and PAb 419 is an irrelevant control antibody. 
For Western blotting, the primary antibody was CM1 at a 1/200 dilution and the secondary 
antibody was anti rabbit Ig horseradish peroxidase from Dako, Aylesbury, at a 1/150 dilution. 
Protein sizes were determined by comparison to prestained size markers from BRL.
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consistent with increased levels of p53 protein in these cell lines. The mutant- 
specific 240 antibody precipitates detectable amounts of p53 protein from both 
resistant lines but, whilst this antibody reacts with a similar level of p53 
protein to the pantropic DO-1 antibody in the OvlPDDP line, substantially 
less p53 is reactive with the 240 antibody compared to the DO-1 antibody in 
the case of the A2780cp70 cell line.
A2780cp70, like the A2780 cell line from which it was selected, has a 
wild type p53 genotype as determined by direct sequencing of PCR products 
derived from cDNA (Brown et al., 1993). Examination of the entire coding 
sequence of the p53 gene in the OvlP and OvlPDDP cell lines revealed no 
difference between them although both possessed a cystine to tyrosine 
substitution at codon 126 (Brown et al., 1993). From this data, one can see that 
the increased p53 protein observed in cisplatin resistant cells cannot be 
explained by mutation in the p53 gene, thus some other cellular constituent 
which interacts with p53 must be involved.
3.2.4 ANALYSIS OF POSSIBLE MEDIATORS OF p53 PROTEIN 
ACCUMULATION IN CISPLATIN RESISTANT CELL LINES
The raised p53 protein levels observed in cisplatin resistant cell lines 
are not due to a mutant p53 gene, so it was of interest to examine other factors 
which could influence p53 protein stability. This section contains an initial 
analysis of possible mechanisms leading to increased p53 protein 
accumulation in the resistant A2780cp70 cell line.
The protein, p53, is phosphorylated by at least four protein kinases 
(Milne et al., 1992a). These could modulate the half life of p53 by altering its 
ability to be recognised by proteases. In order to examine the effect of 
phosphorylation on p53 protein stability, nuclear extracts were prepared from 
A2780 and A2780cp70 cell lines in the presence or absence of the 
phosphatase inhibitors (3-glycerol, sodium orthovanadate, sodium fluoride,
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okadaic acid and microcystin LR. These extracts were subjected to 
electrophoresis then Western blotting and the blot was probed for p53 
immunoreactivity (fig. 3.2.5).
The p53 protein levels in the A2780 line are so low as to be 
undetectable (lanes 1, 2, 3 and 4). This is not unexpected as basal p53 protein 
concentration in the nucleus of this cell line, and most other cell lines with a 
wild type p53 genotype, are generally fairly low. There is much more nuclear 
p53 protein in the A2780cp70 cell line, with three apparent isoforms, but no 
obvious difference in p53 protein quantity between extracts prepared in the 
absence (lanes 5 and 7) or presence (lanes 6 and 8) of phosphatase inhibitors. 
This does not however eliminate the possibility that phosphorylation is 
involved in controlling p53 protein accumulation. Possibly kinases as opposed 
to phosphatases are responsible for targeting p53 protein for degradation. 
These, being more specific than phosphatases, would be more difficult to 
inhibit. Or perhaps the phosphatase inhibitors were simply not allowed 
sufficient time to cause any noticeable affect on p53 protein levels. Also there 
do not appear to be any differences between phosphorylation patterns of p53 
protein as determined by 2 dimensional gel electrophoresis of p53 isoforms 
(L. Gallagher, CRC Dept. Medical Oncology, Glasgow University personal 
communications). It is interesting to note that in the nuclear extracts of these 
two cell lines, differences between p53 protein levels seem to be even more 
extreme than for total cell lysates. This argues against nuclear exclusion of 
p53 protein being the manner in which p53 activity is disrupted in A2780cp70 
cells.
Proteins which interact with p53 protein might protect it from 
degradation by masking a site recognised by proteases. The nuclear 
transcription factor, MDM2 binds to p53 and prevents p53 mediated 
transcriptional transactivation (Momand et al., 1992). An attempt was made to 
probe Western blots of A2780 and A2780cp70 lysates with a monoclonal anti-
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FIGURE 3.2.5 Levels Of p53 Protein In Nuclear Extracts Prepared In The 
Presence Or Absence Of Phosphatase Inhibitors
Nuclear extracts were prepared (section 2.2.3) from A2780 (lanes 1-4) and 
A2780cp70 (lanes 5-8) cell lines in the presence (lanes 2, 4, 6 & 8) or absence (1, 3, 5 & 7) of 
the phosphatase inhibitors (3-glycerol, sodium orthovanadate, sodium fluoride, okadaic acid 
and microcystin LR. Extracts were subjected to electrophoresis on an 8% polyacrylamide gel 
then Western blotting (section 2.5). Crude cell lysate from HT29 cells (20pg) was used as a 
positive control (lane 9). The blot was probed for p53 immunoreactivity using AB2 from 
Oncogene Science at a 1/1000 dilution as a primary antibody. Anti-mouse Ig horseradish 
peroxidase from Amersham was used at a 1/5000 dilution as a secondary antibody. Protein 
sizes were determined by comparison to prestained size markers from BRL.
1 2 3 4 5 6 7 8 9
- + - + - + - +  C
A2780 A2780cp70
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MDM2 antibody, IF2. However, no binding by this antibody was detected for 
either cell line, probably because MDM2 is normally expressed at quite low 
levels and the antibody may be intended for use with cell lines which 
overexpress this protein. The level of MDM2 mRNA is lower in A2780cp70 
cells than A2780 cells as will be detailed in section 3.3.3 and this may have 
implications for steady state levels of p53 protein.
The heatshock protein, Hsp70 has been shown to bind p53 protein, 
particularly mutant p53 which it then sequesters out of the nucleus of the cell 
and into the cytoplasm (Pinhasi-Kimhi et al., 1986; Martinez et al., 1991 ). It 
can prolong the half-life of p53 protein and so an increase in Hsp70 protein 
concentration could potentially be responsible for the enhanced p53 protein 
levels detected in A2780cp70 cells. It therefore seemed worthwhile to 
investigate differences between Hsp70 levels in A2780 and A2780cp70 cells.
Each of these two cell lines were seeded out at 106 cells per 75cm2 
flask. After 24 hours the cells were lysed with high salt lysis buffer and the 
lysates were electrophoresed through an 8% polyacrylamide gel then assessed 
for Hsp70 protein levels by Western blotting then probing of the blot with an 
anti-Hsp70 antibody (fig. 3.2.6a). Lane 1 contains lysate prepared from A2780 
cells and lane 2 contains lysate from A2780cp70 cells. The relative level of 
p53 protein contained in each of the cell lines was estimated after correction 
for protein loading (fig.3.2.6b) and there was found to be 4 fold more Hsp70 
in the cisplatin resistant A2780cp70 cells than the sensitive A2780 line. Thus 
in this example of cisplatin sensitive and resistant counterparts at least, there is 
more Hsp70 protein in the resistant derivative. This provides some clues as to 
why there may be a greater accumulation of p53 protein in resistant than 
sensitive cell lines although it is not necessarily the only, or even the major, 
causative factor. It is possible that the increased p53 protein may be stabilising 
the Hsp70 protein, but wild type p53 has been shown to negatively regulate
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FIGURE 3.2.6
a) A Western Blot Showing Hsp70 Protein 
Levels in A2780 and A2780cp70 
cell lines
1 2
A2780 A2780cp70
w  -Hsp70
b) Relative Levels of Hsp70 Protein
Lane: 1 2
Relative Hsp70 
protein levels: 1 4
A2780 (lane 1) and A2780cp70 (lane 2) cells were seeded out at 10^/75cm^ flask 
and grown in RPMI medium overnight. High salt lysis buffer was used to lyse the cells and 
large cell debris was removed by spinning in a microfuge. Protein concentration was 
determined by the Biorad kit assay, 50pg loaded/lane and proteins were separated on an 8% 
polyacrylamide gel. Western blotting (section 2.5) was carried out using, an anti-Hsp70 
antibody, from Sigma as primary antiboby at a 1/1000 dilution. Anti-mouse Ig horseradish 
peroxidase conjugate from Amersham International was used as secondary antibody at a 
1/5000 dilution. Protein sizes were determined by comparison to prestained size markers from 
BRL. Relative p53 levels were estimated by densitometry.
83
Hsp70 protein levels, at least at the transcriptional level (Agoff et al., 1993). If 
p53 functional activity was inactivated in A2780cp70 cells, increased Hsp70 
protein could be due to reduced repression of transcription.
3.3 ARE THERE DIFFERENCES IN p53 ACTIVITY BETWEEN 
CISPLATIN SENSITIVE AND RESISTANT CELL LINES ?
3.3.1 INDUCTION OF WAF-1 mRNA BY VARIOUS DNA DAMAGING 
AGENTS IN CISPLATIN RESISTANT AND SENSITIVE CELLS
As there are noticeable differences between p53 protein concentration 
in certain cisplatin sensitive and resistant cell lines, it seemed important to 
find out whether there were also differences in p53 protein activity. An 
alteration in p53 protein activity could affect downstream events which might 
have a bearing on whether cells became resistant to cisplatin. WAF-1, also 
known as CIP-1 or p21, is a 21KDa nuclear protein whose expression is 
induced on transcriptional frawsactivation by p53 (El-Deiry et al., 1993). As 
such, WAF-1 mRNA levels provide a convenient way of measuring 
differences in p53 mediated transcriptional frays'activation activity. 
Differences in WAF-1 mRNA levels between resistant and sensitive cells were 
quantified as was the induction of WAF-1 mRNA by cisplatin.
Alteration in WAF-1 mRNA levels in response to cisplatin was 
assessed by seeding out 4x106 A2780 or A2780cp70 cells per 175cm2 flask. 
These flasks were left overnight then given a lpM, 1 hour treatment with 
cisplatin or, in the case of control cells, a medium change to drug-free RPMI 
medium. At timepoints of 4 hours and 24 hours post-treatment, RNA was 
extracted from the cells, and this was used for Northern blotting. The resultant 
blot was probed with WAF-1 DNA (fig.3.3.1a) and then with GAPDH DNA 
(fig.3.3.1b) in order to control for RNA loading. These probes hybridized to 
RNA of the expected sizes, 2.4Kb and 1.2Kb respectively.
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FTGIJRE 3.3.1 Induction Of WAF-1 mRNA By Cisplatin
1 2 3 4 5 6 7 8
^  A2780 A2780cp70 A2780 A2780cp70
WAF-1- • ' *1
b)
GAPDH- I  | | M l |
4 HOURS 24 HOURS
A2780 (lanes 1, 2, 5 & 6) and A2780cp70 (lanes 3, 4, 7 & 8) were seeded at 4x 10^ 
cells/ 175cm^ flask and grown overnight in RPMI medium. Cells were given a medium 
change (lanes 1, 3, 5 & 7) or treated with lp M  cisplatin for 1 hour (lanes 2, 4, 6 & 8) and 
grown for a further 4 (lanes 1-4) or 24 (lanes 5-8) hours in drug-free RPMI. Total RNA was 
extracted with TRIzol^M  and Northern blotting carried out (section 2.4) using WAF-1 and 
GAPDH DNA probes. RNA sizes were determined by comparison to 0.24-9.5kb size markers 
from Gibco, Paisley.
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Basal levels of WAF-1 mRNA were higher in A2780 (lanes 1 and 5) 
than A2780cp70 (lanes 3 and 7) indicating greater p53-mediated 
transcriptional transactivation capacity in the sensitive cell line in spite of its 
lower p53 protein level. Following induction with cisplatin, WAF-1 mRNA 
levels increased 1.3 fold after 4 hours (lane 2) and 4 fold by the 24 hour 
timepoint (lane 6) in A2780 cells (table 3.3.1). In the A2780cp70 cell line 
there was a slight induction of 1.2 fold at 4 hours (lane 4) but none 24 hours 
after cisplatin removal (lane 8). Thus not only are basal WAF-1 mRNA levels 
lower in the resistant cells, but they are also less inducible with cisplatin.
A similar experiment was performed using lpM  transplatin rather than 
cisplatin and the Northern blot obtained is depicted in figure 3.3.2. Again one 
sees more WAF-1 mRNA in uninduced A2780 (lanes 1 and 5) than 
A2780cp70 cells (lanes 3 and 7). Transplatin treatment of cells caused 
induction of WAF-1 to a similar degree as was seen following a cisplatin dose 
of the same concentration. In A2780 cells, WAF-1 was induced 1.8 fold after 4 
hours (lane 2) and 4 fold 24 hours after transplatin treatment (lane 6). With 
A2780cp70 cells there was some induction but not to such an extent as for the 
sensitive parental line. At the 4 hour timepoint, a 1.1 fold induction was 
recorded (lane 4) and this had risen to 1.3 fold by 24 hours after drug 
withdrawal (lane 8). Therefore, one can observe similar effects on WAF-1 
mRNA levels after transplatin treatment as following cisplatin treatment of 
A2780 and A2780cp70 cells. That is, levels of WAF-1 mRNA increase by 4 
hours after drug treatment and rise to a more noticeable extent by the 24 hour 
timepoint in the sensitive A2780 cell line. In the resistant line, there is less 
WAF-1 mRNA in uninduced cells and induction is not so striking.
Ionising radiation is also capable of inducing an increase in WAF-1 
RNA in these two cell lines (fig. 3.3.3). Again, 4xl06 A2780 or A2780cp70 
cells per 175cm2 flask were grown up overnight. These were either exposed to 
2Gy ionising radiation from a 60cobalt source or in the case of control cells,
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FIGURE 3.3.2 Induction Of WAF-1 mRNA By Transplatin
a)
WAF-1
A2780 A2780cp70 A2780 A2780cp70
4 H O U R S  24  H O U R S
A2780 (lanes 1, 2, 5 & 6) and A2780cp70 (lanes 3, 4, 7 & 8) were seeded at 4x 10^ 
cells/ 175cm^ flask and grown overnight in RPMI medium. Cells were given a medium 
change (lanes 1, 3, 5 & 7) or treated with lpM  transplatin for 1 hour (lanes 2, 4, 6 & 8) and 
growN for a further 4 (lanes 1-4) or 24 (lanes 5-8) hours in drug-free RPMI. Total RNA was 
extracted with TRIzol^M  and Northern blotting carried out (section 2.4) using WAF-1 and 
GAPDH DNA probes. RNA sizes were determined by comparison to 0.24-9.5kb size markers 
from Gibco, Paisley.
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FIGURE 3.3.3 Induction Of WAF-1 mRNA By Ionising Radiation
a) 1 2 3 4 5 6 7 8
A2780 A2780cp70 A2780 A2780cp70
YVAF-1
b)
GAPDH-
4 HOURS 24 HOURS
A2780 (lanes 1, 2, 5 & 6) and A2780cp70 (lanes 3, 4, 7 & 8) were seeded at 4x 10^ 
cells/ 175cm^ flask and grown overnight in RPMI medium. Cells were either exposed to 2Gy 
ionising radiation from a co b a lt^  source or left untreated (lanes 1, 3, 5 & 7) and growN for a 
further 4 (lanes 1-4) or 24 (lanes 5-8) hours in drug-free RPMI. Total RNA was extracted with 
TRIzol^M and Northern blotting carried out (section 2.4) using WAF-1 and GAPDH DNA 
probes. RNA sizes were determined by comparison to 0.24-9.5kb size markers from Gibco, 
Paisley.
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left untreated. Then RNA was prepared either 4 hours or 24 hours later and 
used for Northern blotting. At the 4 hour timepoint, there was 4.5 fold more 
WAF-1 RNA in A2780 cells which have been exposed to ionising radiation 
(lane 2) than control A2780 cells (lane 1) and at the 24 hour timepoint there 
was a 4 fold induction (lanes 5 and 6). In A2780cp70 cells WAF-1 mRNA was 
induced 2.4 fold at 4 hours (lanes 3 and 4) and 1.9 fold at 24 hours after 
irradiation (lanes 7 and 8). When ionising radiation is used to treat these cell 
lines one can observe induction of WAF-1 mRNA in both cell lines, although 
not so strongly in the cisplatin resistant A2780cp70 line which also has lower 
uninduced levels of WAF-1 mRNA. The induction is more immediate than 
that seen with transplatin or cisplatin and this may reflect the fact that there is 
no time lost on transport into the cells as is the case for cytotoxic drugs.
In this section we have seen how WAF-1 mRNA expression, which is 
induced via transcriptional fra/wactivation by p53 protein, increases once cells 
have been treated with DNA damaging agents. These agents cause a rise in 
intracellular p53 protein so one would expect to see a concurrent increase in 
p53 activity as measured by its ability to activate transcription of a dependent 
gene, namely WAF-1. A summary of WAF-1 induction data is provided in 
table 3.3.1.
In summary, differences in p53 mediated transcriptional 
tams'activation between the cisplatin sensitive, A2780 cell line and 
A2780cp70, the resistant cell line selected from A2780 by multiple cisplatin 
exposures, were detected. A2780 cells contain 10 fold more basal WAF-1 
mRNA than A2780cp70 cells (table 3.3.2) although they have less p53 
protein, indicating that the p53 protein in the resistant line is somehow less 
active as a transcriptional regulator. Also WAF-1 mRNA is not so powerfully 
induced in the resistant line. Alteration in the transcriptional frmsactivation 
properties of p53 might be due to changes in the sequence of the binding site
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TABLE 3.3.1 Induction Of WAF-1 mRNA Bv DNA Damaging Agents
Cell Line Drue/Radiation Fold Induction Fold Induction
Dose of WAf-1 mRNA 
at 4 Hours
tf..WAF-lmRNA 
at. 24 Hours
A2780
cisplatin (lpM, 
1 hour)
1.3 4
A2780cp70
tf 1.2 1
A2780
+vector
ft 1.9 4
A2780 
+mutant p53
tt 1.7 3.5
A2780
Transplatin 
(lpM, 1 hour)
1.8 4
A2780cp70
it 1.1 1.3
A2780
Ionising
Radiation
<2Gv)
4.5 4
A2780cp70
ff 2.4 1.9
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TABLE 3.3.2 Basal WAF-1 mRNA Levels In A2780 And A2780cp70
Cell Line Relative Level of
WAF-1 mRNA
A2780cd70 1
A2780 10
TABLE 3.3.3 Basal WAF-1 mRNA Levels In A2780 Transfected With A 
Mutantp53 Gene
Cell Line Relative Level of
WAF-1 mRNA
A2780+mutant p53 1
A2780+ vector 3
TABLE 3.3.4 Basal MDM2 mRNA Levels
Cell Line Relative Level of
MDM2 mRNA
A2780cp70 1
A2780 4
ZR-75 1.5
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at the p53 responsive gene or because of altered post-transcriptional 
modifications to p53 protein resulting from mutant modifying proteins.
3.3.2 ALTERATION OF BASAL AND INDUCED WAF-1 mRNA LEVELS 
IN A2780 CELLS FOLLOWING TRANSFECTION WITH A MUTANTp53 
GENE
In order to demonstrate dependence of WAF-1 mRNA levels on the
presence of active p53 protein, induction of WAF-1 mRNA in the presence of
a mutant p53 protein was analysed. Dominant P53 mutants bind wild type
p53 forming heterodimers which abrogate wild type p53activity (Milner & Medcalf, 1991). 
! A2780 cells which had been
transfected with the plasmid pC53-SCX3 (Baker et al., 1990), which expresses 
mutant p53 with a valine to alanine substitution at codon 143, or control cells 
transfected with the vector alone were set up at a concentration of 4X106 cells 
per 175cm2 flask. The following day, experimental cells were treated for 1 
hour with lpM cisplatin and control cells were given a medium change to 
drug-free medium. RNA was extracted at 4 hours and 24 hours after drug 
removal and used for Northern blotting. The blot was probed for WAF-1 and 
GAPDH (fig. 3.3.4).
Introduction of the mutant p53 gene into A2780 cells reduced 
uninduced WAF-1 mRNA 3 fold (table 3.3.3) compared to cells containing the 
vector alone. This difference was not so profound as the difference between 
A2780 and A2780cp70 cell lines where the sensitive line contains 10 times the 
level of WAF-1 mRNA as the resistant line. Also there was very little 
difference in WAF-1 induction between cells containing mutant p53 and 
vector alone controls. Cells transfected with the vector alone exhibited a 1.9 
fold induction at 4 hours after cisplatin treatment (fig. 3.3.4, lanes 1 and 2) and 
a 4 fold induction 24 hours after drug removal (lanes 5 and 6) whereas those 
with the mutant p53 protein showed a 1.7 fold induction after 4 hours (lanes 3 
and 4) and a 3.5 fold induction after 24 hours (lanes 7 and 8). This data is
92
FIGURE 3.3.4 Induction Of WAF-1 mRNA In The Presence Of A Mutant p53 
Gene
8
a)
WAF-l-
b)
GAPDH-
vector alone mutant vector alone mutant
4 HOURS 24 HOURS
A2780 cells transfected with vector alone (lanes 1, 2, 5 & 6) and A2780 cells 
transfected with a mutant p53 expressing plasmid (lanes 3, 4, 7 & 8) known as pC53-SCX3 
(Baker et al., 1990) were seeded at 4x 10® cells/ 175cm^ flask and grown overnight in RPMI 
medium. Cells were treated with lpM  cisplatin for 1 hour and grown for a further 4 (lanes 1- 
4) or 24 (lanes 5-8) hours in drug-free RPMI. Total RNA was extracted with TRIzol^M  and 
Northern blotting carried out (section 2.4) using WAF-1 and GAPDH DNA probes. RNA sizes 
were determined by comparison to 0.24-9.5kb size markers from Gibco, Paisley.
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summarised in table 3.3.1.
Decreased WAF-1 mRNA was observed in A2780 cells when a mutant 
p53 was introduced. This indicates that WAF-1 expression in these cells is p53 
dependent. The presence of mutant p53 does not entirely abolish WAF-1 
mRNA nor does it effectively prevent its induction by cisplatin. This is 
probably due to residual wild-type p53 protein which is not complexed to the 
mutant form.
3.3.3 DIFFERENTIAL EXPRESSION OF MDM2 mRNA IN CISPLATIN 
RESISTANT AND SENSITIVE CELL LINES
Expression of the MDM2 gene is also transcriptionally /rawsactivated 
by p53 and so, differences in MDM2 mRNA levels between A2780 and 
A2780cp70 cells were also interesting as being indicative of p53 protein 
activity. RNA was prepared from the cell lines A2780, A2780cp70 and ZR-75 
(a breast tumour derived cell line which overexpresses MDM2 protein). The 
RNA obtained was analysed by Northern blotting (fig. 3.3.5). After correction 
for loading, there was found to be 1.5 fold more MDM2 mRNA in ZR-75 cells 
than A2780cp70 cells and 4 fold more in A2780 cells than A2780cp70 cells 
(table 3.3.4). This reduced amount of MDM2 in A2780cp70 cells, compared 
with its parental line, provides further circumstantial evidence for a lower 
level of transcriptional control by p53 protein in these cisplatin resistant cells. 
It also suggests that these effects are not limited to WAF-1.
3.3.4 THE USE OF A LUCIFERASE REPORTER SYSTEM TO MEASURE 
TRANSCRIPTIONAL CONTROL BY p53 PROTEIN
In order to measure p53 mediated regulation of transcription more 
directly, an attempt was made to use a reporter gene downstream of a known 
p53 binding site. The plasmid pGUP.PA.8 (fig. 3.3.6a), which contains the 
gene encoding firefly luciferase, was used either alone or with the fragment A
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FIGURE 3.3.5 Levels Of MDM2 mRNA In A278Q. A2780cp70 And ZR-75 
Cell Lines
a)
\IDM 2-
b)
GAPDH-
A2780 A2780cp70 ZR75
A2780 (lane 1), A2780cp70 (lanes 2) and ZR-75 cells were grown to semi- 
confluency in RPMI medium. Total RNA was extracted with TRIzol^M  and Northern 
blotting carried out (section 2.4) using an MDM2 DNA probe. RNA sizes were determined by 
comparison to 0.24-9.5kb size markers from Gibco, Paisley. This work was performed in 
collaboration with L.Gallagher, CRC Department of Medical Oncology, Glasgow University.
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sequence (fig. 3.3.6b) inserted upstream of the luciferase gene i.e Frag.A- 
pGUP.PA.8 (Funk et al., 1992). Fragment A is a 36 bp fragment of a human 
genomic clone known as CBE772 to which p53 binds specifically (Seto et al., 
1990). Luciferase enzyme activity involves oxidation of beetle luciferin via an 
intermediate, luciferyl-CoA in this case, with subsequent chemiluminescent 
photon production.
Either Frag.A-pGUP.PA.8 or the vector alone, pGUP.PA.8, were 
stably transfected into A2780cp70 cells along with a plasmid known as 
pHSG272 (Brady et al., 1984) which contains a selectable marker, the G418 
resistance plasmid. An attempt was also made to transfect these plasmids into 
A2780 cells, however this failed due to the susceptibility of this line to the 
toxic effects of calcium phosphate. Transfectants were selected for G418 
resistance and Southern blotting was employed to conclude whether 
transfection had occurred successfully. A clone which had been transfected 
with Frag.A-pGUP.PA.8 (FA) and one which contained the vector alone (V) 
were then used in induction experiments with DNA damage-inducing agents.
The clones FA and V were seeded out at 106 cells per 75cm2 flask and 
left overnight. They were then given a 1 hour, lpM dose of cisplatin or a 
change of growth medium for control cells. At 4, 24, or 48 hours later the 
cells were lysed and lysates were later assayed for luciferase activity (light 
production) in a luminometer using an empty tube as a control in order to 
estimate background luminescence. The results of this experiment, after 
subtraction of background activity, are depicted graphically in figure 3.3.7. 
Cells containing the vector alone showed approximately background levels of 
activity whether untreated (V-) or treated with cisplatin (V+) at all 3 
timepoints. Cells containing Frag.A-pGUP.PA.8 have above background 
levels of luciferase activity before cisplatin treatment (FA-) at the timepoints 
examined and levels are induced by cisplatin treatment with the greatest 
induction 4 hours after cisplatin removal when luciferase activity is induced 4
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FIGURE 3.3.6a) The Plasmid. pGUP.PA.8
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FIGURE 3.3.7 Induction Of Transcription Bv Cisplatin In A2780cp70 Cells
(legend overleaf)
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' FIGURE 3.7.7
Induction Of Transcription By Cisplatin In A2780cp70 Cells
A2780cp70 cells transfected with the vector, pGUP.PA.8 alone (V) or containing 
fragment A DNA sequence (FA) were seeded out at 10^ cells/ 75cm^ flask and grown 
overnight in RPMI medium. They were then either given a medium change to fresh medium 
(-) or given a lpM  dose of cisplatin for 1 hour (+). At 4 hours (a), 24 hours (b) and 48 hours 
(c) after drug removal cells were lysed, and assayed for luciferase activity in a luminometer 
(section 2.9). Relative luminescence is the luminescence/ sample tube after subtraction of the 
luminescence/ blank tube.
FIGURE 3.7.8
Induction Of Transcription By Transplatin In A278Qcp7Q Cells
A2780cp70 cells transfected with the vector, pGUP.PA.8 alone (V) or containing 
fragment A DNA sequence (FA) were seeded out at 10^ cells/ 75cm ^  flask and grown 
overnight in RPMI medium. They were then either given a medium change to fresh medium 
(-) or given a lpM  dose of transplatin for 1 hour (+). At 4 hours (a), 24 hours (b) and 48 hours 
(c) after drug removal cells were lysed, and assayed for luciferase activity in a luminometer 
(section 2.9). Relative luminescence is the luminescence/ sample tube after subtraction of the 
luminescence/ blank tube.
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FIGURE 3.3.8 Induction Of Transcription Bv Transplatin In A2780cp70 Cells
(legend on previous page)
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fold (fig. 3.3.7a). As luciferase activity must be directly proportional to the 
quantity of luciferase enzyme which is in turn, directly proportional to the 
level of transcription from the luciferase plasmid, this shows that p53 
transcriptional /razzsactivation activity can be assessed using a reporter system 
such as this and that p53 protein activity can be induced by cisplatin.
A similar experiment was performed with transplatin rather than 
cisplatin and the results of this are shown in figure 3.3.8. Again there is little 
luciferase activity displayed by cells transfected with the vector alone either 
with (V+) or without a drug dose (V-). Cells containing the Frag.A- 
pGUP.PA.8 plasmid showed some luminescence activity in the absence of a 
transplatin dose (FA-) and showed an induction of this luciferase activity after 
transplatin treatment (FA+) with the greatest induction at the 4 hour timepoint 
(fig. 3.3.8a) when luciferase activity was 7 fold greater in treated than 
untreated cells. This again demonstrates how p53 mediated transcriptional 
frwwactivation can be induced by a DNA-damaging agent.
It is interesting to note that in both cases of induction with transplatin 
or with cisplatin, the p53 mediated transcriptional transactivation activity was 
induced to a greater extent at the 4 hour timepoint than the 24 or 48 hour 
timepoints. This suggests that p53 activity peaks earlier than p53 protein 
levels which are still increasing until at least 48 hours after drug treatment in 
this line.
3.3.5 ARE CELLS WHICH HAVE BEEN GIVEN ONE CISPLATIN DOSE 
MORE RESISTANT TO A SECOND CISPLATIN TREATMENT?
One might wonder whether increased p53 protein levels, or other such 
factors which alter on treatment with DNA-damaging agents, would serve to 
prepare cells for further assault with cytotoxic substances. Such a situation
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FIGURE 3.3.9 The Effect Of Cisplatin Pretreatment On The Sensitivity Of 
A278Q Cells To A Second Cisplatin Dose (legend overleaf)
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FIGURE 3.3.9 (previous page) The Effect Of Cisplatin Pretreatment On The
Sensitivity Of A2780 Cells To A Second Cisplatin Dose
A2780 cells were seeded out at 10^ cells/75cm^ flask in RPMI medium, cultured 
overnight, then treated with lpM cisplatin for 1 hour (black circles, solid lines) or given a 
medium change (white squares, dotted lines). 4 (a), 24 (b) and 48 (c) hours later, a second 
cisplatin dose of 0, 0.5, 0.75, 1 or 2 pM was given for 24 hours. Cells were cultured for a 
further 10 days in drug free RPMI medium then stained with Giemsa stain and the colonies 
were counted. Each point is the average of at least 2 flasks/ experiment from 2 separate 
experiments. Surviving fractions are calculated from the ratio of number of colonies at a given 
dose /number of colonies at OpM of drug. Error bars shown represent standard deviations.
FIGURE 3.3.10 (overleaf) The Effect Of Cisplatin Pretreatment On The 
Sensitivity Of A2780cp70 Cells To A Second Cisplatin Dose
A2780cp70 cells were seeded out at 10^ cells/75cm^ flask in RPMI medium, 
cultured overnight, then treated with lpM cisplatin for 1 hour (black circles, solid lines) or 
given a medium change (white squares, dotted lines). 4 (a), 24 (b) and 48 (c) hours later, a 
second cisplatin dose of 0, 0.5, 1, 2, 4 or 10 pM was given for 24 hours. Cells were cultured 
for a further 10 days in drug free RPMI medium then stained with Giemsa stain and the 
colonies were counted. Each point is the average of at least 2 flasks/ experiment from 2 
separate experiments. Surviving fractions are calculated from the ratio of number of colonies 
at a given dose /number of colonies at OpM of drug. Error bars shown represent standard 
deviations.
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FIGURE 3.3.10 The Effect Of Cisplatin Pretreatment On The Sensitivity Of
A2780cp70 Cells To A Second Cisplatin Dose (legend on previous page)
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TABLE 3.3.5 The Effect Of Pretreating Cells With Cisplatin On Their
Sensitivity To A Second Cisplatin Dose
Cell Lins Time Between 
Pretreatment and
IBSlLflf
Pretreated Control
Fold
Difference
Second Cisnlatin 
Dose (in hours)
Cells
([iM)
Cells
(jiM)
A2780 4 0.62 0.62 1
A2780 24 0.69 0.57 +1.2
A2780 48 0.28 0.2 +1.4
A2780cp70 4 3.3 3.6 -1.1
A2780cp70 24 4 4 1
A2780cp70 48 4.3 4.5 -1.1
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would be analogous to the immune response system where a pool of "memory 
cells" are retained following infection in order to provide a more rapid 
response when the organism is invaded a second time by a similar foreign 
body.
In order to ascertain the validity of this theory, A2780 or A2780cp70 
cells were either pretreated with lpM cisplatin for 1 hour or, in the case of 
control cells, given a medium change. They were then allowed to recover for 
either 4, 24 or 48 hours before their cisplatin sensitivity was determined by 
clonogenic assay involving a second exposure to cisplatin for 24 hours. The 
range of cisplatin doses used for A2780 cells was lower (0, 0.5, 0.75, 1, 1.5 or 
2 pM) than for A2780cp70 cells (0, 0.5, 1, 2, 4 or 10). The data obtained for 
A2780 cells is depicted in figure 3.3.9 and that for A2780cp70 cells in figure 
3.3.10. Pretreated cells are denoted by black circles and solid lines whereas 
control cells are represented by white squares and dotted lines. There appears 
to be no significant difference between pretreated and control cells and this is 
borne out by comparisons of ID50 values (table 3.3.5). At the 4 hour timepoint 
there is no difference in ID50 value for A2780 cells and a 1.1 fold decrease in 
A2780cp70 cells when pretreated with cisplatin. At 24 hours after 
pretreatment, A2780 cells show a 1.2 fold increase and A2780cp70 cells show 
no difference and at the 48 hour timepoint A2780 ceils exhibit a rise of 1.4 
fold and A2780cp70 cells a 1.1 fold difference in favour of control cells. 
Bearing in mind the confidence limits of this experiment, these small 
alterations in cell survival are not significant. Pretreating cells with cisplatin 
does not significantly protect them from a second cisplatin dose.
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3.4 DISCUSSION
3.4.1 STABILISATION OF p53 PROTEIN IN CISPLATIN RESISTANT 
CELL LINES
Increased levels of p53 protein are seen following cisplatin treatment 
of the A2780 and A2780cp70 cell lines. Higher amounts of this protein are 
also found in cells selected for cisplatin resistance in vitro e.g. A2780cp70 
compared to A2780 cells, from which they originate. This suggests that p53 
protein could be instrumental in causing cisplatin resistance. Using ID2q 
values obtained from clonogenic assay the A2780cp70 cell line was found to 
be 6 fold resistant to a 1 hour cisplatin dose and 17 fold resistant to a 1 hour 
treatment with transplatin when compared to the parental line, A2780. A 4 
fold cisplatin resistance was previously found using a 24 hour dose clonogenic 
assay (Brown et al., 1993) and a 39 fold resistance recorded using a soft agar 
assay (Behrens et al., 1987). This demonstrates the importance of specifying 
the duration of drug exposure and the assay used when quoting data 
concerning drug sensitivity. Also more importantly, a 1 hour, lpM dose of 
either cisplatin or transplatin did not kill more than 30% of a population of 
either cell line. Therefore an adequate yield of various extracts could be 
prepared following such treatments and there was not a significant danger of 
selecting out a more resistant subpopulation of cells.
Induction of p53 protein occurred following transplatin or cisplatin 
exposure in A2780 cells, where peak levels were detected 24 hours after 
cisplatin treatment. In A2780cp70 cells cisplatin-induced p53 protein was still 
rising 72 hours after drug removal but a drop in p53 induction was seen after 
72 hours for transplatin. This discrepancy may be accounted for by the 
observation that transplatin-DNA adducts accumulate for only 6 hours 
compared to 48 hours for cisplatin-DNA adducts (Ciccarelli et al., 1988). 
Another possible explanation could be that transplatin, being less toxic, 
permits overcrowding of cells which attain a quiescent state and switch off
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expression of the p53 gene. To control for this, lysates could be prepared at 
the same time but drug treatments given at different times prior to this. 
Alternatively, cells could be treated with equitoxic drug doses.
As p53 mutations frequently cause enhanced stabilization of the p53 
protein, it was important to investigate the p53 genotype in the cell lines used. 
A common conformation for mutant p53 proteins has been proposed due to 
the ability of the antibody PAb 240 to bind to several different mutant p53 
proteins (Gannon et al., 1990). Immunoprecipitation with this mutant specific 
antibody, followed by Western blotting of precipitated proteins, showed that 
although some p53 was precipitated from the cisplatin resistant cell line 
A2780cp70 this was not as much as for the pantropic DO-1 antibody. 
OvlPDDP contained a p53 protein which was precipitable to equal degrees 
with both antibodies. The implication that A2780cp70 contained a wild type 
p53 gene whereas OvlPDDP contained a mutant p53 gene was borne out by 
direct PCR sequencing of the entirep53 cDNA (Brown et al., 1993).
The p53 protein stabilisation attained in these cisplatin resistant lines 
A2780cp70 and OvlPDDP, is not the result of a mutant p53 gene. Induced 
p53 protein levels do not correlate with induced mRNA levels (Kastan et al., 
1991; Fritsche et al., 1993). Other possible causes are differences in post 
translational modification or binding to a protein which protects it from 
recognition by the ubiquitin protein degradation system. No difference was 
detected between p53 protein concentration in A2780cp70 nuclear extracts 
which had been prepared in the presence or absence of phosphatase inhibitors. 
This may indicate that insufficient time was allowed for these inhibitors to 
exert their effects also phosphorylation of p53 at different sites may have 
opposing affects on stability or activity.
Phosphorylation does appear to be important in the control of p53 
protein activity. There are at least four protein kinases active against p53 as 
demonstrated by fractionation of SV3T3 cells (Milne et al., 1992a). Serine 389
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of p53 protein is phosphorylated by casein kinase II (Meek et al., 1990; 
Herrman et al., 1991). Also a casein kinase like enzyme which separates from 
casein kinase I (CKI) itself on a phosvitin-sepharose affinity column, 
phosphorylates serines 4, 6 and 9 of murine p53 protein. Within the nuclear 
localisation domain of human p53, at serines 312-323, serine 315 is 
phosphorylated by p34cdc2 (Addison et al., 1990). Both interphase and M- 
phase forms of the enzyme are active and p53 is probably phosphorylated at 
this site throughout most of the cell cycle except G1 (Bischoff et al., 1990), 
although two to three fold more 32P is incorporated into p53 protein during G1 
than either G2, S or M phases. Mitogen activated protein (MAP) kinase has 
also been shown to have activity against p53 protein (Milne et al., 1994) as 
has the c-jun kinase, JNK1 (Milne et al., in press). A DNA activated protein 
from HeLa cells phosphorylates p53 (Lees-Miller et al., 1990) at serines 15 
and 37 in the /r<msactivation domain of human p53 (Lees-Miller et al., 1992) 
and serines 7, 9 and 18 of mouse p53 protein (Wang & Eckhardt., 1992).
A change in activity of one of these kinases could profoundly alter p53 
protein stability or activity. This is borne out by the observation that mutation 
of the serine 15 phosphorylation site within human p53 protein to an alanine 
residue reduces the ability of p53 to mediate a G1 phase block (Fiscella et al.,
1993). A mutation of the CKII site of mouse p53 at serine 386, prevented p53 
mediated growth suppression activity as measured by inhibition of colony 
formation in SV3T3 and SV40 transformed baby hamster kidney cells (Milne 
et al., 1992b). Also, it has been shown that okadaic acid can reduce 
transcriptional frvms'activation by p53 protein (Zhang et al., 1994b). This is in 
agreement with the finding that potato acid phosphatase enhances DNA 
binding by p53 (Kern et al., 1991a). It might be possible that a signal which 
serves to activate p53 for transcriptional /ra/wactivation could also be 
responsible for its subsequent destruction thus ensuring dispersal of p53 
protein after carrying out its effects. This idea seems attractive in view of the
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characteristics of p53 protein in A2780cp70 cells where it has greater stability 
but lower activity than in the cisplatin sensitive counterpart, A2780.
Unfortunately it was not possible to obtain results from an 
investigation into MDM2 protein levels in A2780 and A2780cp70 cells. This 
would have been an interesting area for experimentation as this 95KDa protein 
has affinity for p53 protein which can stabilize p53 protein and prevent p53 
mediated transcriptional /ra«sactivation (Momand et al., 1992). An increase in 
MDM2 levels or affinity for p53 protein, again would account for both the 
reduced activity and increased concentration of p53 protein in A2780cp70 
cells relative to the parental line. The reduced levels of mdm2 mRNA in 
A2780cp70 cells would suggest that this theory is unlikely to prove correct but 
there is some evidence for regulation of MDM2 protein levels at the 
translation stage so decreased mRNA would not necessarily correlate with 
decreased MDM2 protein (Landers et al., 1994).
The comparatively high levels of the heatshock protein Hsp70 which 
one detects in the A2780cp70 line could explain why p53 protein exhibits 
reduced activity in this line as this protein has the ability to bind p53 protein 
(Pinhasi-Kimhi et al., 1986). It can therefore remove it to the cytoplasm of the 
cell (Martinez et al., 1991), away from the transcription sites which p53 
protein tfwzsactivates. However this seems an unlikely explanation for 
A2780cp70 cells, bearing in mind the levels of p53 protein seen for nuclear 
extracts of this cell line. The region of p53 protein responsible for this 
interaction has been narrowed down to the 28 amino acids at the N-terminus 
(Hainaut & Milner, 1992; Lam & Calderwood, 1992). The high levels of 
Hsp70 protein which one sees in A2780cp70 cells may result from reduced 
p53 activity, as p53 is able to repress the Hsp70 promoter (Agoff et al., 1993). 
This indicates increasing evidence of a reduced p53 activity in A2780cp70 
cells relative to A2780 parental cells.
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Heatshock proteins are induced following various forms of cellular 
stress including heat exposure. The Hsp70 protein is serum stimulated and is 
normally expressed in late Gl/early S phase of the cell cycle. Certain 
members of the heatshock protein family have been postulated to be involved 
in cisplatin resistance. For example, three isoforms of Hsp25 are induced by 
cisplatin in Erlich ascites tumour cells (Oesterreich et al., 1991). Also 
overexpression of Hsp60 is associated with reduced survival in ovarian 
carcinoma patients and both Hsp60 mRNA and protein can be induced by 
cisplatin (Kimura et al., 1993). Cisplatin and hyperthermia only seem to have 
an additive rather than synergistic effect against ovarian carcinoma cells in 
vitro (Kimura & Howell, 1993).
3.4.2 ALTERED ACTIVITY OF p53 PROTEIN IN CISPLATIN 
RESISTANT CELL LINES
Despite the problem that the overall function of p53 in cells is not 
known, several measurable activities of p53 protein have been found. These 
include its ability to activate transcription from certain promoters (Weintraub 
et al., 1991; Farmer et al., 1992; Zambetti et al., 1992; Okamoto & Beach, 
1994). One promoter which responds to transcriptional /riz/wactivation by p53 
protein is WAF-1 (El-Deiry et al., 1993). I observed an induction of WAF-1 
mRNA expression using various DNA damaging agents. This is consistent 
with similar data from other laboratories (El-Diery et al., 1994). Induction of 
this promoter was more rapid following treatment with 2Gy ionising radiation 
than after exposure to cisplatin or transplatin, probably due to its more direct 
penetration of cells. This would be expected as p53 protein itself is induced 
with faster kinetics using this DNA damaging agent, showing peak p53 
protein level after 8 hours rather than 24 hours after cisplatin treatment. Also 
10 fold lower uninduced levels of WAF-1 mRNA were detected in the 
cisplatin resistant A2780cp70 cell line than the sensitive A2780 cells
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suggesting that p53 protein has lower activity in the resistant cells. 
Transfection of a mutantp53 gene into A2780 cells has the effect of causing a 
3 fold reduction in the basal level of WAF-1 mRNA however it does not 
eradicate WAF-1 expression or prevent WAF-1 induction. This could be due to 
non-p53 mediated transcription from the WAF-1 promoter which has been 
shown to be induced by serum or certain growth factors in fibroblasts from 
mice which lack thep53 gene (Micheili et al., 1994). Alternatively it might be 
caused by the mutant p53 being unable to bind to all wild type p53 protein 
within the cells. Also activation of p53 protein for DNA binding might result 
in post-translational modification which prevents the formation of 
heterodimers with mutant p53 protein due to the binding site on wild type p53 
protein being obscured. The use of cells lacking any p53 gene would be 
required in order to demonstrate conclusively that WAF-1 mRNA 
transcription and its induction by DNA damaging drugs relies on p53 protein 
activity.
Reduced MDM2 mRNA expression in A2780cp70 cells compared to 
A2780 cells is interesting as it provides evidence that decreased expression 
from p53 responsive promoters is not restricted to WAF-1. This negates the 
explanation that reduced activation of transcription could result from a 
mutated p53 binding site upstream of the coding region as it would be unlikely 
for this to occur at two p53 binding sites at once. The implications of reduced 
MDM2 expression were discussed in the previous section.
A luciferase expression system can be utilised to measure p53 
mediated transcriptional /ra/isactivation following stable transfection with the 
plasmids, pGUP.PA.8 or Frag.A.pGUP.PA.8. Some drug-induced expression 
of luciferase from the p53 responsive DNA sequence, fragment A, was 
observed in A2780cp70 cells however, relative luminescence levels were not 
very high and a direct comparison with A2780 was not possible. This is 
congruous with other data which suggest that A2780cp70 has reduced p53
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activity with respect to its parental line, A2780. The data obtained by Northern 
blot analysis is perhaps more meaningful as it involves activation of an 
endogenous gene rather than exogenously transfected DNA.
Another measure of p53 activity is the ability to cause arrest in the G1 
phase of the cell cycle in response to DNA damage inducing agents. This can 
be measured by flow cytometric analysis of BUdR incorporation along with 
propidium iodide staining. An example of an experiment which used the G1 
arrest in response to 2Gy or 4Gy ionising radiation to measure the differential 
p53 activity between A2780 and A2780cp70 cells is provided in figure 3.4.1 
(taken from Brown et al., 1993). In this figure, A2780 cells are represented by 
squares, A2780cp70 by circles. Also the open symbols signify cells treated 
with 4Gy and the closed symbols cells given a 2Gy dose. Following 
irradiation there was a rapid drop in the percentage of A2780 cells entering S 
phase (fig. 3.4.1a) and the percentage of cells in S phase (fig. 3.4.1b) 
compared to untreated control cells. Also the fraction of cells responding to 
DNA damage with a G1 block, rose when the radiation dose was increased. In 
the case of A2780cp70 cells, there was not such a pronounced drop in the 
fraction of cells entering S phase or actually in S phase. Thus transition from 
the cisplatin sensitive cell line, A2780 to resistant A2780cp70 cells involved 
loss of the capacity to arrest in G1 phase of the cell cycle after exposure to 
DNA damage inducing agents. This loss of G1 arrest in A2780cp70 cells is 
symptomatic of reduced p53 activity. Transfection of a mutant p53 gene into 
A2780 cells abrogates G1 arrest in response to ionising radiation (McIlwrath et 
al., 1994). It also prevents G1 and G2 arrests in response to cisplatin 
treatment.
There does appear to be a link between the ability to arrest in G1 phase 
of the cell cycle in response to DNA damage, as determined by flow 
cytometric analysis after treatment with ionising radiation, and the sensitivity
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FIGURE 3.4.1 The Ability To Arrest In G1 Phase After DNA Damage
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of cells to DNA damaging agents (O'Conner et al., 1993; McIlwrath et al.,
1994). However there are likely to be other mechanisms which predominate in 
different cell types which explains why some investigators (Slichenmeyer et 
al., 1993) do not find such a correlation.
It has been shown that transfection of a mutant p53 gene with a valine 
to alanine substitution at codon 143 into A2780cp70, but not A2780 cells, 
raises cisplatin sensitivity 2-3 fold compared to vector alone controls (Brown 
et al., 1993). This suggests that possession of a wild type p53 protein is 
relevant to drug resistance in this cell line at least, despite its reduced activity. 
It is feasible that some factor of a DNA damage response pathway, which 
incorporates p53 protein, has been mutated in this cell line so that p53 protein 
is no longer able to recognise it. The mutant p53 protein conformation might 
be altered in such a way as to restore affinity for this component and "mend" 
the "broken link" in the damage response pathway.
As p53 protein is required for apoptosis in certain circumstances 
(Lowe et al., 1993a; Lowe et al., 1993b; Yonish-Roach et al., 1993; Clarke et 
al., 1993; Lee & Bernstein, 1993), reduced p53 activity might in turn reduce 
the frequency of drug-induced apoptosis thereby permitting greater cell 
survival after DNA damage. Indeed there does appear to be reduced 
susceptibility to apoptosis, as determined by DNA fragmentation 72 hours 
after exposure to y-ray radiation, in A2780cp70 cells when compared to 
A2780 cells (A.McIlwrath, CRC Department of Medical Oncology, Glasgow 
University personal communications).
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CHAPTER 4: DNA DAMAGE RECOGNITION PROTEINS AS
POTENTIAL MEDIATORS OF CISPLATIN RESISTANCE
4.1 INTRODUCTION
4.1.1 THEORETICAL ROLES OF DNA DAMAGE RECOGNITION 
PROTEINS IN DRUG RESISTANCE
In the previous chapter, I have shown that a signal pathway leads from 
cisplatin-induced DNA damage to p53 induction. DNA damage might be 
recognised directly by p53 but it is likely that the signal is transduced by other 
factors. Proteins which bind to lesions of the DNA i.e damage recognition 
proteins are likely candidates for this task. They are of interest anyway as they 
could be involved in alternative DNA damage signal pathways. They may 
prove to be repair proteins or proteins which minimize damage-related DNA 
distortions and thereby be capable of counteracting cisplatin-induced DNA 
damage. However they could simply be trapped because the lesion prevents 
their dissociation from, or progression along, the DNA and may have a 
function unrelated to cisplatin DNA damage metabolism.
An example of DRP involvement in cell survival after DNA damage is 
provided by the Uvr endonuclease-mediated excision pathway. This occurs in 
the prokaryotic organism, Escherichia coli when the DRP, Uvr A binds as a 
dimer to UvrB and this multimeric complex associates with UV-induced DNA 
adducts. Then the UvrC protein becomes associated with and nicks the 
damaged DNA facilitating its removal (Orren & Sancar, 1989). The UvrA 
protein is not involved in incision and functions as a DRP in order to recruit 
the other proteins to the damage site.
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4.1.2 DNA DAMAGE RECOGNITION PROTEINS FOUND USING THE 
GEL MOBILITY SHIFT ASSAY
The gel mobility shift assay operates on the principle that DNA- 
binding proteins will complex to and retard the progress of radiolabelled DNA 
through a non-denaturing polyacrylamide gel. This results in the formation of 
further "bands" on exposure of the gel to photographic film. UV specific 
DRPs have been detected by gel mobility shift analysis in HeLa cells (Chao et 
al., 1991c; van Assendelft et al, 1993), and CV-1 monkey cells. DRPs which 
have affinity for cisplatin-modified DNA have been found in extracts from 
human HeLa cells (Chu & Chang, 1988; Chao et al, 1991c). Also cisplatin- 
DRP activity has been detected using this technique in CHO hamster cells, 
2008 human ovarian, MDCK and LLC-PK kidney tubule cells (Andrews & 
Jones, 1991) and in S. cerevisiae yeast cells (Patterson & Chu, 1989).
Using a cisplatin-damaged, 54 base-paired oligonucleotide (2aG7) in 
the gel mobility shift assay with nuclear extracts prepared from human, 
ovarian tumour cell lines, two complexes designated "Bl" and "B2" were 
detected (K.McLaughlin PhD thesis, Glasgow university). Binding of 2aG7 to 
the damage recognition proteins which form Bl and B2 can be competed out 
using platinated calf thymus DNA but not unplatinated calf thymus DNA 
demonstrating their specificity. Similar complexes can be seen for human, 
murine and feline extracts so the proteins involved appear to be conserved 
amongst mammals. Complex Bl has been found to involve human single 
stranded binding protein (hssB), also known as RPA and RFA, which 
participates in DNA replication (Clugston et al., 1992). However no difference 
in levels of hSSB between the cisplatin sensitive cell lines, OvlP, SuSa, 
A2780 and RT112 and their resistant counterparts could be detected by 
Western blotting. The protein, hSSB, has been demonstrated to be required for 
human DNA excision repair in a cell free system using HeLa cell extracts
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(Coverley et al., 1991). In this chapter the B2 complex will be analysed and 
its identity elucidated.
4.1.3 DNA DAMAGE RECOGNITION PROTEINS FOUND USING 
SOUTH WESTERN BLOTTING
South-western blotting involves the separation of proteins on a 
denaturing concentration gradient gel followed by blotting of the proteins onto 
a nitrocellulose membrane. Proteins attached to the membrane are then 
examined for their DNA hybridization capacity by incubation in the presence 
of a radiolabelled oligonucleotide (see section 2.5.6 for further details). From 
HeLa cells, DNA-damage inducible DRP proteins of 130KDa and 95KDa 
have been detected by South-western blotting (Chao et al., 1991a). Also in 
HeLa cell extracts a cisplatin-DRP doublet of 40-42KDa (Robbins et al.,
1991) and an 81KDa cisplatin DRP (Toney et al., 1989; Bruhn et al., 1992) 
have been found using this modified Western blotting procedure. Using this 
method DRP activity has also been seen for the IXR1 yeast protein (Brown et 
al., 1993) and proteins of 26, 28 and 97KDa in the 2008 ovarian carcinoma 
cell line (Andrews & Jones, 1991).
When South-western blotting was employed to identify cisplatin-DNA 
DRPs in nuclear extracts from the human ovarian carcinoma cell lines A2780, 
OvlP and their cisplatin resistant derivatives, there seemed to be four such 
proteins of 97KDa, 70KDa, 48KDa and 25KDa (K. McLaughlin, PhD thesis, 
Glasgow University). The 97KDa and 48KDa proteins exhibit increased 
expression in the cisplatin resistant OvlPDDP cell line compared to the 
cisplatin sensitive OvlP cells from which they were selected. However there 
is no difference in detectable levels of these proteins between A2780 cells and 
the cisplatin resistant derivative, A2780cp70. This does not however rule out 
the possibility of differential activity of these proteins as DNA damage signal 
transducers. None of the four proteins could be induced by cisplatin exposure
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(McLaughlin PhD thesis, Glasgow university). These proteins could be 
identical to those observed using the gel mobility shift assay or they may be 
entirely different proteins with novel damage recognition sites exposed by 
denaturation. One might wonder whether the 70KDa protein detected on 
South-western blots could represent the 70KDa hSSB subunit, however this 
seems unlikely as the 70KDa DRP was unable to bind to single-stranded DNA 
on South-western blotting. The hSSB protein probably needs to be in a 
complex, constituting 70KDa, 34KDa and 13KDa subunits, in order to show 
DNA binding capacity. This would not happen in South-western blotting as 
the denaturing conditions cause separation of the components of multimeric 
protein complexes.
4.1.4 WHAT ARE HMG PROTEINS AND COULD THEY BE 
RESPONSIBLE FOR B2 COMPLEX FORMATION?
HMG (High Mobility Group) proteins are all less than 30KDa and 
include HMG1 (28KDa), HMG2 (27KDa), HMG 14 and 17 (10-20 KDa) , 
HMG 20 also known as ubiquitin and HMGI/Y, the lOKDa splice variants 
which differ in 11 amino acids which are lacking in HMGY (Eckner & 
Bimstiel, 1989). They interact with DNA and are soluble in 2% TCA (Einck 
& Bustin, 1985). This latter property is not the case for most other proteins. 
Also as HMG1 has been shown to interact with cruciform DNA (Bianchi et 
al., 1989), it seemed feasible that such proteins might have affinity for other 
structural distortions such as cisplatin-damaged DNA. HMG proteins contain 
a high proportion of acidic and basic residues (Einck & Bustin., 1985). They 
have a well conserved primary sequence and can be extracted from nuclei and 
chromatin with 0.35M NaCl.
The B2 complex detected by gel retardation analysis of cisplatin 
treated oligonucleotides could be formed by a protein containing a "HMG 
box", a region of homology to HMG proteins. Examples of such proteins are
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the transcriptional regulators, LEF-1 (Giese et al., 1991) and hUBF (Jantzen et 
al., 1990). The ACP2 gene from the yeast, Saccharomyces cerevisiae has 19% 
amino acid homology with HMG1 (Haggren & Kolodrubetz, 1988). In fact, 
members of the HMG superfamily can be found in organisms as diverse as 
plants, yeast and animals (Laudet et al., 1993).
4.1.5 AIMS OF THIS CHAPTER
1) In this chapter a purification scheme for the protein involved in B2 complex 
formation will be developed using the gel mobility shift assay to determine 
DRP activity.
2) The identity of the B2 forming protein will be determined.
3) The protein, p53 will be shown to have no intrinsic DRP activity as 
measured by the gel mobility shift assay.
RESULTS
4.2 METHOD DEVELOPMENT FOR PURIFICATION OF A DNA 
DAMAGE RECOGNITION PROTEIN
4.2.1 USE OF THE GEL MOBILITY SHIFT ASSAY TO ASSESS DNA 
BINDING ACTIVITY
The gel mobility shift assay has often been used to detect proteins 
which bind to DNA either non-specifically or to DNA of a particular shape or 
sequence. An example (taken from K.McLaughlin., Phd. thesis, Glasgow 
University) is given in figure 4.2.1 of a typical gel mobility shift assay used to 
examine proteins which have affinity for cisplatin-damaged DNA. Lanes 1 
and 2 were control lanes, loaded with radio-labelled oligonucleotide alone. A 
single band representing free oligonucleotide probe can be seen in these lanes. 
Lanes 3-10 were each loaded with reaction products obtained by incubating 
lpg of HeLa cell nuclear extract with the radioactive oligonucleotide, 2aG7. 
In lane 3, unplatinated 2aG7 (DS) was used and no complex observed. When 
2aG7 that had been platinated (PDS), and had thus acquired cisplatin-DNA 
adducts, was used instead (lane 4), 2 other major bands were seen which were 
named Bl and B2. This chapter is concerned with analysing the B2 complex. 
The Bl complex has been shown to contain hSSB protein (Clugston et al.,
1992).
Lanes 5, 6 and 7 were loaded with similar components to lane 4 but 
with the inclusion of increasing amounts of "cold" calf thymus (CT) DNA 
which had no effect on formation of either complex. When "cold" calf thymus 
DNA containing cisplatin-DNA adducts was used as a competitor (lanes 8- 
10), there was a disappearance of both Bl and B2 complexes. This 
demonstrates that the proteins involved in formation of these complexes have 
specific affinity for cisplatin-damaged DNA.
1 22
FIGURE 4.2.1 An Example Of A Gel Mobility Shift Assay
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This example of a gel mobility shift assay (section 2.8) is adapted from K. 
McLaughlin PhD thesis, Glasgow University. 5x 1(F d.p.m. of 2aG 7 either treated with 
cisplatin (lanes 2 & 4-10) or untreated (lanes 1 & 3) was incubated on ice for 30 minutes in a 
final volume of 20pl. lp g  HeLa nuclear extract (section 2.2.3) was included in lanes 3-10. 
Untreated calf thymus DNA was included in lanes 5 (2.5pg), 6 (7.5pg) & 7 (12.5pg). 
Cisplatin treated calf thymus DNA was included in lanes 8, (2.5pg), 9 (7.5pg) & 10 (12.5pg). 
Reaction products were separated out by non-denaturing polyacrylamide gel electrophoresis. 
The gel was dried and exposed to photographic film.
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4.2.2 ASSESSING THE VALIDITY OF ANION EXCHANGE 
CHROMATOGRAPHY AS A METHOD OF DRP PURIFICATION
Anion exchange chromatography was tried out as a method for 
separating the protein involved in B2 complex formation from other nuclear 
constituents. So as to quantify B2 complex formation, the arbitary units "ba" 
(binding activity) will be used, where lba is equal to the binding activity 
found in 8.6mg of crude extract. A large scale nuclear extract (196 mg total) 
was prepared from OvlPDDP cells (see section 2.2.3) and this had a specific 
activity of 0.116ba/mg and a protein concentration of 8.6mg/ml. Anion 
exchange chromatography was carried out as described in section 2.6.2 using 
172mg of this crude nuclear extract as a starting material, a total of 32 
fractions were collected. An equal volume (3pl) of each fraction was assayed 
by comparison to extracts with known B2 complex-forming ability using the 
gel mobility shift assay (section 2.8). Lanes 1-18 contain fractions 3-7 then 
20-32, a negative control which lacks cellular extract was contained in lane 21 
and positive controls of OvlPDDP TCA supernatant and crude nuclear 
extract were loaded on lanes 20 and 22 respectively. Fractions were chosen for 
inclusion in this assay based on the elution profile obtained during anion 
exchange chromatography.
Most B2 complex forming activity is eluted in fractions 27-32 (lanes 
13-18) with peak activity in fraction 28 (lane 14). The total protein content of 
these 6 fractions was estimated as 16.8mg and the total activity was 9ba as 
quantified by comparison to crude nuclear extract. Therefore specific activity 
of these 6 fractions once pooled, was 0.54ba/mg indicating a 5 fold 
purification. Use of an anion exchange column can be used to separate the B2 
complex forming activity although it is not especially efficient.
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FIGURE 4.2.2 A Gel Mobility Shift Assay Of Anion Exchange Fractions
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The proteins in 172mg of crude OvlPDDP nuclear extract (section 2.2.3) were 
separated using a gradient of 100% buffer A (0.1M NaCl, 0.02M Tris -pH 7.6) to 100% buffer 
B (2M NaCl, 0.02M Tris-pH 7.6) on a MonoQ^M column (section 2.6.2). Gel mobility shift 
analysis was carried out (section 2.8): 5x 10^ d.p.m. of 2aG7 treated with cisplatin was 
incubated for 30 minutes on ice in a final volume of 20pT 3pil of fractions 3-7 then 20-32 
were included (lanes 1-18). 3pil of an anion exchange fraction with known DRP activity was 
included in lane 19 as a positive control. 3 pi of 2% TCA soluble OvlPDDP nuclear proteins 
(lane 20) and 3 |wl of crude, nuclear extract (lane 22) were also used as positive controls. 
Reaction products were separated out by non-denaturing polyacrylamide gel electrophoresis. 
The gel was dried and exposed to photographic film.
1 25
4.2.3 THE USE OF TCA TREATMENT AS AN INITIAL CLEAN UP 
STAGE FOR DRP PURIFICATION
Due to an apparent similarity in certain properties between the B2 
complex forming protein and the HMG class of proteins, which are soluble in 
2% TCA unlike most proteins, solubility in TCA was examined as a possible 
method of separation. TCA treatment of nuclear extracts was carried out as 
described in section 2.6.1 and proteins were analysed for DRP activity by gel 
mobility shift assay. The results of such an assay using a TCA treated 
A2780cp70 nuclear extract are depicted in figure 4.2.3. Lanes 1 and 2 are 
control lanes with lane 1 containing unplatinated 2aG7 and lane 2 containing 
platinated 2aG7. No complex is detected in these lanes. In lanes 5 and 6, 1 pi 
of TCA supernatant was incubated with unplatinated or platinated 
oligonucleotide respectively. Binding was only seen when platinated 
oligonucleotide was included indicating that this binding activity was specific 
for cisplatin-damaged DNA. In lanes 3 and 4, lpl of resuspended TCA 
precipitate was included instead of supernatant. It was expected that the 
pelleted proteins would represent all other nuclear proteins except for the TCA 
soluble varieties and so no B2 complex forming activity would be present. On 
the contrary 12 fold more activity was seen in lane 4 compared to lane 6 but 
due to the concentrated nature of the pelleted proteins, this accounts for a 
fraction of total nuclear activity. Some non-specific binding to unplatinated 
oligonucleotide was seen in lane 3 but this had a lower mobility than the 
cisplatin-damage specific activity observed with the supernatant in lane 6. 
Thus most, but not all of this DRP is found in the TCA soluble fraction of a 
nuclear extract.
When 17.2mg of crude nuclear OvlpDDP extract was treated with 
TCA, the supernatant had an affinity for cisplatin-damaged DNA of 6.4ba/mg 
representing a 55 fold purification when compared to crude nuclear starting 
material (table 4.2.1). The DRP activity of this supernatant displayed a
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FIGURE 4.2.3 DRP Activity In A TCA Supernatant
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The proteins in a crude A2780cp70 nuclear extract (section 2.2.3) were treated with 
2% TCA (section 2.6.1) and TCA soluble proteins (2ml) separated out by spinning in a 
microfuge. The pellet was resuspended in 20pl. Gel mobility shift analysis was carried out 
(section 2.8): 5x 1(P d.p.m. of 2aG7 either treated with cisplatin (lanes 2, 4 & 6) or untreated 
(lanes 1, 3 & 5) was incubated for 30 minutes on ice in a final volume of 20(al. 1 (^ 1 of TCA 
pellet was included in lanes 2 & 3 and 1 [il of TCA soluble proteins were included in lanes 5 & 
6. Reaction products were separated out by non-denaturing polyacrylamide gel 
electrophoresis. The gel was dried and exposed to photographic film.
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similar mobility (fig. 4.2.2 lane 20) to that of crude nuclear material (fig.
4.2.2 lane 22) and to the anion exchange fraction used as a positive control 
(lane lp), when these extracts were concomitantly subjected to gel mobility 
shift analysis. Also one can discern no Bl complex formation by the TCA 
supernatant. When 4.5pg of this TCA supernatant was loaded and run on a 
20% polyacrylamide gel only 2 bands close to the 18KDa and 28KDa size 
markers were discernible following coomasie and silver staining. TCA 
treatment of nuclear extract was thus selected as the initial stage in the 
purification scheme and OvlPDDP TCA supernatant was subjected to further 
separation protocols.
4.2.4 USING CHROMATOGRAPHIC TECHNIQUES TO FURTHER 
PURIFY A DRP FROM OTHER TCA SOLUBLE PROTEINS
The OvlPDDP TCA supernatant detailed in section 4.2.3 was loaded 
onto an anion exchange column and proteins were eluted as described in 
section 2.6.2. Fractions were examined for activity by gel mobility shift assay 
(fig. 4.2.4). Lane 1 contains platinated oligonucleotide alone, lane 2 contains 
platinated 2aG7 incubated with crude nuclear OvlPDDP extract as a positive 
control and lanes 3-15 contain fractions 1-13. Activity was found to be in 
lanes 7-13, which when pooled had a specific activity of 7.5ba/mg giving a 64 
fold purification compared to crude extract. These 5 pooled fractions were 
then used for a further purification strategy, heparin column chromatography.
Heparin column separation was performed as recorded in section 2.6.3 
using pooled anion exchange fractions of an OvlPDDP nuclear TCA 
supernatant. 16 fractions were collected and analysed by gel mobility shift 
assay (fig. 4.2.5 lanes 1-16) using an extract-free incubation as a negative 
control (lane 19), also positive controls of OvlPDDP TCA supernatant (lane 
17) and crude nuclear extract (lane 18). Specific activity was 21.2ba/mg thus 
use of this scheme resulted in a 183 fold purification.
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FIGURE 4.2.4 DRP Aclivitv In TCA Treated Anion Exchange Fractions
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
-Bl complex
-B2 complex
*
oligonucleotide
The proteins in 17.2mg of crude OvlPDDP nuclear extract (section 2.2.3) were 
treated with 2% TCA (section 2.6.1) and TCA soluble proteins separated out by spinning in a 
microfuge. Proteins were further separated using a gradient of 100% buffer A (0.1M NaCl, 
0.02M Tris -pH 7.6) to 100% buffer B (2M NaCl, 0.02M Tris-pH 7.6) on a M onoQ ™  
(Pharmacia) anion exchange column (section 2.6.2). Gel mobility shift analysis was carried 
out (section 2.8): 5x 10^ d.p.m. of 2aG7 treated with cisplatin was incubated for 30 minutes 
on ice in a final volume of 20pl. Lane 1 was loaded with a negative control which contained 
no cell extract, 3pl of OvlPDDP nuclear extract was included in a positive control reaction 
(lane 2) and 3pl of fractions 1-13 were included in lanes 3-15. Reaction products were 
separated out by non-denaturing polyacrylamide gel electrophoresis. The gel was dried and 
exposed to photographic film.
*
«
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FIGURE 4.2.5 DRP Activity In Fractions Which Have Been TCA Treated 
Then Purified By Anion Exchange And Heparin Column Chromatography
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Anion exchange fractions of 2% TCA soluble, OvlPDDP nuclear proteins, which 
had DRP activity (figure 4.2.4) were separated further by heparin-sepharose column 
(Pharmacia) chromatography (section 2.6.3) using a gradient of 100% buffer A (0.1M NaCl, 
0.02M Tris -pH 7.6) to 100% buffer B (2M NaCl, 0.02M Tris (pH 7.6). Gel mobility shift 
analysis was carried out (section 2.8): 5x 10^ d.p.m. of 2aG 7 treated with cisplatin was 
incubated on ice for 30 minutes in a final volume of 20pil. 5 pi of fractions 1-16 were included 
in reactions loaded on lanes 1-16 respectively. Also, as positive controls lp l of 2% TCA 
soluble, OvlPDDP nuclear extract and lp l of crude nuclear extract were included in a 
reactions (lane 17 and lane 18 respectively). Lane 19 was a negative control lane containing 
no cell extract. Reaction products were separated out by non-denaturing polyacrylamide gel 
electrophoresis. The gel was dried and exposed to photographic film.
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TABLE 4.2.1 Partial Purification of A DRP
Eudfteatton
Stage
Total
iVctmty:
units (ba) 
defined below
totein
Concentration
(mg/ml)
totem
Content
(mg)
Specific
Aefiyite
(ba/mg)
M 4
Purification
crude
nudear
2 8.6 17.2 0.116 1
TCA
supernatant
1.91 0.15 0.3 6.4 55
anion
exchange
1.49 0.02 0.2 7.5 64
heparin
column
0.38 0.018 0.018 21.2 183
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4.3 CHARACTERISATION OF A DAMAGE RECOGNITION
PROTEIN (DRP)
4.3.1 ANALYSING THE SPECIFICITY OF THE B2 COMPLEX- 
FORMING ACTIVITY FOR CISPLATIN DAMAGED DNA
It was important to know that the activity responsible for the B2 band 
was specific for cisplatin-damaged DNA rather than being a more general 
DNA binding protein as this affects how relevant the activity is to cisplatin 
resistance. To confirm specificity, partially purified DRP activity obtained by 
HPLC separation of TCA soluble proteins (see section 4.3.2 for details) were 
examined by inclusion of competitor oligonucleotides in a gel mobility shift 
assay (section 2.8).
The results of this assay are presented in figure 4.3.1. Lane 1 contains 
platinated 2aG7 incubated with a known B2 complex-forming activity as a 
positive control. Lanes 2-21 were all loaded with lpil of pooled positive HPLC 
fractions from a TCA soluble portion of an OvlPDDP nuclear extract. No 
competitor was included in lanes 2,3 and 15 and so the retarded band observed 
in these lanes represents the full B2 complex-forming capacity of this semi- 
pure extract. Either lOOng, 500ng or 5pg of "cold" calf thymus DNA were 
included in the incubations loaded on lanes 4, 5 and 6 respectively. The B2 
band seen in each of these lanes does not appear to be diminished by the 
presence of calf thymus DNA . This indicates that the DNA binding activity 
has a preference for the cisplatin treated, radiolabelled DNA as opposed to the 
"cold" DNA without damage. Lanes 7, 8 and 9 were loaded with incubations 
containing lOOng, 500ng or 5pg respectively of "cold", UV treated DNA. 
Some reduction of the B2 band can be detected in lane 9 indicating that B2 
forming activity also has some degree of affinity for UV mediated DNA 
damage.
This competition is not nearly so dramatic as that seen on inclusion of 
cisplatin-treated, "cold" calf thymus DNA. Although 2ng of this (lane 10)
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FIGURE 4.3.1 Specificity Of Semi-Pure DRP Activity For Cisplalin-
Damaged DNA (legend overleaf)
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FIGURE 4.3.1 Specificity Of Semi-Pure DRP Activity For Cisplatin- 
Damaged DNA
2% TCA soluble, OvlPDDP, nuclear proteins were separated by reverse phase 
HPLC (section 2.6.4) on a Biorad Hipore butyl C4  silica-based column (30nm pore, 
4.6x250mm dimensions using a Waters HPLC unit (Millipore, Herts). A zinc lamp with a 
214nm filter was used for monitoring. A gradient was set up of 15%-50% then 50%-100% 
buffer B (0.1% trifluoroacetic acid in acetonitriler^O at a v/v ratio of 95:5 -pH 2.11) was set 
up. Buffer A was 0.1% trifluoroacetic acid in H2 O (pH 0.5). Gel mobility shift analysis was 
carried out (section 2.8): 5x 1 0  ^ d.p.m. of 2aG7 treated with cisplatin was incubated on ice 
for 30 minutes in a final volume of 20pl. HPLC fractions with DRP activity were pooled and 
lpl included per reaction (lanes 2-21). An anion exchange fraction was included as a positive 
control (lane 1). Competitors were lOOng (lane 4), 500ng (lane 5) or 5pg (lane 6 ) of calf 
thymus (CT) DNA, lOOng (lane 7), 500ng (lane 8 ) or 5pg (lane 9) of UV-treated CT DNA, 
2ng (lane 10), 20ng (lanes 11 & 16), lOOng (lane 12 & 17), 500ng (lanes 13 & 18) or 5pg 
(lane 14) of cisplatin-treated CT DNA and 20ng (lane 19), lOOng (lane 20) or 500 ng (lane 21) 
of transplatin-treated CT DNA. No competitor was included in reactions loaded in lanes 1-3 
or 15. Reaction products were separated out by non-denaturing polyacrylamide gel 
electrophoresis. The gel was dried and exposed to photographic filmjThis work was carried out 
in collaboration with Dr Donald Bisset, CRC Dept, of Medical Oncology.
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produces no marked effect on the B2 band intensity, when 20ng of cisplatin- 
damaged DNA are included (lanes 11 and 16), there is a sharp decrease in B2 
forming activity. When lOOng (lanes 12 and 17), 500ng (lanes 13 and 18) or 
5pg (lane 14) of "cold", cisplatin-damaged DNA are used as competitor, no 
apparent B2 complex can be discerned which suggests that virtually all the 
damage recognition activity is competed out by this DNA due to its higher 
concentration in these incubations. DNA treated with the trans isomer is 
ineffective as a competitor (lanes 19-21) demonstrating how specific this 
affinity is for cisplatin-induced DNA damage. Thus the B2 complex forming, 
damage recognition protein shows a preference for cisplatin-treated DNA 
rather than untreated, transplatin-treated or UV-treated DNA.
4.3.2 IS THE B2 COMPLEX-FORMING DAMAGE RECOGNITION 
PROTEIN A MEMBER OF THE HMG CLASS OF PROTEINS?
As discussed in section 4.1, there are certain similarities between the 
damage recognition protein responsible for the B2 complex seen in gel 
mobility shift assays and members of the HMG class of proteins. Reverse 
phase HPLC can be used to separate out HMG proteins from each other (Elton 
& Reeves., 1986). Therefore this seemed to be an appropriate point to begin 
analysis into the identity of the B2 complex-forming protein.
HPLC separation of 37.3pg of TCA soluble proteins from an 
OvlPDDP nuclear extract was done as described in section 2.6.4 and fractions 
were assayed for cisplatin-DNA damage affinity by gel mobility shift analysis 
as detailed in chapter 2.8. The elution profile is given in figure 4.3.2a and the 
result of the subsequent assay of fractions is shown in figure 4.3.2b. The 
cisplatin-DNA damage recognition activity seen was presumed to be identical 
to that found in the starting material. However a more objective investigation 
into this activity was given in figure 4.3.1.
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FIGURE 4.3.2 HPLC Separation of TCA Soluble Proteins (legend overleaf)
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HPLC Trace of a TCA Supernatant Prepared 
from an OvlP/DDP Nuclear Extract
active fractions 53-63
HPLC Separation of TCA Soluble Proteins
TCA soluble, OvlPDDP, nuclear proteins were separated by reverse phase HPLC 
(section 2.6.4) on a Biorad Hipore butyl C4  silica-based column using a Waters HPLC unit 
(Millipore, Herts.). Monitoring was carried out using a zinc lamp with a 214nm filter. A 
gradient was set up of 15%-50% then 50%-100% buffer B (0.1% trifluoroacetic acid in 
acetonitrile:H2 0  at a v/v ratio of 95:5 -pH 2.11) was set up. Buffer A was 0.1% trifluoroacetic 
acid in H2 O (pH 0.5). The trace obtained is shown (a). Gel mobility shift analysis was 
carried out (section 2.8): 5x 10  ^ d.p.m. of 2aG7 treated with cisplatin was incubated for 30 
minutes on ice in a final volume of 20pl. Fractions 53-79 (lOp.1 of one fraction/reaction) were 
included in reactions (lanes 1-27 respectively). Reaction products were separated out by non­
denaturing polyacrylamide gel electrophoresis. The gel was dried and exposed to 
photographic film (b).
From comparison to similar HPLC traces, the 2 large peaks seen 
between fractions 58 and 66 of the elution profile bore some resemblance to 
HMG1 and HMG2 peaks whereas the region representing DRP activity 
(fractions 53-63) had a similar appearance to a HMGI peak. This indicated 
that the DRP under investigation might be identical to HMGI.
4.3.3 IS HMGI RESPONSIBLE FOR THE B2 COMPLEX DETECTED BY 
GEL MOBILITY SHIFT ANALYSIS?
Due to the result obtained in the previous section, it seemed reasonable 
to further investigate whether the B2 complex was caused by HMGI binding 
to cisplatin-damaged DNA. In order to do this, anti-HMGI antibodies were 
used to examine whether they could bind to the complex, reducing its 
mobility and causing a supershift of the complex to a region further up on the 
gel.
Prior to gel mobility shift analysis (chapter 2.8), 1.5pg of TCA soluble 
proteins (per lane) were incubated for 30 minutes either alone, with 
preimmune serum or with anti-HMGI antibody then for a further 30 minutes 
with protein A. Also 500ng of recombinant HMGI were used in a gel mobility 
shift incubation. The products of these incubations were loaded and run on a 
gel (section 2.8.2) and results of this are shown in figure 4.3.3.
Lanes 1, 2 and 3 were negative control lanes containing unplatinated, 
platinated 2aG7 DNA or unplatinated 2aG7 incubated with TCA soluble 
proteins respectively. Lane 4 contained 1.5pg of TCA supernatant which had 
been incubated with platinated 2aG7, giving rise to a B2 band, as a positive 
control. Lanes 5 and 6 were essentially the same as lanes 3 and 4 but with the 
inclusion of protein A which made no difference to the number or intensity of 
any bands observed. Lanes 7-14 all contained 1.5p.g of TCA soluble nuclear 
proteins incubated with platinated 2aG7. Of these, lanes 11 and 13 also 
contained preimmune serum, lanes 7 and 9 contained preimmune serum and
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FIGURE 4.3.3 HMGI Does Not Bind To Cisplalin-Damaged DNA (1)
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1.5pg/lane of 2% TCA soluble, OvlPDDP, nuclear proteins were incubated alone 
(lanes 3 & 4), with 25pl of protein A (Amersham International) for 30 minutes (lanes 5 & 6), 
with 2pl of either preimmune serum (lanes 11 & 13) or anti-HMGI (lanes 12 & 14) for 30 
minutes or with 25pl protein A for 30 minutes followed by a further 30 minutes with either 
2pl of preimmune serum (lanes 7 & 9) or 2pl of anti-HMGI (lanes 8 & 10). Gel mobility shift 
reactions were then set up (section 2.8): 5x 10^ d.p.m. of 2aG7 either untreated (lanes 1, 3 & 
5) or treated with cisplatin (lanes 2, 4 & 6-15) was incubated for 30 minutes in a final volume 
of 45pl. Also 500ng of HMGI protein in 5pl of TMS buffer was included in a gel mobility 
shift reaction in the absence of cell extract (lane 15). All incubations were carried out on ice. 
Reaction products were separated out by non-denaturing polyacrylamide gel electrophoresis. 
The gel was dried and exposed to photographic film. Anti-HMGI and pre-immune serum were 
each stored at a 1/500 dilution in PBS, 0.02% sodium azide. AH incubations were carried out 
on ice.
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FIGURE 4.3.4 HMGI Does Not Bind To Cisplalin-Damaged DNA (2)
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0.8pg/lane of 2% TCA soluble, OvlPDDP, nuclear proteins were incubated alone 
(lanes 3 & 4), with lp l of preimmune serum (lane 5) or with lp l (lane 6), 0.1 pi (lane 7), 
0.01 pi (lane 8) or 0.001 pi (lane 9) of anti-HMGI for 30 minutes. Gel mobility shift reactions 
were then set up (section 2.8): 5x 10^ d.p.m. of 2aG7 either untreated (lanes 1, 3 & 10) or 
treated with cisplatin (lanes 2, 4-9 & 11-13 ) was incubated for 30 minutes in a final volume 
of 20pl. Also 500ng of HMGI protein/reaction was included in gel mobility shift reactions 
without cell extract and either without antibody (lanes 10 & 11), with lp l preimmune serum 
(lane 12) or with lp l anti-HMGI (lane 13). All incubations were carried out on ice. Reaction 
products were separated out by non-denaturing polyacrylamide gel electrophoresis. The gel 
was dried and exposed to photographic film. Anti-HMGI and pre-immune serum were each 
stored at a 1/500 dilution in PBS, 0.02% sodium azide.
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protein A, lanes 12 and 14 contained anti-HMGI and lanes 8 and 10 contained 
anti-HMGI along with protein A. There was no difference in the number of 
retarded bands seen in any of these lanes, although they all possessed a band 
not seen for TCA supernatant alone (lane 4). This band has been designated 
the "z complex". As there was no difference in the number of complexes seen 
for incubations including preimmune serum or anti-HMGI, as the B2 complex 
is not diminished in any of these lanes and as recombinant HMGI alone is 
unable to retard the platinated oligonucleotide (lane 15), one must conclude 
that the B2 complex does not involve HMGI.
The results of a similar experiment are depicted in figure 4.3.4. Again 
no shift of 2aG7 oligonucleotide DNA was detected for negative control lanes 
(1-3) but a B2 complex was seen for the positive control, lane 4, which 
contained an incubation of 0.75pg of TCA soluble proteins with platinated 
2aG7. When preimmune serum (lane 5) or anti-HMGI (lane 6) were incubated 
with TCA supernatant before addition of 2aG7, the z complex was seen again 
and this disappeared on dilution of anti-HMGI (lanes 7-9). Recombinant 
HMGI was examined for its capacity to retard platinated oligonucleotide by 
incubation with unplatinated 2aG7 (lane 10), platinated 2aG7 (lane 11), 
platinated 2aG7 and preimmune serum (lane 12) or platinated 2aG7 and anti- 
HMGI (lane 13). Although the entire free oligonucleotide band seems to have 
been shifted upwards in each of these lanes, it is streaky, forms no discrete 
band indicating no specific affinity and there is no evidence for recombinant 
HMGI being capable of forming a B2 complex. Thus HMGI does not seem to 
be the protein involved in B2 complex formation.
4.3.4 HMGI IS INVOLVED IN FORMATION OF THE B2 COMPLEX
To examine whether HMGI might be responsible for the B2 complex 
which one detects with the gel mobility shift assay, a similar experiment to
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FIGURE 4.3.5 HMGI Binds To Cisplatin-Damaged DNA
supershift-
B2 complex-
free 
oligo.{
1 2 3 4  5 6 7  8 9  10
0.75pg/lane of 2% TCA soluble, OvlPDDP, nuclear proteins were incubated with 
lp l of anti-HMGI for 30 minutes on ice before addition of radiolabelled DNA (lanes 7 & 8). 
Gel mobility shift reactions were then set up (section 2.8): 5x 10-^  d.p.m. of 2aG 7 either 
untreated (lanes 1 ,3 , 5, 7 & 9) or treated with cisplatin (lanes 2, 4 , 6, 8 & 10) was incubated 
for 30 minutes in a final volume of 20pl. 0.75mg of 2% TCA soluble nuclear extract was 
included in reactions without antibody (lanes 3 & 4) and with lp l anti-HMGI added at the 
same time as DNA (lanes 5, 6). Also lOpg of HMGI protein was included in gel mobility 
shift reactions (lanes 9 & 10). All incubations were carried out on ice. Reaction products were 
separated out by non-denaturing polyacrylamide gel electrophoresis. The gel was dried and 
exposed to photographic film.
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FIGURE 4.3.6
a) A South-Western Blot b) A South-Western Blot 
Probed with Probed with
Unplatinated 2aG7 Platinated 2aG7
f 28 KDa
17.5 KDa
15.5 KDa
HMGI HMG2 A2780 HMGI HMG2 A2780
1 2  3 1 2  3
South-western blotting (section 2.5.6) was carried out on lp g  of HMGI (lane 1), lp g  
of HMG2 (lane 2) and 50 pg of A2780 nuclear extract (lane 3): Proteins were separated on a 
5-15% polyacrylamide gradient gel and transferred to a nitrocellulose filter which was probed 
with 2x10^ d.p.m/ml of either untreated (a) or cisplatin-treated 2aG 7 (b). Protein sizes were 
estimated using prestained molecular weight standards, BRL.
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those described in section 4.3.3 was carried out using an anti-HMGI antibody 
and recombinant HMGI. Results of this are presented in figure 4.3.5. Lanes 
1, 2 and 3 are negative control lanes loaded with unplatinated 2aGl, 
platinated 2aG7 or unplatinated 2aG7 which had been incubated with 0.75pg 
of TCA soluble proteins. Lane 4, the positive control lane, was loaded with an 
incubation of 0.75pg of TCA soluble proteins and platinated 2aG7 and this 
clearly demonstrates B2 complex formation. When anti-HMGI was included 
in the incubation at the same time as 2aG7, no additional complex was 
detected (lane 6). However, when anti-HMGI was incubated with the proteins 
for 30 minutes prior to 2aG7 being added, a supershift of the B2 complex was 
perceived (lane 8). Also lpg of recombinant HMGI was able to retard the 
platinated 2aG7 (lane 10) but not the unplatinated version (lane 9). This data 
suggests that HMGI is the protein responsible for the B2 complex attained by 
gel mobility shift analysis of nuclear proteins.
Recombinant HMGI and HMG2 proteins were also examined for their 
affinity for platinated DNA by South-western blotting (section 2.5.6). Either 
lpg HMGI, lpg HMG2 or 50pg crude A2780 nuclear extract were 
electrophoresed through a polyacrylamide gel, blotted onto nitrocellulose and 
the blot was probed for binding by unplatinated 2aG7 (fig. 4.3.6a) then re­
probed with platinated 2aG7. No binding was detected with the unplatinated 
oligonucleotide but a faint band was seen in the 25KDa region for A2780 
extract (lane 3 of fig. 4.3.6b) and a more intense band observed for HMGI 
(lane 1) and HMG2 (lane 2). The HMGI band has slightly slower mobility 
than the HMG2 band or the band in the A2780 lane but small differences in 
mobility between nuclear extract proteins and recombinant proteins could be 
accounted for by post translational modification. This data suggests that 
HMGI and HMG2 are able to bind specifically to platinated DNA under 
denaturing conditions.
144
4.3.5 AN INVESTIGATION INTO WHETHER p53 HAS AFFINITY FOR 
CISPLATIN-INDUCED DNA DAMAGE
In order to examine whether p53 or proteins which bind to p53 have 
affinity for cisplatin-damaged DNA, immunoprecipitated p53 protein was 
analysed for DNA damage recognition capacity. Also in the hope of co- 
precipitating any proteins responsible for transducing the DNA damage signal 
to p53 protein and thus causing induction of p53 protein levels, lysis was 
carried out with and without a prior cisplatin treatment. Semi-confluent A2780 
or A2780cp70 cells were lysed with high salt lysis buffer in 175cm2 flasks 
immediately after a lhour, lpM cisplatin dose or a medium change in the case 
of control cells. Lysates were split into 3 equal portions and each of these was 
used for immunoprecipitation reactions (section 2.6.5) with one of the 
following antibodies, PAb419 (a control antibody), PAb240 (reactive with 
mutant p53 protein) or PAb DO-1 (reactive against both mutant and wild-type 
p53 protein).
Immunoprecipitated proteins were separated and examined by Western 
blotting as described in chapter 2.5. The results of this are shown in figure 
4.3.7. No p53 immunoreactivity was detected for A2780 cells (lanes 1-6). This 
was expected as A2780 has very low levels of p53 protein. No p53 was 
detected for A2780cp70 proteins immunoprecipitated with the control 
antibody (lanes 7 and 8). Some p53 protein was precipitated from A2780cp70 
cells by the mutant specific antibody (lanes 9 and 10) but not as much as with 
the pantropic DO-1 antibody (lanes 11 and 12). There was no difference 
between levels of p53 protein precipitated from cisplatin untreated and treated 
cells (lane 9 compared to lane 10 and lane 11 compared to lane 12 
respectively) as p53 protein levels had not been given sufficient time to 
respond to the DNA damage. Thus detectable levels of p53 protein were 
precipitated from A2780cp70 cells by PAb 240 and PAb DO-1 but not 
PAb419 or from the A2780 cell line.
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FIGURE 4.3.7 Immunoprecipitation Of p53 Protein
1 2 3 4 5 6 7 8 9 10 11 12 13 
- + - + -  + - +  -  +  -  +
-P53
419 240 DO-1 419 240 DO-1
A2780 A2780cp70 HT29
Immunoprecipitation (section 2.6.5) was performed on cells which had been given a 
lpM , 1 hour cisplatin dose an hour beforehand (lanes 2, 4, 6, 8, 10 & 12) or control cells 
(lanes 1, 3, 5, 7, 9 & 11) followed by separation of proteins on an 8% polyacrylamide gel. 
Western blotting (section 2.5) of immunoprecipitated p53 protein from A2780 (lanes 1-6), 
A2780cp70 (lanes 6-12) and lOOpg of crude cell lysate from HT29 cells (lane 13) as a 
positive control was carried out. Extracts were immunoprecipitated with the antibodies PAb 
DO-1 (lanes 5, 6, 11 & 12), PAb 240 (lanes 3, 4, 9 & 10) and PAb 419 (lanes 1, 2, 7 & 8). 
PAb DO-1 is a pantropic anti-p53 antibody, PAb 240 is specific for mutant p53 and PAb 419 
is an irrelevant control antibody. For Western blotting, the primary antibody was CM1 at a 
1/200 dilution and the secondary antibody was anti rabbit Ig horseradish peroxidase from 
Dako, Aylesbury, at a 1/150 dilution. Protein sizes were determined by comparison to 
prestained size markers from BRL.
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FIGURE 4.3.8 DRP Aclivity Of p53 Immunoprecipitates
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Gel mobility shift analysis (section 2.8) was carried out: 5x 1(P d.p.m. of 2aG7 
treated with cisplatin was incubated for 30 minutes in a final volume of 20pl. 8pg of O vlP  
nuclear extract was included as a positive control (lane 1). Immunoprecipitated proteins from 
A2780 (lanes 2-7) and A2780cp70 (lanes 8-13) cells were included. A 1 hour, lp.M cisplatin 
dose had been given to certain cells, 1 hour before immunoprecipitation (lanes 3, 5, 7, 9, 11 & 
13). Extracts were immunoprecipitated with PAb 419 (lanes 2, 3, 8 & 9), PAb240 (lanes 4, 5, 
10 & 11) or PAb DO-1 (lanes 6, 7, 12 & 13). All incubations were carried out on ice. Reaction 
products were separated out by non-denaturing polyacrylamide gel electrophoresis. The gel 
was dried and exposed to photographic film.
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The immunoprecipitated proteins were then assessed for the ability to 
bind platinated 2aG7 DNA by gel mobility shift assay (section 2.8). The 
results of this experiment are depicted in figure 4.3.8. Lane 1 contained the 
positive control, an incubation of a crude nuclear OvlP extract with known 
DRP activity and platinated 2aG7 oligonucleotide. Lane 14 contained the 
platinated oligonucleotide alone as a negative control. All of the 
immunoprecipitates obtained contained a DRP with similar mobility to the B2 
complex and another DRP activity designated the "x complex". These 
proteins have probably been precipitated as background proteins, due to their 
relative abundance, by binding to the G protein used in the 
immunoprecipitation protocol. No difference in DRP bands can be discerned 
between those precipitates which showed p53 protein immunoreactivity (lanes 
10-13) and those which did not (lanes 2-10). Therefore this experiment 
provides no evidence for a cisplatin-DNA damage recognition capacity 
inherent to p53 protein or any proteins tightly complexed to p53 protein.
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4.4 DISCUSSION
4.4.1 PURIFICATION OF A DNA DAMAGE RECOGNITION PROTEIN
Progress was made in developing a purification scheme for separating 
the protein responsible for the B2 complex seen on gel mobility shift analysis, 
from other nuclear components. TCA treatment was the most efficient stage, 
giving a 55 fold purification fold with respect to crude nuclear extract. The 
subsequent anion exchange chromatography and heparin column 
chromatography gave a final 183 fold purification compared to crude, nuclear 
extract. A heparin column was used as it is thought to mimic DNA in shape 
and should therefore be relevant to purification of a DNA binding protein. In 
retrospect, the use of reverse phase HPLC and custom made cisplatin- 
damaged DNA affinity columns may have been worth further investigation as 
possible purification stages. However, once the protein of interest had been 
identified as a HMG protein, purification was no longer a priority. Partially 
purified activity retains specificity for cisplatin damaged DNA as shown by 
competition gel mobility shift assay. At times faint bands could be observed 
either just above or below the main B2 complex. These may be other DRPs 
which are not usually detected due to their low intracellular concentration, 
degradation products or multimers of the major B2 forming protein or bands 
formed when oligonucleotide is bound by the protein and released as it 
progresses through the gel.
4.4.2 THE DISCOVERY THAT THE B2 COMPLEX-FORMING 
ACTIVITY IS A HMG PROTEIN
TCA treatment followed by reverse phase HPLC indicated that HMG 
1, 2, 14 and 17 were unlikely candidates for the DRP involved in B2 complex 
formation, from comparison with other HPLC traces of HMG proteins. 
However this can only be used as a rough guide-line rather than firm evidence 
as different cell lines will obviously give varying HPLC traces. Antibodies
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specific for a particular HMG protein were utilised to show that the protein 
was a genuine HMG protein. Using an anti HMGI antibody in the gel mobility 
shift assay did not result in a supershift of the B2 complex. Therefore this 
antibody did not recognise the protein involved. An extra band was seen on 
inclusion of either preimmune or immune serum and this was presumed to 
represent another DRP native to the preimmune serum rather than a supershift 
of the B2 complex.
An antibody which recognises HMGI however, was able to give a 
supershift of the B2 complex when included in a gel mobility shift assay. As 
no preimmune serum was available this is not conclusive alone but taken with 
the fact that recombinant HMGI protein displayed affinity for cisplatin- 
damaged DNA this suggests that HMGI is the protein which causes B2 
complex formation. Furthermore HMGI has been shown to have specific 
binding activity for 1,2-intrastrand crosslinked d(GpG), d(ApG) adducts and 
l,3-d(GpTpG) adducts (Pil & Lippard., 1992). HMG 1 and 2 can be purified 
using a combination of ion exchange chromatography and cisplatin-damaged 
DNA affinity chromatography (Hughes et al., 1992) and HMG2 is able to bind 
DNA damaged by cisplatin, carboplatin or iproplatin (Billings et al., 1992). 
Also human cDNA clones encoding a protein of predicted MW 81 KDa which 
contains a HMG box comprising 75 amino acids with 47% homology to 
HMGI have been isolated (Bruhn et al., 1992). This protein, named SSRP1 
recognises cisplatin induced DNA distortions. The murine homologue of 
SSRP1 is thought to be involved in immunoglobulin recombinational 
signalling (Shirakata et al., 1991). Other proteins which posses a HMG box 
and have cisplatin-DNA damage affinity are the 80KDa yeast protein encoded 
by the Ixrl gene (Brown et al., 1993) and the human transcriptional control 
protein hUBF (Treiber et al., 1994). This latter protein exhibits a similar 
affinity for cisplatin-damaged DNA as it does for its natural target, the 
ribosomal RNA promoter. It has been suggested therefore that cisplatin
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adducts may titrate hUBF away from its site of action thereby representing 
another mechanism by which cisplatin mediates cellular toxicity.
HMGI and 2 are thought to be involved in maintaining chromatin 
structure but a requirement for these proteins in transcription of class II genes 
such as trout protamine, human B-globin, adenovirus 2 major late promoter 
and herpes simplex virus (HSV) thymidine kinase has been demonstrated 
(Singh et al., 1990). Also by binding to cruciform structures caused by 
negative supercoiling, HMGI alters the DNA conformation. This may allow 
RNA polymerase to continue along its route thereby permitting transcription 
to occur. Possibly, tolerance of cisplatin could be attained in a similar manner 
if HMGI were able to bend cisplatin damaged DNA to resemble undamaged 
DNA in shape. The ability of both HMGI and HMG2 to recognise cisplatin- 
damaged DNA under the denaturing conditions of South-western blotting 
lends support to the theory that the 25KDa protein observed in human, nuclear 
extracts using this technique, is also involved in B2 complex formation.
4.4.3 NO CISPLATIN-DRP ACTIVITY CAN BE DISCERNED FOR P53 
PROTEIN
Gel mobility shift analysis of immunoprecipitated p53 protein suggests 
that p53 does not have inherent cisplatin-damage recognition capabilities nor 
do proteins tightly complexed to p53 protein. If they did, when p53 specific 
antibodies were used in the gel mobility shift assay, one would expect to see 
additional bands to those where immunoprecipitates of the irrelevant antibody, 
PAb419 were used. This does not happen but such findings do not eliminate 
the possibility that DRPs bind p53 transiently or that several intermediate 
signal transducers convey the DNA-damage message to p53 protein which 
then becomes stabilized. Also the gel mobility shift assay may not be sensitive 
enough to detect proteins with DRP activity that are expressed at a low level.
1 51
Chapter 5
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CHAPTER 5: GENERAL DISCUSSION
5.1 DNA DAMAGE RESPONSE PATHWAYS AND CISPLATIN 
SENSITIVITY
5.1.1 DNA DAMAGE RESPONSE INE.COLI
The bacterium, Rcoli is able to repair DNA damage which could 
prove toxic, by various means , the best characterized being the "ABC 
exinuclease". In this response pathway, a dimer of UvrA forms, which then 
binds to a UvrB molecule and the complex reacts with DNA. UvrA dissociates 
from the DNA and it has been postulated that the UvrB which is bound to the 
DNA permits UvrC association (Orren & Sancar, 1989). UvrC nicks the DNA 
strand and excised nucleotides are then replaced using UvrD, polymerase I 
and DNA ligase. This response pathway is effective in removal of a variety of 
DNA adducts including cisplatin induced d(GpG) lesions. Mutant strains of 
E.coli such as uvrA6, uwB5 or uvrC34 which are defective in excision repair 
of cisplatin-damaged plasmid DNA, are also highly sensitive to cisplatin but 
not transplatin (Beck et al., 1988). It would seem that DNA damage response 
is important in determining cisplatin sensitivity in this organism.
5.1.2 DNA DAMAGE RESPONSE IN S. CEREVISIAE
Many genes with an involvement in DNA damage repair have been 
found for the yeast S.cerevisiae by the use of mutants which were 
hypersensitive to UV or ionising radiation. These genes have been categorized 
into three epistasis groups on the basis of whether double mutants were 
synergysticaly sensitive. The RAD 3 epistasis group is involved in nucleotide 
excision repair. The RAD 52 group is responsible for recombinational repair 
and the RAD 6 group of gene products carry out post-replication repair. For a 
review of the genes involved in DNA repair in S. cerevisiae see Freidberg et
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al., 1988. Also in S.Cerevisiae, an enzyme known as photolyase exists which 
catalyses the removal of pyrimidine dimers from the DNA in a light dependent 
reaction. The gene encoding the apoenzyme, PHR1, is induced in response to 
certain DNA-damaging agents (Sebastian et al., 1990). Also yeast photolyase 
has been demonstrated to have DRP activity (Patterson & Chu, 1989). Again 
DNA repair is vital to the survival of this organism after exposure to DNA 
damaging agents.
5.1.3 DNA DAMAGE RESPONSE IN HIGHER EUKARYOTES
In multicellular organisms such as humans, the survival of individual 
cells is no longer a priority. Indeed unwarranted cell survival would be 
detrimental to the health of the organism. Thus DNA damage response 
pathways in multicellular organisms would probably have additional functions 
to those of single-celled organisms. As well as repairing DNA damage, it 
would be beneficial to the organism to have a means of aborting cellular 
survival in the incidence of excessive damage.
Analysis of diseases such as xeroderma pigmentosum provides some 
clues concerning the DNA damage response in humans. Extreme sensitivity to 
UV light, pigmentation abnormalities and a high incidence of cancer are 
characteristic symptoms of this autosomal, recessive disorder. XP cells are 
deficient in DNA repair including repair of cisplatin mediated lesions as 
measured by reactivation of a cisplatin-damaged CAT reporter construct (Chu 
& Berg, 1987). Cell lines derived from xeroderma pigmentosum patients are 
also more sensitive to cisplatin than normal human cells (Plooy et al., 1985). 
Thus sensitivity to cisplatin in eukaryotic cells also correlates with cellular 
repair capacity and one could extrapolate from this that resistant cells would 
have particularly efficient DNA repair mechanisms. Enhanced repair has been 
reported for certain cisplatin resistant cell lines. For instance the cisplatin 
resistant human, ovarian adenocarcinoma line A2780cp70 cells been shown to
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incorporate 2-3 fold more 3H thymidine, a measure of unscheduled DNA 
synthesis, than their more sensitive parental cell line, A2780 (Lai et al., 1988).
In response to insurmountable DNA damage, mammalian cells are 
proposed to undergo apoptosis and a possible pathway by which this may 
occur is represented below in figure 5.1.1. If cells were able to by-pass this 
pathway in some way, then resistance to DNA-damage inducing agents such 
as cisplatin would arise.
FIGURE 5.1.1. A Hypothetical DNA Damage Response Pathway
DNA damage
binding of damage 
recognition proteins
signal
pathway
p53 activation
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In this mechanism, DNA damage such as that elicited by cisplatin 
would cause changes in a signal pathway culminating in induction and 
activation of p53 protein and subsequent p53-dependent apoptosis. The 
response pathway may involve DRPs in the initial stages of DNA-damage 
signal transduction. The signal pathway could also have elements in common 
with repair pathways. DRP binding to DNA could stimulate activation of 
enzymes or kinases within the cell, which at a low level would enhance repair 
and once a threshold level were surpassed an apoptotic death programme 
would be initiated. The products of the AT genes could also be involved in 
early stages as cells from AT patients show a delayed or reduced induction of 
p53 protein following DNA damage (Kastan et al., 1992). The final events in 
the DNA response pathway may be carried out by the products of genes 
subject to p53-mediated transcriptional control.
5.2. p53, THE DNA DAMAGE RESPONSE PATHWAY AND 
CISPLATIN RESISTANCE
5.2.1 p53 STABILIZATION FOLLOWING DNA DAMAGE
Induced levels of p53 protein causes cells to arrest in G1 phase of the 
cell cycle in response to DNA damage (Kastan et al., 1991; Kuerbitz et al.,
1992). This may allow time for DNA repair before the genome is replicated at 
S phase in cells which are only mildly damaged. It could also allow 
accumulation of signaling proteins involved in the promotion of apoptosis in 
severely damaged cells. Perhaps such proteins would be titrated out or 
destroyed if cell cycling were permitted to continue.
In this thesis, Western blotting data is presented showing an induction 
of p53 protein in the human, ovarian, adenocarcinoma line A2780 and its 
cisplatin resitant derivative A2780cp70 by both cisplatin and transplatin. Peak 
p53 levels were attained 24 hours after drug removal in both cell lines. The
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lpM, 1 hour dose of these drugs did not result in less than 70% survival, as 
determined by clonogenic assay, so was not overly toxic to the cells. Basal 
levels of p53 protein were 8 fold higher in the resistant line.
High levels of p53 protein are often observed when the p53 gene is 
mutated (Bartek et al., 1990). Immunoprecipitation of p53 from A2780cp70 
was greater with a pantropic antibody (PAb DO-1) than a mutant specific 
antibody (PAb 240). This was not the case for another cisplatin resistant 
human ovarian adenocarcinoma cell line, OvlPDDP, from which equal levels 
of p53 were precipitated by the two antibodies. Direct PCR sequencing 
confirmed that p53 in the A2780 and A2780cp70 cell lines was wild-type 
whereas in the OvlPDDP line and its cisplatin sensitive parental, OvlP, there 
was a mutation at codon 126 giving a cystine to tyrosine substitution. Other 
situations where p53 protein levels are enhanced in the absence of a mutant 
p53 gene have been reported. For instance, high p53 protein levels have been 
detected in the normal tissue of a patient suffering from a familial 
susceptibility to breast cancer (Barnes et al., 1992). Also unusually high p53 
protein concentration has been observed in the cytoplasm of normal, lactating 
breast tissue (Moll et al., 1992) and in normal human skin after exposure to 
UV light (Hall et al., 1993).
Induction of p53 protein by DNA damaging agents, in the absence of 
a concommitentp53 mRNA increase, has been observed (Kastan et al., 1991; 
Fritsche et al., 1993). As p53 protein stabilisation is generally carried out by 
post-translational means, p53 protein stability in A2780 and A2780cp70 
nuclear extracts prepared in the presence or absence of phosphatase inhibitors 
was examined but no difference was detected between these conditions. The 
levels of other cellular proteins known to interact with p53 were also 
examined. Hsp70 has been shown to bind p53 and may remove it from its 
nuclear site of action (Pinhasi-Kimhi et al., 1986; Martinez et al., 1991). 
Western blotting with a Hsp70 specific antibody showed 4 fold higher levels
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of Hsp70 protein in A2780cp70 cell lysates than A2780 lysates. However the 
observation that nuclear extracts of A2780cp70 cells contained extremely high 
levels of p53 protein would suggest that Hsp70 is not responsible for 
stabilising p53 by removing it to the cytoplasm. The altered level of Hsp70 
protein in the A2780cp70 cell line compared to the parental A2780, is 
probably due to reduced p53 protein activity since p53 has been shown to 
repress transcription from the Hsp70 promoter (Ginsberg et al., 1991; Agoff et 
al., 1993). Induction of certain heatshock proteins has been implicated in 
cisplatin resistance. This does not however include Hsp70 as neither Hsp70 
protein (Oestereich et al., 1991) or the mRNA (Vikhanskaya et al., 1993) are 
induced by cisplatin exposure.
The high levels of p53 protein detected in A2780cp70 cells may be due 
to interaction with some other nuclear protein which may also prevent p53 
from interacting with its natural targets. By interacting with the N-terminal 
region of p53, another protein would prevent recognition of the amino 
terminal residues by the ubiquitin protein degradation system which is 
probably responsible for the rapid turnover of p53 protein (Scheffner et al., 
1990; Ciechanover et al., 1991). Binding to the N-terminal region would also 
directly interfere with p53 mediated transcriptional activation as N- 
terminal regions are responsible for this activity (O'Rourke et al., 1990; Fields 
& Jang, 1990; Jackson et al., 1993). The MDM2 protein is a possibility but 
the reduced MDM2 mRNA detected in A2780cp70 cells relative to A2780 
cells would argue against such an involvement. Interactions of p53 with other 
cellular proteins has been observed (Maxwell & Roth, 1993) and any one of 
these may be involved in stabilising p53 protein in A2780cp70 cells. Post 
translational modifications of p53 protein may be necessary to activate p53 
and to stimulate p53 degradation and this may involve subtle changes in 
phosphorylation. Also association of p53 protein with other intracellular 
molecules such as RNA could be involved in its recognition by proteases.
5.2.2 DISRUPTION OF p53 MEDIATED APOPTOSIS IN CISPLATIN 
RESISTANCE?
Apoptosis has been reported to be involved in the cyotoxicity and anti­
tumour activity of cisplatin and circumvention of the apoptotic machinery may 
result in cisplatin resistance (Eastman, 1990; Barry et al, 1990; Dive & 
Hickman, 1991; Evans et al., 1994; Frankfurt et al., 1994; Ormerod et al., 
1994). p53 is required for apoptosis in certain cell types and in response to 
certain stimuli particularly DNA-damaging agents (Yonish-Roach et al., 1993; 
Lowe et al., 1993a & b; Clarke et al., 1993; Morgenbesser et al., 1994; Zhu et 
al., 1994). This may be due to p53-mediated cell cycle arrest or may be an 
entirely different function of p53. Both p53 induced cell cycle arrest and 
apoptosis are likely to involve the ability of p53 to modulate transcription of 
certain genes. These transcriptional control functions are summarised in table 
5.2.1.
It has been demonstrated that p53 is able to induce apoptosis in the 
absence of transcriptional activation thereby indicating that transcriptional 
repression may be of greater importance in p53 stimulated apoptosis (Caelles 
et al., 1994). Thus the ability of p53 protein to inhibit bcl-2 transcription 
(Myashita et al., 1994a & b) provides an attractive explanation for the effects 
of p53 on apoptosis. Bcl-2 is involved in preventing apoptosis (for a review 
see Korsmeyer, 1992) and so, reduction in the levels of this protein caused by 
p53 mediated transcriptional repression would allow apoptosis to take place. 
Likewise, perturbation of p53 activity would allow cells to avoid apoptosis 
and become resistant to cisplatin. j Also, p53 transcriptionally transactivates 
the box gene, whose product interacts j with bcl-2 and promotes j  apoptosis
j (Miyashita et al., 1994a). The (decision to enter apoptosis mayjdepend on whether
bcl-2 or bax levels j  predominate and p53 seems to J  be directly responsible for
regulating the j balance between these two J proteins.
I 1
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TABLE 5.2.1 Genes Which Respond To p53-Mediated Transcriptional
Regulation
Gene or 
promoter
Activated 
bv wild- 
tvpe p53
Repressed 
bv p53 
wild-tvDe
Gene product 
function
Reference
hRGC + - ribosomes for 
protein translation
Farmer et al (1990)
MCK + - murine muscle 
creatine kinase
Weintraub et al 
(1991)
cyclin G + - ? (probably cell 
cycle control)
Okamoto & Beach 
(1994)
p53 + - tumour suppressor Deffie et al (1993)
GADD45 + - DNA-damage
induced
Kastan et al (1992)
MDM2 + - possible 
transcription factor
Juven et al (1993)
WAF-1 + - inhibits cyclin 
dependent kinases
El-Deiry et al 
(1993)
bax + - promotes apoptosis Myashita et al 
(1994)
minimal
promoter
- + none Seto et al (1992)
hsp70 + "heatshock" stress 
response protein
Ginsberg et al 
(1991) ;Agoff et al 
(1993)
c-fos + AP-1 mediated 
transcription in 
response to serum 
stimulation
Ginsberg (1991)
c-jun - + I If
p53 - + tumour suppressor I
B-actin - + cellular structural 
protein
tt
IL6 - + interleukin 6, a 
cytokine
Sanantham et al 
(1991)
mdrl - + p-glycoprotein 
membrane pump
Chin et al (1992)
Rb - + tumour suppressor Shiio et al (1992)
bcl-2 • + antagonizes
apoptosis
Myashita et al 
(1994)
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5.2.3 ALTERED p53 ACTIVITY IN CISPLATIN RESISTANT CELLS
Transfection of a p53 responsive luciferase construct into A2780cp70 
cells, demonstrated that although there was very little p53 transcriptional 
transactivation by p53 in this cell line, p53-mediated transcription could still 
be induced by DNA damage inflicted using lpM cisplatin or transplatin for 1 
hour. Transcriptional trans activation by p53 can be determined by Northern 
blot analysis of p53 responsive genes such as WAF-1 relative to a control gene 
such as GAPDH. Induction of WAF-1 mRNA in A2780 and A2780cp70 cell 
lines has been examined in this thesis. Cisplatin or transplatin doses of lpM 
for 1 hour caused induction of WAF-1 mRNA which was detectable 4 hours 
after drug treatment and which was increased further up to a 4 fold induction 
by 24 hours after drug removal. Treatment with ionising radiation evoked a 
more rapid response with a 4.5 fold peak induction 4 hours after exposure. 
This is consistent with data from elsewhere showing induction of p53 DNA 
binding activity after DNA damage (Tischler et al., 1993) and induction of 
WAF-1 mRNA by DNA damage (El-Deiry et al., 1994). Also it demonstrates 
that p53 activity is not impaired when p53 protein levels are induced in 
response to DNA damage. WAF-1 mRNA basal levels were 10 fold lower in 
the cisplatin resistant cell line A2780cp70 than in the sensitive line A2780. 
This indicates that there is reduced p53-mediated transcriptional control in the 
resistant cell line.
Transfection of A2780 cells with a mutant p53 expression plasmid, 
pC53-SCX3 (Baker et al., 1990) did not severely alter WAF-1 inducibility by 
p53, however there was a reduction in basal levels of WAF-1 expression by 3- 
fold compared to A2780 cells transfected with the vector alone. Thus 
transfection of A2780 cells with mutant p53 gives a WAF-1 mRNA reduction 
similar to, but not as strong as that seen for A2780cp70 compared to A2780 
cells. Also a 4 fold reduction in levels of mRNA from another p53 responsive
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gene, MDM2 were detected in the cisplatin resistant, A2780cp70 cells 
compared to A2780 cells.
This reduced p53 activity in the cisplatin resistant cell line A2780cp70, 
compared to the sensitive line from which it was derived, may allow survival 
of these cells following DNA damage levels which would be toxic to sensitive 
cells. Reduced p53 transcriptional regulation activity may affect other p53 
functions such as inhibition of cell cycle progression in response to DNA 
damage and p53-dependent apoptosis particularly if one considers that these 
effects are transduced by genes downstream of p53 in the response pathway. 
Examination of the functions of p53 responsive genes summarised in table
5.2.1 would indicate that this may indeed be the case.
A2780cp70 cells also have a reduced capacity to arrest in G1 phase of 
the cell cycle in response to ionising radiation doses of 2Gy or 4Gy as 
determined by FACS analysis. This ds consistent with reduced p53 activity 
in cisplatin resistant cells. Also recent data shows that there is a greater 
induction of non-random DNA fragmentation after ionising radiation exposure 
in the A2780 cells than the cisplatin resistant derivative, A2780cp70. This is 
indicative of reduced DNA damage-induced apoptosis in the resistant cell line 
which may permit resistance of these cells to DNA damaging agents such as 
cisplatin (A.McIlwrath, CRC Dept, of Medical Oncology,personal communications).
It would be interesting to determine how this reduced activity and 
enhanced level of p53 protein is attained. As mentioned in section 5.2.1, this 
may be mediated by mutation of a p53 post-translational modifying enzyme or 
altered expression of a p53 interactive protein. Perturbation of the p53 DNA 
damage response pathway by mutation of the p53 gene or by transfection of 
mutant p53 into cells has been examined elsewhere. A significant correlation 
between the ability to arrest in G1 phase of the cell cycle and the degree of 
sensitivity to DNA damage induced by ionising radiation has been detected in 
various cell lines (McIlwrath et al., 1994). Also transfection of mutant p53 into
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A2780 cells reduced both the ability to arrest in G1 phase of the cell cycle in 
response to ionising radiation induced DNA damage and the cellular 
sensitivity to such damage. Thymocytes from transgenic mice with a mutant 
p53 gene were more sensitive to ionising radiation induced apoptosis than 
thymocytes from wild-type littermates, demonstrating the importance of a 
wild-type p53 gene for DNA damage induced apoptosis (Lee & Bernstein,
1993). Although DNA damage sensitivity of some cell lines seems to be 
indifferent to changes in the p53 signal pathway other mechanisms may 
predominate in different cell types. The lack of correlation between G1 arrest 
and sensitivity following DNA damage in colorectal carcinoma cell lines with 
wild-type or mutant p53 genes (Slichenmeyer et al., 1993) may be related to 
these cell lines expressing particularly high levels of Bcl2 protein and being 
more intrinsically resistant to cisplatin. Analysis of several Burkitts lymphoma 
and lymphoblastoid cell lines showed that there was a significant correlation 
between p53 status, ability to arrest in G1 phase of the cell cycle in response 
to DNA damage and sensitivity to ionising radiation (O'Conner et al., 1993). 
Even so, certain exceptions exist such as the P3HR1 Burkitt's lymphoma cell 
line which is sensitive to DNA damage but lacks wild-type p53 or a radiation 
induced G1 arrest. Some of this data is summarised in table 5.2.2.
Also in this thesis the sensitivity of A2780 and A2780cp70 cells to a 
second cisplatin treatment after an initial pretreatment with lpM cisplatin for 
1 hour was investigated. It was reasoned that a pretreatment might elicit 
changes in cellular compnents such as p53 protein which might protect the 
cells from further DNA damage or prime them for apoptosis in response to 
further DNA damage. No difference in sensitivity was detected between 
pretreated and control cells when the second dose was given at 4, 24 or 48 
hours following the first dose. These are times when one would expect p53 
protein to be induced following the first cisplatin exposure so it would seem
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that the induced p53 protein levels have no bearing on sensitivity to further 
DNA damage elicited after p53 induction.
TABLE 5.2.2 A Summary Of Data From our Laboratory And Others Showing 
The Correlation Between p53 Activity And DNA-Damage Sensitivity 
(ND= not determined)
Cell line p53
status
G1 arrest Sensitivity Waf-1
after DNA to ionising expression
damage radiation level
A2780 (human, ovarian 
adenocarcinoma).
wild-type +++ +++ ++++
A2780cp70 (a cisplatin resistant 
derivative of A2780).
wild-type - + +
A2780 + pC53-SCX3 (a mutant 
p53 expressing plasmid-Baker et 
al, 1990).
mutant p53 
from 
plasmid
+ ++
SW480 ( human, colorectal 
carcinoma-Slichenmeyer, 1993).
mutant - ++ ND
RKO (human, colorectal 
carcinoma-Slichenmeyer, 1993).
wild type +++ -H- ND
RKO +HPV E6 (Slichenmeyer, 
1993).
functionally 
null due to 
HPVE6 
expression.
++ ND
WMN, AG876, SHO (Burkitt's 
lymphoma-O'Conner et al, 1993).
wild-type +++ +++ ND
JLP119, EW36 """. wild-type + + ND
AKAU, ST486 """. wild
type/mutant
- + ND
CA46, Ramos, SG568, Namalwa, 
MCI 16, HWL, JD38
mutant - + ND
P3HR1,M"'. mutant - -H-+ ND
164
5.3 DRPs IN DNA DAMAGE RESPONSE AND CISPLATIN 
RESISTANCE
5.3.1 HOW DRPs MAY AFFECT CISPLATIN SENSITIVITY OF CELLS
As mentioned in section 5.1.3, DRPs may be interlinked with the p53 
apoptotic pathway or they may be| involved in a separate response pathway 
concerned with DNA repair. In either case, alteration in their activity or 
intracellular concentration might alter cisplatin-induced cytotoxicity. Even if 
DRPs themselves are not the rate limiting stage in a DNA damage response 
pathway, they merit investigation as possible response pathway constituents. 
Alternatively they may be irrelevant proteins which are trapped by the 
cisplatin molecule and are unable to dissociate from the DNA. This too may 
have an effect on cell survival if cisplatin lesions impede the normal function 
of the DRP.
Data concerning partial purification of a DRP which binds to cisplatin- 
damaged DNA giving rise to the "B2 complex" in the gel mobility shift assay 
has been presented in this thesis. A strategy was developed using treatment of 
nuclear extracts with 2% TCA followed by anion exchange and heparin 
column chromatography. At each stage, binding activity was assessed by gel 
mobility shift analysis. This led to a final purification fold of 183. Other 
purification stages which may have proved useful in purifying the DRP further 
are HPLC and affinity chromatography using cisplatin modified DNA 
immobilised on cellulose. Specificity of partially purified DRP activity for 
cisplatin-damaged DNA over UV damaged or untreated DNA was 
demonstrated by competition gel mobility shift analysis.
5.3.2 HMG PROTEINS AND CISPLATIN RESISTANCE
In this thesis the protein responsible for the "B2 complex" seen on gel 
mobility shift analysis was examined for identity with members of the HMG
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class of proteins. Antibodies reactive with HMGI were unable to give rise to a 
supershift of the "B2 complex" on gel mobility shift analysis, however 
antibodies reactive with HMGI were. Furthermore, recombinant HMGI 
bound to cisplatin-damaged DNA in the gel mobility shift assay, retarding the 
DNA to a similar extent as one would observe for the "B2 complex" itself. 
Both HMGI and HMG2 were able to bind cisplatin-damaged DNA in the 
South-western binding assay. This is consistent with data from other 
laboratories demonstrating an affinity of HMGI and HMG2 for cisplatin- 
damaged DNA (Pil & Lippard., 1992; Billings et al., 1992; Hughes et al.,
1992). DRPs with HMG-homologous regions (HMG boxes) have also been 
reported. These include the 81KDa SSRP1 (Bruhn et al., 1992), the human 
ribosomal upstream binding factor, hUBF (Treiber et al., 1994) and the IXR1 
protein of S.cerevisiae (Brown et al., 1993).
It is feasible that HMG proteins have a role to play in cisplatin 
resistance. They may reduce the DNA distortion caused by the cisplatin-DNA 
adduct allowing increased tolerance of cisplatin damage. They may prevent 
recognition by a DNA damage response pathway leading to apoptosis. The 
mouse homologue of SSRP1 is involved in recombinational control (Shirataka 
et al., 1991) and so, HMG protein interaction with cisplatin-damaged DNA 
may have implications for recombinational repair.
5.3.3 ARE DRPs INVOLVED IN THE p53-MEDIATED DNA DAMAGE 
RESPONSE PATHWAY?
It was of interest to determine whether p53 is able to recognise 
cisplatin-damaged DNA. If p53 or proteins which interact with p53 were able 
to bind to cisplatin adducts, one could envisage a situation where cisplatin 
damage was directly transduced to the p53 mediated apoptotic response 
pathway. In this thesis, p53 immunoprecipitates were assessed for cisplatin- 
recognition by the gel mobility shift assay. Cisplatin treated cells were also
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used in immunoprecipitation reactions in order to determine whether DRPs 
would be induced to interact with p53 protein immediately after cisplatin 
treatment. No difference in DRPs precipitated with p53 specific antibodies or 
a control antibody could be discerned. This does not eliminate the possibility 
that DRPs are involved in the p53 DNA damage response, however. DRPs 
may become altered in conformation upon binding to cisplatin damage and 
this may result in modification of an intermediary protein which transduces 
the DNA damage distress signal to p53 protein.
5.4 THE FUTURE FOR CISPLATIN CHEMOTHERAPY
The indication that an altered p53 response pathway prevents apoptosis 
in response to DNA damage has depressing implications as p53 mutations or 
deletions are common occurances in cancer (Srivastava et al., 1990; Malkin et 
al., 1990; Cunningham et al., 1992; Allred et al., 1993; Bums et al., 1993). 
Thus, mutations of the p53 gene would not only be instrumental in causing 
cancer but would also prevent response to chemotherapy. A greater 
understanding of the apoptotic mechanisms and how p53 activity is modulated 
in vivo will eventually lead to means of modulating the cytotoxicity of 
cisplatin. The use of the genetic supressor element strategy (Gudkov et al.,
1993) may show which domains of p53 are involved in prevention of cisplatin 
resistance and may lead to the discovery of more genes which determine 
efficacy of chemotherapy. A deeper knowledge of the signal transduction 
events linking DNA damage to p53 induction is required. Also the role of 
DNA repair in influencing susceptibility of cells to apoptosis should be 
addressed. Meanwhile hope of circumventing cisplatin resistance is provided 
by the synergistic effect of tamoxifen on cisplatin activity (M^lay et al., 
1992).
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